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CHAPTER ONE: SUMMARY.
1. SUMMARY.
Acute intermittent porphyria (AIP) is an autosomal dominant disorder caused by partial 
deficiency of the enzyme porphobilinogen deaminase (PBG-D). It is heterogeneous and 
commonly gene carriers of the disorder remain asymptomatic and may not always be diagnosed
ft
by convetional biochemical methods. Since detection of gene carriers is of central importance to 
the management of this condition, an alternative method of diagnosis is essential. Mutations 
causing acute intermittent porphyria have not however, been fully characterised. In the current 
study, direct cDNA sequencing of polymerase chain reaction (PCR) amplified templates has been 
developed and applied for the characterisation of mutations associated with this disorder.
The procedure was developed by amplifying RNA from various sources including human 
placenta, chorion, lymphocytes and lymphoblastoid cells. The amplification was performed by a 
technique referred to as reverse-transcriptase polymerase chain reaction (R-T PCR) in which 
both the first strand cDNA synthesis and the subsequent amplification are performed in the same 
reaction mixture. Two approaches to the R-T PCR amplification were employed and compared.
In the first approach, the first strand cDNA synthesis was carried out with one of the primers 
complementary to the non-erythroid PBG-D mRNA and in the second, by using oligo(dT)12.18- 
Both methods were successful and comparable, but the later was preferred because it could be 
modified in asymmetric PCR to directly produce either the sense or the anti-sense strand.
The PBG-D cDNA synthesised and amplified by the R-T PCR was either directly sequenced as 
double-stranded (ds) templates or eluted and reamplified by asymmetric PCR to produce single­
stranded templates. Alternatively, single-stranded templates were produced directly by 
‘asymmetric’ R-T PCR. Prior to sequencing, the PCR amplified templates were concentrated, 
desalted and purified to remove excess deoxyribonucleoside triphosphates (dNTPs) and 
amplification primers. Several purification methods were employed and their efficacy compared. 
These included, spun-column chromatography, nucleic acid chromatography system (NACS) 
purification, centrifuge-driven dialysis, geneclean™ purification, gel fractionation and selective 
precipitation in ammonium acetate and propan-2-ol. Selective precipitation with ammonium
acetate and propan-2-ol was found to be the simplest and most effective method of template 
purification. In addition it was also inexpensive, reliable and convenient.
Dideoxy sequencing of both double-stranded and single-stranded (ss) templates was performed 
with either Sequenase T7 DNA polymerase or Taq DNA polymerase. Sequencing of the single­
stranded templates, especially when produced by asymmetric reamplification of cDNA gave the 
most consistent and reliable results. For routine sequencing, there was no difference in the 
performance of the two sequencing enzymes used, although Taq DNA polymerase was better 
than Sequenase T7 DNA polymerase in handling templates with complex secondary structures.
The procedure of direct sequencing was applied on asymetrically amplified templates of thirty 
patients with acute intermittent porphyria (AIP) and ten normal controls. The diagnosis of acute 
intermittent porphyria was based on increased excretion of aminolevulinic acid (ALA) and 
porphobilinogen (PBG) in urine and decreased activity of erythrocyte porphobilinogen 
deaminase (PBG-D) coupled with a clinical history of one or more acute attacks. The mean 
erythrocyte porphobilinogen activity in the acute intermittent porphyria patients was 22.3 
nmol/h/ml erythrocytes. The normal adult activity range for the enzyme is 25-42 nmol/h/ml 
erythrocytes in the females and 30-48 in males. After optimisation of the R-T PCR, correct sized 
products were obtained from the amplification of all samples, indicating absence of any major 
deletions* Sequencing of these products revealed seven
point mutations in twelve patients with acute intermittent porphyria and none in the control 
subjects. All mutations were due to single base substitutions, four of which were associated with 
amino acid substitutions and are likely to be the cause of AIP in these individuals. The remaining 
three were silent mutations without change of amino acid and are therefore regarded as neutral 
polymorphisms. The detected mutations were Q34K (C100->A) seen in two related individuals, 
L177R (T530->G) also observed in two unrelated individuals, R167Q (G500->A) and H256N 
(C766->A) each seen separately in single subjects. The silent mutation L42L (G117->A) was seen 
in one individual whereas S45S (G135->A) and V202V (G606->T) were seen in two and four 
individuals respectively. With the exception of the mutation R167Q which has been previously
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reported in four other individuals, the rest of the mutations were novel, emphasising the 
heterogeneity of this condition. Among the four mutations that were associated with amino acid 
substitutions, three of them (Q34K, R167Q and L177R) occurred in highly conserved domains of 
the PBG-D cDNA, involving amino acids which are identical in all six species in which the gene 
has been sequenced. The remaining mutation (H256N), involved a conserved charge. Three of 
the mutations namely, L177R, H256N and S45S abolish recognition sites for restriction 
enzymes, Alul, Banl and Rsal respectively, which can be used for tracking of these mutations in 
affected family members and possibly in the community at large. Prediction of the secondary 
structure changes likely to be caused by these mutations was performed using the 
PEPTIDESTRUCTURE and PLOTSTRUCTURE computer programmes. From this it was 
predicted that among the four delineated mutations, the Q34K was the only mutation that was 
likely to be associated with a configurational change in the protein structure. This mutation was 
predicted to lead to the disruption of [3-strand. It must, however, be emphasised that three of 
these mutations affected highly conserved ammo acids and one a conserved charge. Moreover, 
despite the lack of prediction in alteration of the secondary structure, previous expression studies 
have demonstrated that mutation R167Q is associated with a drastically reduced optimal pH of 
the porphobilinogen deaminase.
Finally, it was possible to simplify this procedure of direct sequencing of PCR amplified 
products by doing the reverse-transcription and the subsequent direct sequencing from crude 
RNA preparations of lymphocytes, thus bypassing the need for elaborate RNA extractions. This 
modification, greatly saved time and labour and and in addition, was found to be reliable. 
Furthermore, this procedure of direct sequencing of PCR amplified productcs can be used as a 
prototype to investigate the molecular pathology of any other single gene disorder as shown in 
this study by being applied to demonstrate the G551D (G1(784->A) mutation in cystic fibrosis.
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CHAPTER TWO: INTRODUCTION.
2. INTRODUCTION.
2.1. Molecular pathology of single gene disorders.
Single gene disorders generally arise from two main types of molecular pathology, namely 
gross aberrations and point mutations. Gross aberrations are caused by insertions, deletions or 
rearrangements of genes and these may be large enough to be visible under light microscopy if 
the change involves more than 4,000 kilobases (kb). These aberrations are most commonly 
observed in tandemly duplicated genes (i.e. two genes with a similar nucleotide sequence on the 
same chromosomal location) because of non-homologous pairing and crossing over during 
meiosis (Antonarakis, 1989). In genes like the beta-globin and factor VTII gene that have only 
one copy per chromosome, deletions or rearrangements are relatively rare and account for 1 to 5 
% of mutations (Antonarakis et al., 1985a, Gitschier et 1986; Youssoufian et al., 1987). Deletions 
were first described in the human globin gene clusters in relation to thalassaemias and hereditary 
persistence of foetal haemoglobin. In some forms of a-thalassaemia, different-sized deletions 
remove one a-globin gene and leave one functional gene per haploid genome. These deletions 
arise from unequal crossing over between homologous pairs of chromosome 16, leaving one a- 
globin on one of the chromosomes and three on the other (Embury et al., 1980; Antonarakis et 
al., 1985b; Weatherall, 1985). Deletions have also been described in the dystrophin gene 
(Monaco et al., 1985; Kunkel, 1986; Read et al., 1988; Chamberlain et al., 1988; Cooke et a l ., 
1990) where they account for up to 60% of mutations of this gene. These mutations lead to either 
Duchenne muscular dystrophy (DMD) or its milder allelic form, Becker muscular dystrophy 
(BMD). Other conditions in which deletions have also been described include; factor IX 
deficiency (Gianelli et al., 1984), antithrombin III deficiency (Prochovnik et a l ., 1983), familial 
hypercholesterolaemia (Sudhof et el., 1985; Lehman et al., 1986) and Lesch-Nyhan syndrome 
(Yang et al., 1984; Wilson et al., 1986). Rearrangements like duplication and translocation 
leading to DMD have also been described in the dystrophin gene (Ray et al., 1985; Cooke et al.,
1990). Insertions have been reported in dihydropteridine reductase (NADH) deficiency (Howells
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et al., 1990) and hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency (Davidson 
et al., 1991).
Point mutations, on the other hand, are sub-microscopic lesions caused by substitutions, 
deletions, or insertion of one, or a few nucleotides in critical regions of genes. These mutations 
are inherited as mendelian traits (McKusick, 1990). Single base substitutions may either be due 
to transitions or transversions. Transitions refers to those changes where one purine is substituted 
by another purine or when a pyrimidine is substituted for a pyrimidine. On the other hand, in a 
transversion, a pyrimidine is substituted by a purine or vice versa. Although point mutations may 
affect single nucleotides, such changes can still have profound effects on the gene product, either 
by affecting the transcription of the gene into mRNA or the processing of mRNA during the 
production of its mature form or even the translation of mRNA into protein. Point mutations may 
bring about these adverse effects by causing important amino acid substitutions in the protein 
product (Antonarakis, 1989), by prematurely introducing stop codons leading to the production 
of truncated proteins (Scobie et al., 1990; Lee and Anvret, 1991), by altering splicing sites with 
or without subsequent skipping of exons (Grandchamp et al., 1989a; Grandchamp et al., 1989b; 
Delfau et al., 1990), or by altering regulatory ‘boxes’ and poly A addition signals (Weatherall, 
1965).
The mechanism of the exon-intron junction splicing is not fully known. Primary transcripts are 
large mRNA precursors which correspond to the entire gene, including exons and introns. Before 
release these mRNA precursors are processed in the cell where the mRNA corresponding to 
introns are excised and the exons spliced together. There are at least three different splicing 
systems involving rRNA, tRNA and mRNA. In the case of the mRNA precursors, the 5’ exon- 
intron junction has a conserved segment of nine nucleotides in which introns tend to begin with 
GT and end with AG (consensus sequences), obeying the so called GT-AG rule. The nine- 
nucleotide consensus for the 5’ junction extends three residues upstream and six residues 
downstream from the splice point. The conserved sequence of the 3’ splice junction is on the 
other hand composed of a pyrimidine-rich region of a variable length (at least ten bases long)
followed by a short consensus sequence extending three bases upstream and one base 
downstream from the splice point (Mount, 1982). The pyrimidine-rich region is devoid of the 
sequence AG, which is the invariant dinucleotide at the end of the 3’ intron-exon junction. Thus 
the 5’ exon-intron junction always has the bases G and T, whereas the 3’ junction has A and G. 
Use of the 5’ splice site is abolished by changes in the invariant GT sequence and is decreased by 
mutations elsewhere in the in the nine conserved bases (Watson et al., 1987). 5’ splice mutations, 
besides abolishing splice sites, may activate new sites (cryptic splice sites). Splice site mutations 
have been described in phenelalanine hydroxylase (PAH) gene (Dianzani et al., 1991) and the 
PBG-D gene (Grandchamp et al.,1991a, 1991b, 1991c). hi the PBG-D gene, one of these 
mutations, a G to A transition within the donor splicing site of intron 12 has been observed to 
lead to the skipping of exon 12 during post-transcriptional maturation of the primary transcripts. 
As the junction of exon 11 to exon 13 does not disrupt the reading frame, the mutant RNA is 
translated into a truncated protein missing 40 amino acid residues encoded by exon 12 
(Grandchamp et al., 1991c). Splice site mutations leading to activation of cryptic splice sites and 
hence abnormal proteins have been described in (3-thalassaemia and haemoglobin E. These 
includes G to A transitions at position 110 of the first intron and exon of the (3-globin gene 
respectively (Weatherall, 1985). In the first, the mutation produces a new splice acceptor site 
which tends to be used more frequently then the original site resulting in the production of 
mRNA containing intron sequences. This abnormal RNA cannot be used as a template for the (3- 
globin chain synthesis and therefore results in (3-thalassaemia. In the second mutation, a G to A 
substitution in exon 1 of the (3-globin gene activates a cryptic splice site which is utilised at a 
lower rate. This leads to the production of some abnormal mRNA lacking exon sequences and 
having a premature stop codon resulting in haemoglobin E phenotype. Thus despite of their 
similarity, these two processing mutations of the (3-globin gene lead to different conditions.
Processing defects may also occur when mutations involve other consensus domains like 
regulatory ‘boxes’ and poly(A)+ addition signals. Towards the 3’ end of DNA sense strands 
(upstream), genes have consensus sequences called enhancer and promoter regions which are
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responsible for the regulation of gene activity. The promoter is involved in the attachment of 
RNA polymerase to the DNA sense strand during transcription. Many promoters have an 
element called a TATA box (Goldberg-Hogness box) with the sequence TATAAA, 25-30 bp 
upstream from the start. Further upstream there are often one or more promoter elements 
including the sequences CCAAT and GGGCGG. The activity of many promoters is modulated 
by an enhancer, a separate regulatory element located on the same DNA molecule. This can 
be situated, either upstream or downstream and may be as far as 1 Kb from the promoter region. 
At the 5’ end of the gene, there is a consensus sequence AATAAA, which signals the addition of 
the poly(A)+ tail. Mutations of both the TATA box and the poly(A)+ additional signal leading to 
mRNA processing defects has been described. These for instance, include mutations involving 
the TATA and CCAAT boxes resulting in (3-thalassaemia phenotype (Orkin et al., 1983; 
Weatherall, 1985). Poly(A)+ addition signal mutations have been described in both a- and (3- 
thalassaemias where an AATAAA to AATAAG mutation of the a-2-globin gene causing a- 
thalassaemia has been reported. In this mutation, presumably the A to G transition at the last 
position of the consensus poly (A)+ additional signal interferes with mRNA polyadenalation. This 
will therefore, prevent the transportation of the mRNA into the cytoplasm (Higgs et al., 1983). A 
similar mutation, AATAAA to AACAAA in the (3-globin gene has been reported as a cause of 
(3-thalassaemia (Weatherall, 1985). Finally, there is yet another type of mRNA processing 
mutation whereby the abolishing of the termination codon leads to die production of an abnormal 
protein. An example of this is the haemoglobin Constant Spring, which is a cause of a- 
thalassaemia phenotype (Weatherall, 1985). In this mutation, a T to C transition in the a-globin 
gene, converts the termination codon TAA (UAA) to CAA encoding for glutamine. This results 
in the production of an unstable a-globin chain variant with 31 additional amino acids residues at 
the C-terminal end.
On the basis of the amino acid or codon changes, point mutations have also been classified into 
missense and nonsense mutations, whereby missense mutations include those in which one 
amino acid is substituted for another and nonsense mutations refer to changes that lead to a
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premature introduction of a stop codon. Given that there are only three stop codons, it therefore 
follows that most of the point mutations are likely to be of missense rather than the nonsense 
type. As any new protein arising from a missense mutation contains only a single amino acid 
substitution, it often possesses some of the biological activities of the original protein. Quite 
often, missense proteins fail to function only at a higher than normal temperature and are 
therefore known as temperature-sensitive mutations. Missense mutations have been described in 
many conditions including, (3-thalassaemia (Ristaldi et al., 1989), sickle cell anaemia (Chang and 
Kan, 1982), a -1-antitrypsin deficiency (Graham et al., 1990), factor IX deficiency (Montadon et 
al., 1990), cystic fibrosis (Cutting et al., 1990), factor VIII deficiency (Youssoufian et al., 1988; 
Higuchi et al., 1990), phenylketonuria (Konecki et al., 1991), AIP (Lee et al., 1990, Delfau et al., 
1990,1991) and HPRT deficiency (Gibbs et al., 1989; Davidson et al., 1991).
Due to degeneracy of the genetic code, up to a quarter of point mutations lead to no change in 
the amino acid (Connor and Fergusson-Smith, 1991). Such changes are referred to as silent or 
same-sense mutations. Usually these mutations lead to no pathology. However, in some highly 
expressed genes, there are certain codons which may be preferred to others in the translation of 
proteins and that such codons even when changed to another same-sense codon, result in 
inefficient production of the encoded amino acids. Silent mutations may also lead to alterations 
of recognition sites for restriction enzymes, making it possible to directly detect mutations. 
Alternatively, such silent mutations may create restriction fragment length polymorphism 
(RFLPs) which may also be used to detect mutations through linkage analysis. Of particular 
interest to this study, such silent mutations have also been described in the PBG-D gene where in 
some cases they have been useful in the tracking of mutations of this gene (Grandchamp et al., 
1987; Gu, 1991; Lee, 1991a; Picat et al., 1991)
On the other hand, as nonsense mutations lead to premature termination of the protein product, 
the length of the final product and theoretically the severity of the deficiency will therefore 
depend on the site of the mutation. Nevertheless, most prematurely terminated proteins 
(irrespective of the size), lead to reduced or no biological activity. Such nonsense mutations have
been described in porphobilinogen deaminase gene (Scobie et al., 1990; Delfau et al., 1990, 
Delfau et al., 1991; Lee and Anvret 1991a), factor VIII gene (Youssofian et al., 1886 and 1988; 
Higuchi et al., 1990), a- and (3 thalassaemias (Weatherall, 1985; Wong et al., 1987), factor IX 
gene (Montandon et al., 1990), cystic fibrosis gene (Cutting et al., 1990), HPRT gene (McKeran 
et al., 1975; Davidson et al., 1991), and PAH gene (Wang et al., 1989,1890, Svensson et al.,
1990). Nonsense mutations may also arise from insertions or deletions of one or a few bases 
leading to alteration of the open reading frame, the so called frame-shift mutations. This may 
also lead to a premature introduction of a stop codon. These insertions or deletions are thought to 
arise from displacement of bases from either the growing strand in the case of insertions, or from 
the template strand in the case of deletions. Such mutations tend to occur particularly at sites 
with runs of identical bases in a DNA fragment, where the displacement can be stabilised by 
normal base pairing beyond the unpaired base. When the miscopied DNA strand acts as a 
template, the insertion or deletion is usually copied accurately, thus fixing the mutation. Since 
frame-shift mutations alter the open reading frame, they tend to cause complete disruption of 
protein synthesis (Ghosal and Saedler 1978). Examples of these mutations have been described 
in p-thalassaemia (Orkin et al., 1881; Wong et al, 1990), factor VIII gene (Higuchi et al., 1990) 
and cystic fibrosis (White et al., 1990; Ianuzzi et al., 1991) and PBG-D gene (Nordmann et al.,
1991). In the case of cystic fibrosis, two mutations have been identified in exon 7, one caused by 
a two-nucleotide insertion at position 1154 and the other caused by a one-nucleotide deletion at 
position 1213, both causing frame-shifts. This leads to the premature insertion of termination 
codons at residues 369 and 368 respectively (Ianuzzi, 1991). A frame-shift mutation of the cystic 
fibrosis gene caused by a two-nucleotide insertion at exon 13, leading to the introduction of a 
stop codon at residue 821 has also been described (White). Therefore, in many conditions, like 
a-thalassaemia, [3-thallassaemia, pheylketonuria, haemophilia A, haemophilia B, Lesch-Nyhan 
syndrome and ALP, the same phenotype may be caused by different mutations of the same gene.
Although error rates for different bases do vary by a hundred fold, on average a nucleotide is 
likely to be changed by mistake about once for every 109 times it is replicated. These mutations
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do not occur at the same rate in all sites. There are some areas in certain genes that are more 
likely to under go mutations and are generally referred to as ‘hot spots’ (Benzer, 1961). This 
often occurs at CpG dinucleotides, which in higher animals seem to play a major role in 
mutagenesis (Mandel and Chambon, 1979; Bird, 1980; Nussinov, 1981; Barker and White, 1982; 
Barker et al., 1984; Youssoufian et al., 1988; Delfau et al, 1990). Evidence in support of this 
includes the underrepresentation of this dinucleotide in vertebrate genomes (Nussinov, 1981), a 
higher frequency of polymorphism observed with restriction enzymes that contain CpG in their 
recognition sequences (Barker et al., 1984) and the observation of many mutations in different 
disorders involving this dinucleotide. Mutations that involve CpG dinucleotide have been for 
instance, described in cq-antitrypsin gene (Kidd et al., 1983), adenosine deaminase (Bonthron et 
al., 1989), insulin (Shibasaki et al., 1985), antithrombin III (Duchange et al., 1986), factor IX 
deficiency (Bentley et al., 1886), protein C (Romeo et al., 1987), factor VIII deficiency 
(Youssoufian et al., 1986 1988), ornithine transcarbamylase (Lee and Nassbaum, 1989) and 
porphobilinogen deaminase gene (Grandchamp et al., 1989b; Delfau et al., 1990; Lee 1991b).
2.2. Methods used in studying molecular pathology of monogenic disorders.
In recent years many techniques have been developed for the manipulation and study of genes, 
leading to tremendous progress in the understanding of structure and function of human genes. 
These achievements have led to the understanding of the biochemical mechanisms and basic 
diagnosis at the DNA level of many diseases, especially those due to single gene defects 
(Antonarakis, 1989). Among these new techniques, the polymerase chain reaction (PCR), has 
undoubtly contributed most to the attainment of these achievements (Vosberg, 1989).
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2.2.1. Polymerase chain reaction.
Polymerase chain reaction is an enzyme-catalyzed in vitro method of selective multiplication of 
DNA or RNA segments of interest, starting from small amounts of material. This is done by 
flanking the segment of interest (template) with two synthetic oligonucleotides commonly 
referred to as amplification primers, in such a way that their 3’ ends point to each other when 
hybridized to the corresponding strands of the template. Through an enzyme controlled 
polymerisation, the amplification primers are then made to extend towards each other with 
repetition of this process many times, usually between 30 to 40 cycles as illustrated in figure 1. 
The essential steps in each cycle are, thermal denaturation of double stranded target molecules 
followed by annealing of the amplification primers to each strand and finally the polymerase 
controlled DNA synthesis. Since both strands of a given target DNA are used as templates, the 
number of target sequences multiplies exponentially ending with large amounts of the targeted 
DNA segment as defined by the 5’ ends of the amplification primers (White et al., 1989). This 
feature of PCR, does not only account for its sensitivity but its specificity as well, since the 
selective amplification of the targeted region conversely reduces the background of unwanted 
sequences.
Moreover, PCR can also be used to amplify RNA transcripts. This is made possible after 
converting mRNA to first strand cDNA with reverse transcriptase (Saiki et al., 1988) as 
illustrated diagrammatically in figure 2. This can be achieved by using either oligo(dT)12.1g, 
random hexamers or by using a forward (upstream) primer, the primer that is complementary to 
the original mRNA.
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Polymerase chain reaction is sensitive enough to enable amplification of single DNA molecule 
and is now routinely used in the extraction of single-copy genes from complex genomic mixtures 
(Kim and Smithies, 1988, Li et al., 1988). For example, Saiki and co-workers (1988), were able 
to amplify certain targeted sequences of the [3-globin gene with a homozygous deletion contained 
in a 10'6 dilution of genomic DNA. This suggests that PCR is able to amplify target sequences 
that are present only once in 105 to 106 cells. This high sensitivity has been shown in the 
handling of mRNA as well (Harbath and Vosberg, 1988), where indeed, amplification has been 
possible from the RNA content of a single cell (Rappolee et al., 1988). It is the combination of 
this sensitivity and specificity that makes PCR a very versatile procedure. The technique can be 
performed on virtually any DNA or RNA-containing material and has for instance been 
successfully carried out from individual hair roots (Higuchi et al., 1988a), single sperm (Li et al., 
1988), buccal cells, (Lench et al., 1988) and epithelial cells in urine (Gasparini et al., 1989). This 
technique can also be performed on partially degraded DNA (Paabo et al., 1988) and on 
paraffin-embedded tissues (Impraim et al., 1987; Shibata et al., 1988; Jackson et al 1989).
The discovery that restriction site sequences could easily be introduced into DNA fragments 
through PCR has further increased the scope of applications of this procedure. Scharf et al., 
(1986) found that this could be done by merely attaching the restriction sequences to the 5’ end 
of the amplification primers. Despite these sequences being mismatched to the DNA template, 
they seem to interfere with neither the efficiency nor the specificity of the PCR. As strands 
initiated by these primers are copied including their added on 5’ tails, the restriction sites 
sequences become incorporated in the PCR products, hi this way fragments of up to 45 bases can 
be added onto DNA fragments, as for instance the addition of a G+C rich segment to augment 
mutation detection in denaturing gradient gel electrophoresis (Sheffield et al., 1989). The 
introduction of restriction sites onto PCR products facilitates their further handling such as in 
cloning (Scharf et al., 1986). Besides addition of restriction sites, these 5’ tails can be used to 
incorporate a phage promoter necessary for reverse-transcdptase mediated RNA or DNA 
sequencing (Stoflet et al., 1988; Sarkar and Sommer 1988; Sarkar and Sommer 1989). Also
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based on this principle, several other methods of modifying DNA fragments have been 
described. At its simplest the principle can be applied to specifically label a particular strand or 
both strands of PCR products with a radioactive, biotin or fluorescent tag (Lo et al., 1988; 
Gyllensten, 1989; Hutman et al., 1989). It can also be used to introduce defined mutations at 
specific sites in DNA segments (Higuchi et al., 1988; Vallete et al., 1989) and in DNA 
recombination procedures (Horton et al., 1989).
This diversity in protocols and applications of PCR entails the need for different amplification 
conditions. Quite often there is a need for optimisation of the PCR conditions before they can be 
applied routinely in a particular protocol (Saiki, 1989a; Innis et al., 1990). Variables which need 
to be optimised include the concentrations of templates, magnesium ions, deoxynucleoside 
triphosphates, enzyme and amplification primers. Specificity and efficiency of the amplification 
is also influenced by the cyclic thermal profile and the number of cycles. Failure of optimisation 
may lead to poor or no amplfication of the desired product as well as non-specific amplification. 
At times, the amplification of these non-specific products may be so efficient as to become 
equally or more predominant than the desired product (Saiki et al., 1988; Feldman et al., 1988; 
Haqqi et et al., 1988; Anwar et al., 1990). Lack of optimisation may also lead to 
misincorporation of bases (Innis and Gelfand, 1989). Another problem associated with PCR is 
the presence of false positive results. This is linked to the high sensitivity of the procedure, since 
the commonest source of these false positive reactions tend to be contaminations carried over 
from previous positive amplifications (Li et al., 1988; Sarkar and Sommer, 1990).
Currently, there are several PCR based methods for direct detection of nucleotide variations in 
genetic conditions. These include restriction fragment length polymorphism analysis (Saiki et al., 
1985; Kogan et al., 1987; Lee et al., 1990), single-stranded conformation polymorphism analysis 
(Orita et. al., 1989a; Orita et al., 1989b), denaturing gradient gel electrophoresis (Cariello et al., 
1988; Traystman et al., 1990), RNase cleavage analysis (Myers et al., 1988) chemical cleavage 
of mismatch detection (Cotton et al., 1988; Grompe et al., 1991), allele specific oligonucleotide 
hybridisation (Embury et al., 1987; Lo et al., 1988), amplification refractory mutation system
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analysis (Newton et al., 1989) and direct genomic sequencing (Wrishchnik et al., 1987; Wong et 
al., 1987; Newton et al., 1988).
2.2.2. Restriction fragment length polymorphism (RFLP) analysis.
Until recently, the usual method for the identification of mutations through linkage analysis 
required amounts of undegraded DNA in the order of 5-10 ug, to be cleaved, gel electrophoresed, 
Southern blotted and the RFLP haplotypes probed with radioactive DNA. Using PCR, however, 
one can now amplify the region of interest containing the polymorphic site starting with genomic 
material of 1 ng or less. The presence of the diagnostic site is then directly demonstrated by 
cleavage or absence of cleavage of the amplified DNA fragment. Heterozygosity can be 
identified by the demonstration of both alleles (Feldman et al., 1988). Furthermore, PCR being 
an in vitro synthetic process, gives rise to a product that does not contain 5-methylcytosine 
residue and cannot therefore reflect any methylation pattern present in the original template. This 
has led to the identification of new RFLPs, which had previously gone unnoticed because of 
inhibition of restriction enzyme cleavage by the methylation of cytosine. This has, for instance 
been used in the identification of Hhal and Apal RFLPs in the factor IX and PBG-D genes 
respectively (Winship et al., 1989; Picat, et al., 1991). Direct detection of mutations through 
demonstration of RFLPs has for example, been applied in the diagnoses of haemophilia A 
(Kogan et al. 1987) and sickle cell anaemia (Saiki et al.,1985). Direct RFLP analysis however 
requires prior knowledge of the sequence of the DNA segment of interest. Unfortunately only 5 
to 10 percent of point mutations can be directly detected by this method (Antonarakis 1989).
Where direct detection is not possible, linkage analysis can still be very valuable in the tracking 
of mutations. PCR based RFLP linkage studies have been, for example used in prenatal diagnosis 
of a -1-antitrypsin deficiency (Abbot et al., 1988) and in the diagnosis of haemophilia B (Reiss et 
al., 1990), cystic fibrosis (Northrup et al., 1989; Rosenbloom et al., 1989; Huth et al., 1989) as 
well as acute intermittent porphyria (Lee, 1991a). Linkage studies can benefit from the high 
sensitivity of the PCR technology by the fact that it can be used to process minute amounts or
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even partially degraded material of key family members who may otherwise be unavailable for 
analysis because of death or other reasons. This is due to the fact that PCR can still be performed 
on their preserved tissues when available, as amplification can be successfully carried out on 
formalin-fixed or paraffin-embedded tissues (Impraim et al., 1987) and on Guthrie spots 
(Williams et al., 1988).
Nevertheless, it being an indirect method, RFLP linkage analysis will always have the 
disadvantage of depending on key family members whose specimens may at times be 
unavailable to the investigator. Other problems associated with linkage analysis include 
recombination, non-paternity and non-informative key family members. In RFLP linkage 
analysis, key family members who may include, parents and some of their relatives, grandparents 
or previously bom children, need to be studied to establish linkage and phase before results can 
be useful for the subsequent detection of mutations, hi some cases both parents may have the 
same RFLP and make it impossible to establish linkage with the sought mutation. Such parents 
are said to be non-informative. In seeking to establish autosomal linkage, the ideal mating is a 
mating where one partner is heterozygous for both the disease and the RFLP and the other is 
homozygous for the RFLP and the normal allele (a double backcross mating). In addition to this, 
for an RFLP to be useful, it must be tightly linked to the mutant gene to avoid problems due to 
recombination. Besides, with this method one cannot detect mutations if present in less than 5% 
of the studied cells, as may occur in mosaicism (Haliassos et al., 1989).
PCR technology has simplified and increased the sensitivity of RFLP analysis for both direct 
and indirect detection of genetic variation, but the procedure still retains some of the inherent 
limitations associated with linkage analysis. Furthermore, there are many single base mutations 
that do not alter any restriction enyzme sites and therefore, are not amenable to direct detection 
by this method. Detection of these mutations will require alternative methods as described in 
subsequent sections.
2.2.3. Single-stranded conformation polymorphism (SSCP) analysis.
The electrophoretic mobility of single-stranded nucleic acids depends not only on size but also 
on their sequences. Under non-denaturing conditions, ssDNA may have a folded conformation 
that is stabilized by intrastrand interaction. Any base change can interrupt this conformity and 
alter mobility which can be detected by comparing the mutant sample along with the wild-type as 
a control (Orita et al., 1989a; Orita et al., 1989b, Labrune et al., 1991). The sequences to be 
examined are amplified and labelled simultaneously by PCR using either labelled primers or a 
labelled nucleotide. In a typical PCR, as up to 10% of the amplifying primers and 
deoxynucleotides as substrates are incorporated in the amplification products, the efficiency of 
labelling of the targeted molecules is very high compared to that in RFLP detection by Southern 
blotting. The labelled PCR products are then denatured and resolved in polyacrylamide gels 
containing 10% glycerol for the SSCP analysis. This is based on the fact that, the conformation 
of a single-stranded nucleic acid is presumably determined by the balance between thermal 
fluctuation and weak local stabilizing forces such as short intrastrand base pairings and base 
stacking. Therefore, changes in the gel conditions, such as the running temperature or presence 
of glycerol will be liable to cause conformational changes and will be detected as an 
electrophoretic mobility shift. This effect of sequence change on electrophoretic mobility is, 
however, unpredictable and in some cases may not be significant enough so as to be detectable 
(Orita et al., 1989b; Labrune et al., 1991).
Although SSCP analysis is faster than Southern blotting, it 
still has some limitations. These include the fact that as a prerequisite, sequences of the targeted 
DNA need to be known, both for the construction of amplification primers and the preparation of 
suitable templates. This is necessary, especially for long DNA segments because of a limitation 
in the size that can be analysed by this method (Orita et al., 1989). SSCP analysis is most suitable 
for the screening of DNA fragments of less than 200 base pairs (bp) in length. (Orita et al.,
1989b). Moreover SSCP analysis can only suggest the presence of a nucleotide variation, but not 
reveal its exact nature or location. Following the detection of such changes DNA sequencing
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needs to be done to determine the exact nature of the pathology. Therefore, at its best, SSCP is 
suitable only in the screening for nucleotide variations including polymorphisms and to some 
extent for the tracking of known mutations within family members.
2.2.4. Denaturing gradient gel electrophoresis (DGGE).
DGGE allows the separation of DNA molecules differing by single base changes (Fischer and 
Lerman 1983; Myers et al., 1985a). This separation is based on the fact that when in solution, 
DNA molecules melt in discrete segments called melting domains, which may vary from 25 base 
pairs (bp) up to several hundred bp. The melting temperature (Tm) of each melting domain is 
highly dependent on its nucleotide sequence (Myers et al., 1989). In the DGGE system, DNA 
fragments are separated according to their melting properties by electrophoresis through a 
linearly increasing gradient of denaturants. When a DNA fragment is run through such a system 
it remains double stranded until it reaches the concentration of denaturants equivalent to a Tm 
that causes the lower-temperature melting domains of the fragment to melt. When this occurs, 
the molecule begins to branch, sharply decreasing the mobility of the DNA fragment in the gel 
and eventually separating the two segments differing in as little as a single nucleotide (Sheffield 
et al., 1989). Strand separation will, however, not occur in DNA fragments located in the highest 
melting domain, because of the loss of sequence-dependent migration caused by the completion 
of strand separation (Myers et al., 1985a). Because of this limitation, it has been estimated that 
on average the method is able to detect only 50% of the possible single base changes in 
fragments ranging from 50 bp to several hundred bp in size (Myers et al., 1985b). To circumvent 
this, a G+C rich segment, commonly referred to as a GC-clamp can be attached to a segment that 
melts in two domains (Myers et al., 1985b; 1985c). This G+C segment, consisting of around 40 
bases, is attached to the 5’ end of one of the primers used in PCR for the amplification of the 
targeted segment. The PCR based DGGE system with GC-clamps, not only improves the 
detection rate of mutations but also simplifies the method considerably, obviating the necessity 
for radioactive labelling. Prior to this improvement, the standard DGGE required 5-10 ug of
genomic DNA for each analysis, whereas the PCR based DGGE allows analysis to be done on 
samples with less than 5 ng of genomic DNA. Moreover, PCR based DGGE enables results to be 
examined directly by ethidium bromide staining, thus increasing the speed of detection (Sheffield 
et al., 1989).
Although the method can be used to detect mutations in DNA
segments of up to 1000 bases long, it is most suitable for screening fragments of around 100-500 
bases. The limitation in the size of DNA fragments that can be screened by DGGE is due to poor 
resolution and presence of unpredictable secondary structures in long DNA fragments. Further to 
this, DNA fragments longer than a few hundred base pairs travel very slowly in polyacrylamide 
gels so that impractical times are required to resolve them (Sheffield et al., 1987). Another and 
probably more serious problem associated with this technique is the presence of spurious PCR 
products, since successful detection of mutations in amplified DNA fragments by DGGE 
analysis requires the presence of single DNA species. In some cases however, different 
molecules other than the targeted DNA are produced and may even be in excess of the desired 
product. In such cases, the additional fragments will interfere with the analysis. Moreover, 
misincorporation may occur during the PCR, producing extra background bands in the DGGE. 
Although this varies from template to template and depends on the PCR conditions, it has been 
estimated to occur at the rate of 0.25% in a 30 cycle PCR using Thermus aquaticus (Taq) DNA 
Polymerase (Saiki et al., 1988a). It must be mentioned that the synthesis of these long primers 
with GC-clamps adds to the cost of this technique.
Like the previously mentioned techniques DGGE analysis can neither reveal the type of the 
mutation nor its exact location. Therefore unless solely used for linkage analysis it needs to be 
complemented with DNA sequencing (Cariello et al., 1988; Myers et al.,1989).
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2.2.5. RNase cleavage analysis.
Single base changes in DNA can be detected by cleavage of mismatches in RNA:DNA 
duplexes with the enzyme RNase (Myers et al.,1985d; Winter et al., 1985; Gibbs and Caskey
1987). This is done by mixing a uniformly labelled ssRNA probe with double-stranded test 
DNA. The ssRNA probes are synthesized as run-off transcripts from cloned DNA templates 
while the source of test dsDNA can either be from genomic, cloned or PCR amplified products. 
The RNA:DNA mixture is heated to melt the DNA strands. This is then followed by an 
annealing reaction whereby the labelled RNA probe is allowed to anneal with its complementary 
strand in the test DNA fragment forming an RNA:DNA duplex. The presence of any base 
changes in the test DNA will cause base mismatches in the RNArDNA duplex. The annealed 
mixture is then treated with the enzyme RNase A to cleave the RNA strand at the mismatched 
sites. After the cleavage reaction, the duplex is treated with denaturants to separate the strands 
and then run on a denaturing gel to separate the RNA fragments according to their sizes and 
visualized by radioautography. This procedure can efficently detect 30 to 40% of all possible 
mismatches in the RNA:DNA duplexes. The detection rate can however, be improved to detect 
up to 60 to 70% of the possible base changes, by testing a DNA fragment with each of its two 
corresponding labelled RNA probes in separate cleavage reactions (Meyer et al., 1985d). This 
method is most suitable for screening DNA fragments between 100 and 1000 bp long. Fragments 
longer than 1000 bp are difficult to screen because of random cleavages which occur even in 
perfectly matched bases and may be numerous enough to interfere with the results. Moreover, 
analysis of such long RNA fragments requires the use of denaturing agarose gels (Meyers et al.,
1988). Therefore, the most obvious limitation of this method is that it cannot detect all possible 
mismatches. Furthermore, the method requires extra cloning for probe production and that the 
screening is limited to DNA fragments of up to 1000 bp only.
2.2.6. Chemical cleavage of mismatch (CCM) detection.
CCM, also known as amplification and mismatch detection (AMD), had been developed to 
screen for point mutations but can also be used for the detection of deletions and insertions that 
are otherwise too small to be demonstrated by ordinary gel electrophoretic techniques. The 
method is based on the formation of heteroduplexes between wild-type and mutant DNA or RNA 
molecules. Any base changes in the mutant molecules will create mismatches in these 
heteroduplexes. When chemically modified, the mismatched bases become sensitive to cleavage 
with piperidine and their positions can then be located by running the samples in denaturing 
polyacrylamide gels (Cotton et al., 1988; Cotton and Campbell, 1989; Montandon et al., 1989).
In the method, reference DNA probe is mixed with excess test DNA or RNA, and the mixture 
heated to cause strand separation, then cooled to allow reannealing and hence heteroduplex 
formation in which mismatched or unmatched base pairs occupy the mutation site. The probe is 
then modified at the mismatched C or T base by reacting with hydroxylamine or osmium 
tetroxide respectively and subsequently cleaved by piperidine treatment. The samples are finally 
run on denaturing polyacrylamide gels similar to sequencing gels, to locate the site of cleavage 
and hence the mutation (Cotton, 1989). As mismatched A or G bases are transposed to 
mismatched T and C respectively, they should be detectable by the probe of the opposite strand. 
Moreover, matched bases adjacent or close to mismatched or unmatched bases become reactive 
by transmission of the distortion, thus indirectly allowing mutation detection (Cotton et al., 1988; 
Cotton 1989). This also enables detection of insertions (Cotton 1989). Deletions are also 
detectable because of the reactivity of unmatched C and T bases. Therefore, one of the strong 
points of this method, is its potential ability to detect all classes of point mutations. (Grompe et 
al., 1989).
This PCR-based technique can be performed by using either uniformly labelled or end labelled 
probes. Either of these can be used when the investigated DNA or RNA fragment is expected to 
have a single mutation in the whole region covered by the probe. However, in the case where 
multiple mutations are expected, it is advisable to use end labelled probes as they will generate a
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single specific band for each reactive C or T base. CCM analysis is therefore useful in screening 
for mutations by not only demonstrating the site but also the base changes. The method has been 
used successfuly in scanning DNA segments of up to 1200 bp, localizing mutations to within 30 
bp (Grompe et al., 1989). Therefore, unlike all other methods mentioned above, CCM analysis is 
able to predict the site and nature of mutations. In addition, it is not affected by misincorporation 
of bases due to the infidelity of Taq DNA Polymerase or reverse-transcriptase used in PCR or 
cDNA synthesis, as both the probe and test DNA would represent a population of PCR products 
in which alterations would be randomly distributed through out the sequence (Grompe et al.,
1989). It should however, be emphasised that CCM analysis is merely a screening method 
developed to circumvent the need to sequence large fragments of DNA in search of unknown 
mutations. With this technique it is therefore, possible to limit DNA sequencing to the regions 
around the mismatched sites with the added high degree of confidence that the detected changes 
are genuine rather than artefacts. Once a mutation has been detected and characterized by DNA 
sequencing, subsequent detection in individuals, families or populations should be carried out 
using other simpler mutation detection methods such as oligonucleotide hybridisation (Grompe 
etal., 1989; Cotton 1989). The main disadvantage of this procedure is that it requires the use of 
very toxic chemicals and a complex protocol.
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2.2.7. Allele specific oligonucleotide hybridisation.
In this method, oligonucleotides specifically constructed to recognize wild-type or mutant 
alleles are labelled with a radioisotope and used as probes. Under very stringent conditions, such 
probes will only hybridise to their perfectly homologous sequences and not to those that vary 
even by a single nucleotide residue. Thus a normal gene can be detected using the wild-type 
probe and the mutant gene with the probe containing the same mutation (Studencki and Wallace.,
1984). In practice, for the routine analysis “dot-blot” filter hybridisation is used and detection is 
done by radioactive probes (Saiki et al., 1986), though biotinylated and enzyme-labelled probes 
can be used as well (Bugawan et al., 1988; Saiki et al., 1988b; Lo et al., 1988). This method also 
allows simultaneous amplification and analysis of multiple polymorphic sites by using ASO 
probes of identical length and tetramethylammonium chloride (TMAC1). When washed in 3 M 
TMAC1, perfectly matched oligonucleotides of the same length tend to dissociate from the 
hybridised test DNA sample at the same temperature thus leaving behind the mismatched probes 
(Wood et al., 1985; Kogan et al.,1987). Alternatively a “reverse dot-blot” procedure can be used 
in which the oligonucleotide probe is immobilised on a membrane and hybridised to labelled 
PCR products (Saiki et al., 1989b). In this method a panel of different probes can be used to 
screen simultanously for several mutations in a given PCR product.
There are, however, some limitations associated with ASO hybridisation analysis. Firstly, as a 
prerequisite for the oligonucleotide hybridisation analysis, the mutations to be studied need to 
have been precisely defined previously. Secondly, in many autosomal dominant disorders the 
mutations tend to be unique to each family thus limiting the usefulness of each probe to a 
particular family.
2.2.8. Amplification refractory mutation system (ARMS) analysis.
The amplification refractory mutation system analysis has been developed for the detection of 
known mutations in genomic DNA. The method entails PCR amplification of the target DNA 
with a normal or mutant primer and a common end primer. The normal and the mutant primer 
differ at their 3’ ends by only a single base which corresponds to the normal and mutant alleles 
(Newton et al., 1989). The technique is based on the concept that template amplification through 
PCR in which one of the amplification primers is mismatched at the 3’ end is not possible. This 
is attributed to the lack of a 3’ exonucleolytic proof-reading activity of Taq DNA polymerase 
(Tindall and Kunkel, 1988). The technique is performed by amplifying a test DNA with a mutant 
amplification primer and a common primer. As a control, internal primers are added in the same 
reaction. Similarly, another set of reaction is performed using normal and common primers. In 
the same way as before, as a control reaction, internal primers are also added to this reaction. 
After PCR amplifications, the products are size fractionated in agarose gels and visualised after 
staining with ethidium bromide. With a normal sample, amplification will only be positive in the 
reaction with the normal and the common primer as well as with the control internal primers but 
not in the reaction containing the mutant primer. On the other hand, both the mutant and the 
normal primers when used with the common end primer will show positive amplifications of 
samples which are heterozygous for the mutation being investigated, whereas no amplification 
will be seen in homozygous mutant samples amplified with normal primers. This technique is 
therefore, rapid, non-isotopic and can distinguish heterozygotes from homozygotes. The method 
is, however, limited to the investigation of mutations that have already been characterised or 
those that are linked to a characterised polymorphism. As a means of direct detection of 
mutations, this technique is therefore useful only in the tracking of known mutations within 
family members in much the same way as ASO.
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2.2.9. D irect genom ic sequencing.
Almost without exception, the complete characterization of any mutation depends on 
sequencing, as this will determine the exact variation and its position in the gene (Cotton, 1989). 
The two most popular techniques of genomic sequencing are based on the chemical method 
developed by Maxam and Gilbert (1977) and the enzymatic method of Sanger et al., (1987). In 
the Maxam and Gilbert method, the DNA is cleaved into fragments which are then radioactively 
labelled at one end, and subsequently divided up into four batches, each of which is treated 
differently by chemicals to modify a particular base or bases resulting in very small DNA 
fragments, some of which will be end-labelled. The fragments are then resolved in denaturing 
polyacrylamide gels resulting in base specific bands on autoradiography. The Sanger method, on 
the other hand is an in v/VroDNA synthesis in which the growing chain of the DNA synthesised 
is stopped randomly at frequent points leading to numerous fragments. The DNA synthesis starts 
at one site where the sequencing primer anneals to the template and is facilitated by DNA 
polymerases in the presence of deoxynucleoside triphosphates (dNTPs). The synthesis is 
terminated by the incorporation of dideoxynucleoside triphosphates (ddNTPs) present in the 
mixture. Dideoxynucleoside triphosphates bring about this termination because they lack the 3’- 
hydroxyl residue necessary for chain elongation. With the right mixtures of dNTPs and each of 
the ddNTPs, the polymerisation will terminate at each point of ddDNTP incorporation, thus 
giving full sequence information. To enable interpretation of the results a radioactively labelled 
nucleoside is included in the synthesis, so that labelled chains of various length can be visualized 
by autoradiography following separation in denaturing polyacrylamide gels. Of the two methods, 
Sanger’s method popularly known as dideoxy sequencing is the most widely used. This method 
is diagrammatically represented in figure 3, using sequencing of the PBG-D cDNA to illustrate 
the principles involved. The illustration represents an actual sequencing of the PBG-D cDNA 
anti-sense strand of a control subject in whom the junctional region around exons 12 and 13 was 
sequenced with primer R4.
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EXON 12 /  EXON 13
ssPBG-D cDNA 3 ' — / / - - - - - - - - - - - - - - G A G G A A G G T C C A C --- - - - - - J  f.- - - - - - - 5 1
SEQUENCING PRIMER R4 5  ‘ » C T C
I
T7 DNA POLYMERASE (SEQUENASE) OR Taq DNA POLYMERASE IN THE PRESENCE OF:
T C G A
dCTP dCTP dCTP dCTP
dGTP dGTP dGTP dGTP
dTTP dTTP dTTP dTTP
U - 35SldATP [<? -3^S]dATP [^-35SldATP [*-35SldATP 
ddTTP ddCTP ddGTP ddATP
I I  I 1
9.5'aCTCCTTCCAGGddT 10. 5 ,-CTCCTTCCAGGT^///T
8. 5'-CTCCTTCCAGrtftT 
7. 5'-CTCCTTCCA4M?
5. 5'»CTCCTTC^//^ 6 . 5 CTCCTTCC/////7
3.5'mClCCWi/r l |. 5'mClGCTTddd
2.5,-CTCCddT 1. 5'»CTCddC
I__________________________________________________________
I
GEL ELECTROPHORESIS AND AUTORADIOGRAPHY 
1
PRIMER SYNTHESISED PBG-D cDNA 
10. S'-CTCCTTCCAGGTt/t/^
9. S'-CTCCTTCCAGGj/w/A 
8. S'-CTCCTTCCAGflW 
7. 5'b CTCCTTCCA^^
6 .  5 ' " C T C C T T C C / / ^
S.S'mCICCTlCddC 
i|. 5'»CTCCTT^i1C
3. 5'»CTCCTddT ~-
2. 5'-CTCCddT 
1. S'-CTCddC
FIGURE 3: DIAGRAMMATIC REPRESENTATION OF THE DJDEOXY-MEDIATED SEQUENCING METHOD.
THE NUMBERS ON THE I f lT  REPRESENT THE ORDER IN WHICH EXTENSION-TERMINATION REACTIONS TAKE PUCE IN THE 
GROWING CHAIN OF THE SYNTHESISED DNA OR cDNA. THE UST G BAND AT THE 5' (TOP) END OF THE GEL CORRESPONDS 
TO NUCLEOTIDE 776 IN WHICH A C TO A TRANSVERSION HAS BEEN DETECTED IN AN AIP PATIENT IN THIS STUDY.
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The main drawback of genomic sequencing, no matter how comprehensive and definitive it 
may be, is that it is a labour intensive procedure. This is especially so when used for 
characterisation of unknown mutations in long DNA segments. The advent of PCR and 
subsequent direct sequencing of the PCR products has to a great extend reduced the time and 
labour required in RNA or DNA sequencing. Direct sequencing as opposed to conventional 
sequencing based on cloning, is faster, simpler and more reliable since for each sample, only a 
single sequence needs to be determined. This is based on the fact that it virtually abolishes 
potential errors due to Taq DNA polymerase infidelity in the amplification process since such 
errors would not be detectable against the much greater signals of the consensus sequence. 
Moreover it is amenable to automation because being an in vitro method it is independent of any 
cultured organisms (Gyllensten, 1989; Gibbs et al., 1989).
There are two main approaches to direct sequencing of PCR products. Hie first is based on a 
method of sequencing dsDNA as produced by a standard PCR and involves a denaturation step 
of boiling or alkaline treatment prior to annealing of the template with die sequencing primer 
(Wrishchnick et al., 1987; Higuchi et al., 1988a; Newton et al., 1988; Gyllensten 1989). In the 
heat denaturation method, the template is melted by boiling in the presence of the sequencing 
primer and the mixture snap frozen at -70°C. To prevent renaturation, the sequencing reaction is 
then done immediatly following die shortest possible annealing stage. Although the annealing 
step seems to be very crucial in direct sequencing of PCR products, there have been very few 
attempts at its optimimisation prior to the work of Casanova and co-workers (1990). 
Recommended durations, incubation temperatures and the template:primer ratios for the 
annealing step seem to vary from author to author (Wrischnik et al., 1987; Newton et al., 1988; 
Higuchi et al., 1988; Kretz et al., 1989; Winship 1989). For optimum results it is, however, 
recommended to perform the primer-template annealing by first denaturing the template in the 
presence of the primer at 100°C for 2 min and then immediately freeze at -70°C, for 15 to 45 
seconds using a primentemplate ratio of approximately 1:20 (Casanova et al., 1990). Alkaline 
denaturation of PCR products prior to primer-template annealing is based on methods that have
annealing is based on methods that have been developed for the sequencing of supercoiled 
plasmid DNA (Chen and Seeburg, 1985; Hattori and Sakaki, 1986; Lim and Pene, 1988; Saiki et 
al., 1988c; Hsiao, 1991). The DNA template is denatured by incubation in NaOH at 37°C., for 30 
minutes, neutralized with sodium acetate or HC1, then precipitated and washed in alcohol. The 
DNA pellet is finally dissolved in an appropiate volume of either water or TE buffer ready for 
annealing to the sequencing primer. Alkaline denaturation of ds templates has been claimed to be 
superior to the heat denaturation method (Chen and Seeburg, 1985). Sequencing of ds PCR 
products is, however, not invariably satisfactory because of the fact that short linear PCR 
products tend to reassociate very rapidly thus preventing primer-template annealing or extension 
(Kreitman and Landweber, 1989).
One way of improving the quality of dsPCR sequencing is by using 5’ end-labelled sequencing 
primer. Unfortunately this entails the use of 32P-label, sacrificing the safer 35S with its superior 
resolution. Moreover, the kinasing reaction necessary for end labelling introduces an additional 
enzymatic step (Kreitman and Landweber, 1989). Finally, a new method of sequencing dsPCR 
products with Taq DNA polymerase in cyclic reactions has been described (Lee, 1991b). This 
method which combines the techniques of PCR and dideoxy sequencing, involves performing 
cyclic sequencing reactions on PCR products in a thermal cycler in the presence of excess 
amounts of sequencing primer and a radioactive isotope such as (a-35)S d ATP. The repeated 
cyclic reactions performed in this method enables good sequencing ladders to be generated from 
minute template quantities. The method also obviates the need for denaturation of the double­
stranded templates (Lee, 1991b) and additionally, the use of Taq DNA Polymerase in 
sequencing, allows high annealing and extension temperatures which is beneficial for some 
templates, especially those with strong secondary structures (Innis et al., 1988). Despite these 
improvements sequencing of dsPCR products remain problematic and to alleviate this a second 
approach based on sequencing of ssPCR products has been developed.
Several methods of generating ssPCR templates for sequencing have been described. These 
include methods that preferentially produce ss template in the PCR as well as those that at first
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produce dsPCR products which are subsequently manipulated to generate ss templates. Single­
stranded PCR products are produced by a method that has come to be known of as asymmetric 
PCR (Glyllesten and Erlich, 1988; Saiki et al., 1988c; Kreitman and Landweber, 1989). 
Asymmetric PCR is performed by using unequal amounts of amplifying primers at a ratio of 
between 50-100:1, in otherwise unchanged amplification parameters. During the first 20 to 25 
cycles this will generate ds products in the usual manner, but following the inevitable exhaustion 
of the limiting primer, the subsequent products will be single stranded complementary to the 
limiting primer. The production of the ss template is not as efficent as dsPCR but nevertheless is 
sufficient for direct sequencing (Saiki et al., 1988c). Alternatively ss templates can be generated 
by at first performing the standard dsPCR, followed by ethanol precipitation and then 
reamplification of the products using only one of the amplifying primers, thus by default making 
the absent primer limiting. In both cases, the generated ss template is then sequenced using either 
the limiting primer or a nested (internal) primer complementary to the template.
Single-stranded templates suitable for sequencing can also be prepared by removal or 
separation of one of the strands produced by the normal dsPCR. Several methods have been 
developed to achieve this, ranging from physical separation to enzymatic or chemical reactions. 
Strand separation and the subsequent DNA sequencing has for instance been accomplished by 
using biotinylated primers and magnetic beads (Schofield et al., 1989; Hultman et al., 1989). In 
this method one of the amplifying primers is biotinylated at the 5’ end. After amplification, the 
amplified product is mixed with magnetic beads to bind the biotinylated strand. The non- 
biotinylated strand is then eluted with alkali to yield the ssDNA template immobilised at the 5’ 
end, to be used in solid phase sequencing.
Another approach to preparing ss templates is through enzymatic digestion of one of the strands 
whilst protecting the other. One of such methods is based on the ability of 5’-0-(l- 
thiotriphosphates) to block the nucleolytic action of exonuclease III when incorporated into 
substrate DNA (Putney et al., 1981). In this procedure the PCR amplification products are 
thiolated using Klenow Polymerase and then cleaved with a restriction enzyme to produce
asymmetrically protected fragments. Finally, the cleaved products are digested to completion 
with exonuclease III which will only digest the unprotected strand (Ward et al., 1989). 
Alternatively, single-stranded templates can be derived from dsPCR products by chemical 
means. Nakamaye and co-workers (1989) have described a method based on the incorporation of 
deoxynucleotide analogues carrying a phosphorothioate substitution in the a-position (dNTPaS) 
during PCR. The phosphorothioate-containing DNA is subsequently chemically cleaved by 
alkylating agents such as 2,3-epoxy-1-propanol or 2-iodoethanol. In the method, four separate 
PCRs are performed each with a different dNTPtf S and the radioactive label being introduced in 
a strand specific manner by either 5’ end-labelling of one of the primers or by labelling the PCR 
products. In the latter method, amplification is carried out with only one of the primers being 
phosphorylated. At the end of the PCR, the non-phosphorylated primer will then be able to 
accept radioisotope through its free 5’-end hydroxyl group. To sequence the opposite strand a 
second round of PCR amplification is done in which the phosphorylation or end labelling of the 
primer is reversed (Nakamaye et al., 1988).
Alternatively, following dsPCR, one of the strands may be made suceptible to enzyme digestion 
with lamda-exonuclease by phosphorylating its 5’ end (Little et al., 1967). To facilitate this one 
of the amplifying primers is either synthesized with a 5 ’ terminal phosphate or is kinased prior to 
the PCR. At the end of the PCR amplification, the products are digested with lamda-exonuclease, 
a 5’ to 3’ nuclease which attacks dsDNA only when there is a 5’ terminal phosphate. This would 
therefore, digest the strand derived from the phosphorylated primer leaving behind the opposite 
strand suitable for sequencing (Higuchi and Ochman, 1988).
Direct sequencing of PCR products can also be done through the incorporation of phage 
promoters onto the PCR products. This has been done for the sequencing of both DNA and RNA 
templates (Stoflet et al., 1988; Sarkar and Sommer, 1988; Sarkar and Sommer, 1989). It is 
achieved by attaching phage promoter sequences onto at least one of the amplification primers.
In the direct genomic sequencing, the segments amplified by PCR are transcribed to provide 
single-stranded templates for reverse trascriptase-mediated sequencing. The transcription
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reaction besides providing single-stranded templates, also increases the sensitivity of the method 
by augmenting the PCR amplification and in deed at times, may compensate for a sub-optimal 
PCR amplification. With slight modification this method has been used to directly sequence 
amplify RNA segments. At first cDNA is synthesized with either oligo(dT) or an mRNA specific 
oligonucleotide primer and then amplified by PCR, in which at least one of the amplification 
primers contains a phage promoter attached to a sequence complementary to the region to be 
amplified. The PCR products are subsequently transcribed with the phage promoter and the 
transcripts used in reverse transcriptase-mediated dideoxy sequencing using nested primers 
(Sarkar and Sommer, 1988,1989). Use of phage promoters in the sequencing of either DNA or 
RNA has the advantage of producing a second round of amplification through the transcription 
reaction obviating the need for purification of the PCR products. It also provides up to a 
billionfold amplification, enabling detection of mRNAs present at less than one copy per cell 
(Sarkar and Sommer, 1989). Phage incorporation however increases the cost of amplifying 
primers especially when both strands need to be sequenced. Moreover, the need to use reverse 
transcriptase for sequencing, precludes the use of other sequencing enzymes.
Single-stranded templates can also be prepared from dsPCR products by removal of a 
complementary strand with ssDNA of an M 13 clone (Gal and Hohn, 1989). The procedure 
requires the cloning of one variant of the sequence into an M 13 vector to be used in all 
subsequent sequencing of the related DNA segments. Excess of this M 13 ssDNA is added to the 
dsPCR products to remove its complementary strand, thus allowing the sequencing primer to 
anneal to the single-stranded template thus generated. The usefulness of the cloned ssDNA in 
this procedure is limited to the particular DNA segment for which it was tailored. In addition 
both the amplification and the sequencing primers must be located outside the cloned region so 
as to have no homology with the M 13 ssDNA.
Double-stranded PCR productcs can also be directly cloned into M 13 vectors. To facilitate this, 
primers are constructed in such a way as to include suitable restriction sites (linkers) near their 5’ 
ends. These 5’ tails as mentioned before, do not seem to interfere with PCR amplification. After
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amplification the PCR products are cleaved with the appropriate restriction enzymes, dialysed to 
remove inhibitors of ligation and ligated into the M 13 vectors. Unlike standard cloning 
protocols, cloning of PCR products circumvents the construction and screening of full genomic 
libraries. In addition it allows sequencing from nanogram amounts of DNA (Scharf et al., 1986). 
The main disadvantage of the procedure as mentioned earliear, is the need to sequence several 
clones, firstly to ensure the sequencing of both alleles and secondly to distinguish changes that 
may arise from the infidelity of Taq DNA Polymerase used in the PCR amplification.
The presence of many different procedures for the direct detection of mutations indicates that 
currently there is not a single method suitable for all methods. The choice of the method to be 
used will depend on the length of the DNA to be analysed, type of mutations and the purpose of 
the test. The approach to detection of mutations in a long DNA fragment with unknown number 
of mutations will obviously be different from that of a short fragment with a known single base 
change. Similarly, a choice of method needed for the characterisation of unknown mutations, by 
necessity, needs to be different from a mere screening test or a test needed for confimation of an 
already known mutation. Evidence is now emerging that characterisation of unknown mutations 
in a large gene would require a combination of at least two of these methods. A sound strategy 
would for example, be to scan such a gene by means of CCM analysis and then characterise the 
mutations by direct sequencing of the affected regions. For subsequent detection of these 
mutations in families of the affected individuals, a simple method like ASO analysis by dot blot 
hybridisation or ARMS analysis can then be used (Cotton, 1989). In a small gene, however, it 
may be possible and even advisable to characterize all mutations cost effectively by direct 
sequencing alone.
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2.3. Application of methods of mutation detection in acute 
intermittent porphyria.
Acute intermittent porphyria is an autosomal dominant disorder caused by reduced activity of 
porphobilinogen deaminase (PBG-D, EC4.1.3.8) the third enzyme in the heme biosynthetic 
pathway. PBG-D catalyses the condensation of four porphobilinogen monomers to form 
hydroxymethylbilane (preuroporphobilinogen), a linear tetrapyrole, prior to cyclisation to 
uroporphyrinogens I or III (Battersby et al., 1980). The deficiency of PBG-D activity causes 
reduction in heme synthesis and increased activity of amninolevulinic (ALA) synthase, since the 
later is under negative feedback control by heme. The combination of increased ALA synthase 
activity and the partial enzymatic block, leads to the accumulation of the porphyrin precursors, 
delta-aminolevulinic acid and porphobilinogen which being highly water soluble are excreted in 
urine, particularly during acute attacks and tend to decrease with the clinical improvement 
(Tschudy et al., 1975). Most carriers of the AIP gene (approximately 90%) however, do not 
demonstrate excess urinary excretion of delta-aminolevulinic and porphobilinogen and remain 
clinically latent (Kappas et al., 1983).
Using mouse-human clones, Meisler et al. (1980, 1981) showed that PBG-D is determined by a 
gene in chromosome 11 and Wang et al., 1981) assigned the locus to the long arm in the region 
llq23-qter. This was supported by de Vemeuil et al. (1982) who studied the dosage effect in 
three children with trisomy llqter and confirmed the assignment to region llq23.2-llqter. The 
PBG-D gene measures 10 kb in length and is split into 15 exons (Raich et al., 1986). It is 
transcribed into two distinct mRNAs through alternative splicing of two primary transcripts 
arising from two promoters located approximately three kilobases apart. The upstream promoter 
with a housekeeping function is active in all cells, whereas the downstream promoter is active 
only in erythroid cells (Chretien et al., 1988). The 5’ terminal segment of the ubiquitous PBG-D 
mRNA is transcribed from exon 1, which lies 3.1 kb upstream from the common region of the 
two mRNAs. Thus in the ubiquitous (housekeeping) mRNA, the primary transcript is spliced so 
that exon 1 is linked to exon 3 as shown in figure 4. In contrast, the 5 ’ terminal segment of the
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erythroid PBG-D mRNA is transcribed from exon 2, which lies 2.9 kb 3’ to exon 1 and 175 bp 
upstream from exon 3. The primary transcript is then spliced and joined in such a way that exon 
2 is joined to exon 3 without exon 1 (Chretien et al., 1988. It has been deduced that the protein 
sequence of the two isoforms of the PBG-D, differ by the presence of an additional stretch of 17 
amino acid residues at the amino terminus of the non-erythroid form (Grandchamp et al., 1987). 
This rpay also explain the difference in their molecular weights, whereby the erythroid PBG-D is 
40 kDA whilst the non-eryrthroid PBG-D is 42 kDA (Lannfelt et al., 1989). The reading frame 
of the non-erythropoid PBG-D gene is 1083 bp long and encodes 361 amino acid residues 
whereas the erythroid form encodes 344 residues (Grandchamp et al.,1987).
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Structure of the human PBGD gene. The exons and introns are drawn to scale. Dashed boxes represent untranslated regions.
Figure 4 : Structure o f human PBG-D gene.
(From Chretien et al., 1988). Alternative splicing of the PBG-D gene for erythroid and non- 
erythroid mRNA is indicated. PH stands for the housekeeping promoter and PE the erythroid 
promoter. The non-coding regions of the erythropoietic cDNA comprise 81 bases at the 5’ end 
preceding the initiation methionine codon, and 267 bases at the 3’ end followed by 14 bases of 
the consensus poly(A)+ additional signal and poly(A)+ tail respectively (Lee, 1991a).
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Acute intermittent porphyria occurs in all races, though the actual prevalence in each is not 
known and seem to variable in different communities. The highest prevalence is in Lapland, 
Northern Sweden where it has been estimated as 1/10,000. The general prevalence in subjects of 
European stock is, however, estimated at 1/20,000 (Goldberg et al., 1987).
Acute intermittent porphyria is a heterogeneous disorder as has been demonstrated by 
immunological methods, whereby four different forms of PBG-D deficiency have been 
delineated (Mustajoki and Desnick, 1985). These different classes of AIP have been identified on 
the basis of presence and amounts of the immunological cross-reactive enzyme protein 
commonly referred to as cross-reactive immunological material or CRIM. The majority of AIP 
gene carriers (approximately 85%) are CRIM-negative and the remaining 15% are CRIM 
positive (Anderson et al., 1981; Desnick et al., 1985). The CRIM-negative group is further 
subdivided into two types depending on the erythrocyte PBG-D activity, whereby in CRIM- 
negative type 1 there is half the normal and in type 2, normal activity. Similarly, the CRIM 
positive group is divisible into two types. CRIM-positive type 1 consists of individuals with a 
CRIM/PBG-D activity ratio of 1.6 and type 2 with a ratio of 5.6. This suggests that in CRIM- 
positive type 2 there is a greater formation of the inactive enzyme protein. Within affected 
families, each member has the same CRIM reaction and type. Although it has been postulated 
that CRIM-positive type 2 is associated with a milder form of AIP (Mustajoki and Desnick
1985), no systematic evaluation of severity of this condition in relation to the CRIM phenotype 
has been made. Furthermore, the heterogeneity of the molecular pathology seem to be more 
complex than this, since the same CRIM phenotype and subtype may be caused by different 
mutations of the PBG-D gene. Theoretically, it would seem logical that, nonsense, deletions and 
frame-shift mutations which generate premature stop codons and therefore truncated and 
unstable proteins would be associated more with CRIM-negative phenotype. In contrast, CRIM- 
positive phenotype would be expected to be associated more with missense mutations, since 
these are likely to produce a kinetically defective protein differing from PBG-D by only a single 
amino acid. In practice, this has not strictly proved to be the case. Among the three CRIM
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positive mutations that have been reported to date, two are of the missense type with the 
substitution of arginine to glutamine (Delfau et al., 1990) and the other is a splice defect which 
leads to the skipping of exon 12 which encodes for 40 amino acid residues (Grandchamp et al., 
1980c). CRIM-negative mutations have proved to be more heterogenous as none of the several 
mutations described in this group, has so far been reported in more than one or two index 
families. Molecular pathology which cause CRIM-negative phenotypes include, splice site 
mutations (Grandchamp et al., 1989a, 1989b), missense mutations (Lee et al., 1990, Nordmann et 
al., 1990; Delfau et al., 1991), nonsense mutations (Scobie et al., 1990; Lee and Anvret, 1991a; 
Delfau et al., 1991), a frame-shift mutation and a nine base deletion (Nordmami et al, 1991).
The clinical course and natural history of AIP is very variable. Patients with manifest disease 
may suffer periodic attacks with normal intervals between. The frequency of attacks varies 
markedly with some having very few attacks, while others may have regular episodes sometimes 
with hardly any remissions. The severity of attacks also vary widely; from mild episodes of 
abdominal discomfort to fulminant attacks with fatal outcome. In addition, clinical 
manifestations of acute attacks also vary between individuals and even in the same individual 
from one attack to another. Commonly gene carriers in AIP, remain asymptomatic unless 
exposed to precipitants which include certain drugs (Tschudy et al., Kappas et al 1983), alcohol, 
calorie restriction (Felsher and Redeker 1967), infections (Dudzinski and Weinstein 1984) and 
endocrine factors (Levit et al., 1957; Welland et al., 1964). These can result in neurovisceral 
crises with abnominal pain, vomiting, mental dysfunction and peripheral neuoropathy. The latter 
occurs in two-thirds of acute porphyric attacks and may result in permanent disability or be fatal 
if the respiratory muscles become involved (Goldberg, 1959; Stein and Tschudy, 1970; Becker 
and Kramer 1977). Identification of gene carriers within these families and counselling about 
avoidance of precipitants is thus of central importance to the management of this condition. 
Symptomatic patients excrete large amounts of delta-aminolevulinic acid and porphobilinogen in 
their urine and often have reduced levels (to approximately 50% of normal) of porphobilinogen 
deaminase in erythrocytes. Accurate identification or exclusion of carrier status by conventional
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biochemical methods is however not always possible (Bonaiti-Pellie et al., 1984; Pierach et al., 
1987; Kauppinen et al., 1990). Asymptomatic carriers for instance do not consistently excrete 
abnormal amounts of porphyrins or the porphyrin precursors, delta-aminolevulinic acid and 
porphobilinogen (Kappas et al., 1983). Moreover, determination of the erythrocyte PBG-D 
activity may not always be reliable or conclusive as there is an overlap between the normal and 
the affected, whereby up to 20% of then affected individuals may have normal activity (Lammon 
et al., 1979; Pierach et al., 1987). PBG-D activity may also be affected by the presence of other 
diseases. The activity is for instance reduced in uremia (Andriola et al., 1980), chronic 
polyarthritis (Blum et al., 1978) and increased in haemolytic disorders (Anderson et al 1977), 
hepatic diseases (Blum et al., 1978) and haematological malignancies (Epstein et al., 1983). 
PBG-D activity is also raised in the neonatal period (Hughes and Rifkind 1981). In addition there 
is a group of AIP patients with normal erythrocyte PBG-activity (Desnick et al., 1985; 
Grandchamp et al, 1989a; Grandchamp et al., 1989b). Therefore, molecular analysis offers an 
alternative approach to carrier detection.
Three PBG-D intragenic DNA polymorphisms are available for gene tracking within affected 
families (Llewellyn et al., 1987; Lee et al., 1988; Kauppinen et al., 1990). This can be used in 
conjuction with biochemical carrier detection and appears to be more reliable. For example, in 
the study of Kuappinen et al. (1990), of the 62 persons at 1 in 2 risk, 30 were shown to have 
inherited the disease-linked haplotype yet five of these had normal results on biochemical testing 
and in a further patient the result was equivocal. This approach is, however, limited by the need 
to study multiple key family members some of whom may be deceased or otherwise unavailable 
as mentioned earlier.
RNase protection assays have been used to study the molecular pathology of the PBG-D gene.
In their study Llewellyn et al. (1988) reported a deletion in which exon 13 was suspected to have 
been skipped. Direct sequencing of PCR-amplified material has been attempted for the 
characterisation of mutations in AIP but without much success (Grandchamp et al., 1989b). Most 
of the known mutations in AIP to date have been determined through sequencing of cloned PCR
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amplified cDNA in association with ASO hybridisation by ‘dot-blot’ analysis. The described 
mutations include splicing defects in exon 1 (Grandchamp et al., 1989a), intron 1 (Grandchamp 
et al., 1989b), exon 12 (Grandchamp et al., 1989c), exon 10 (Delfau et al., 1991) and a stop 
codon mutation in exon 9 (Scobbie et al., 1990a) all being caused by single base substitutions. 
Other single base substitutions with subsequent amino acid changes have been described in exon 
8 (Lee et al., 1990), and in exons 9, and 12 (Nordmann et al., 1990, Delfau et al., 1991). The 
majority of these mutations, totalling five, have in fact been reported in exon 10 (Delfau et al., 
1990; Nordmann et al., 1990; Lee et al., 1991; Delfau et al., 1991). Finally a T deletion in exon 
14 causing a frame shift of a stop codon has been described (Nordmann et al., 1990; Delfau et 
al., 1991). The diversity of these mutations confirms the heterogeneity of this condition. This is 
further underscored by the fact that virtually all mutations described todate have been unique to 
the original family of detection. Exception to this, are two G to A mutations at nucleotide 
positions 500 and 518 in exon 10 (respectively).
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2.4. Aims of the present study.
The main aim of this study was to develop a method of direct genomic sequencing of PCR 
amplified templates for the detection and characterisation of molecular pathology in monogenic 
disoders and apply the method to investigate the porphobilinogen deaminase gene in patients 
with acute intermittent porphyria.
Specific aims of the study were:
2.4.1. To extract total cellular RNA and synthesise
non-erythroid PBG-D cDNA.
2.4.2. To optimise and evaluate different methods of R-T PCR
amplifications of the non-erythroid PBG-D cDNA.
2.4.3. To compare different methods of purifying PCR amplified
templates and determine the most cost-effective method.
2.4.4. To develop protocols for the direct sequencing of PCR
amplified products.
2.4.5. To evaluate the efficacy of different methods of direct
sequencing of PCR amplified templates.
2.4.6. To characterise mutations that cause AIP by direct
sequencing of the PCR amplified PBG-D cDNA.
2.4.7. To determine the significance of these mutations and
compare them to those that have been reported in the 
literature.
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CHAPTER THREE: METHODOLOGY.
3. PATIENTS, MATERIALS AND METHODS.
3.1. Patients and controls.
Families with biochemically confirmed AIP were identified through the records of the 
Porphyrias Research Unit at the Western Infirmary, Glasgow. After obtaining appropiate 
consents from both the patients and their general practitioners, blood samples were collected and 
immortalised lymphoblastoid cell line established. Controls were randomly selected from 
individuals who presented with problems other than AIP. The first thirty patients with AIP, two 
of whom were related and ten control subjects were included in the study. Diagnosis of ATP was 
based on increased excretion of delta-aminolevulinic and porphobilinogen in urine and decreased 
activity of erythrocyte PBG-D coupled with a clinical history of one or more acute attacks 
(Moore et al., 1987). Clinical assessement was made according to the methods given by McColl 
et al (1986). Porphyrins in urine and faeces were measured by the method of Moore (1983) and 
the erythrocyte PBG-D activity according to Piepkotn et al (1983). The mean erythrocyte PBG-D 
activity in the AIP patients was 22.3 nmol/h/ml erythrocytes, ranging from 11.7 to 24.7 
nmol/h/ml erythrocytes. The normal adult activity range for the enzyme is 25-42 nmol/h/ml 
erythrocytes in females and 30-48 in males.
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3.2. Total cellular RNA extraction.
In the handling of RNA, proper precautions were observed at all the times to avoid 
contamination with RNAases. Glassware and plasticware used for the preparation and storage of 
RNA were soaked in 0.1% diethyl pyrocarbonate (DEPC) in water for 14-16 h and rinsed several 
times with distilled water before being autoclaved for 15 min at 15 lb/sq in, in liquid cycle. When 
autoclaving was impossible the utensils were rinsed with chloroform. All glassware and 
plasticware for RNA work were kept aside from the general use. Electrophoresis tank used for 
running RNA gels was strictly reserved for that purpose. Prior to RNA electrophoresis, the tank 
was filled with 3% solution of hydrogen peroxide (H20 2) and left to stand at room temperature 
for 10 min, then thoroughly rinsed with DEPC treated water. Additionally all solutions used for 
handling of RNA were prepared using autoclaved water and RNAase free utensils. Whenever 
possible such solutions were treated for at least 12 h with 0.1% DEPC in water, prior to 
autoclaving. Tris containing solutions were however not treated with DEPC but had to be used 
freshly prepared because DEPC readily reacts with amines. Furthermore, gloves were worn at all 
the times while preparing reagents and utensils for use in RNA procedures. This was adhered to 
even more rigorously when handling the RNA itself.
Total cellular RNA was extracted from buccal epithelial cells, lymphocytes and lymphoblafoid 
cells. Extraction of RNA from buccal cells and lymphocytes was modified from methods 
described by Lench et al. (1988) and Sherman et al. (1989), whereas extraction of total cellular 
RNA from lymphoblastoid cells was based on methods of Glisin et al (1974), Ullrich et al.
(1977) and MacDonald et al. (1987).
3.2.1. Extraction of RNA from buccal epithelial cells.
Subjects rinsed their mouths first with water then with 15 ml of 0.9% saline for about 10 s. 
Buccal epithelial cells were pelleted by centrifugation at 500 £ for 10 min. Supernatants were 
discarded and cell pellets washed in cold phosphate buffered glucose (6 mM Na2HP04, ImM 
KH2P 04, 300 mM glucose, pH 7.4) and resuspended in 50 ul 0.1% DEPC in water in microfuge
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tubes. The cells were lysed by immersing the tubes in a water bath at 100°C for 5 min and 
cooling quickly on ice. Debris was removed by centrifugation for 5 min and supernatants 
transferred to 0.5 ml microfuge tubes to be used in reverse-transcriptase PCR (R-T PCR).
3.2.2. Extraction of RNA from lymphocytes.
20 ml of venous blood was collected in heparinised bottles and diluted 1:1 with 10% foetal calf 
serum (FCS). The diluted blood was carefully layered over 8 ml of lymphoprep (9.6% sodium 
metrizoate/5.6% ficoll) without breaching the interface and centrifuged at 400 g  for 40 min at 
room temperature. After centrifugation mononuclear cells including lymphocytes form a distinct 
band between the sample layer and lymphoprep. The layer of mononuclear cells was carefully 
removed with a pasteur pipette and washed in 20 ml of 10% FCS, then pelleted by centrifugation 
at 400 g  for 20 min. The supernatant was dispensed in chloros and the cell pellet resuspended in 
phosphate buffered glucose (pH 7.4) to determine cell count. Four million cells were then 
removed and washed in phosphate buffered glucose and pelleted in a microcentrifuge by 
centrifugation at 1000 g  for 10 min. The cell pellet was resuspended in 50 ul of 0.1% DEPC in 
water and the cells lysed by boiling in a water bath at 100°C for 5 min and then quickly chilled 
on ice. The debris was removed by centrifugation and 50 ul of the cell lysate transferred to a 0.5 
ml microfuge tube to be used in PCR amplification.
3.2.3. Extraction of total cellular RNA from lymphoblastoid cells.
Two different methods using chaotropic agents were used to extract total cellular RNA from 
lymphoblastoid cells. In the first method RNA was extracted with guanidinium thiocyanate 
followed by equilibrium centrifugation with caesium chloride according to Glisin et al. (1977) 
and Ullrich et al. (1977), whereas in the second method, extraction was done with guanidine 
hydrochloride and organic solvents according to MacDonald et al. (1987).
3.2.3.I. Extraction of RNA with guanidinium thiocyanate and centrifugation in caesium 
chloride.
Harvested cells from lymphoblastoid cell lines were stored at -80°C till required. To each cell 
pellet in a 30 ml Sorvall tube, five volumes of guanidinium thiocyanate homogenisation buffer ( 
4 M guanidinium thiocyanate, 0.1 M Tris.Cl pH 7.5, 1% f3-mercaptoethanol) was added. As (3- 
mercaptoethanol is unstable in solutions, to prepare the homogenisation buffer, 50 g of 
guanidinium thiocyanate was dissolved in 10 ml of 1 M Tris.HCl (pH 7.5) and brought up to 100 
ml with water. The solution was filtered and stored at room temperature and (3-mercaptoethanol 
was added to a final concentration of 1% (0.14 M) just before use. Homogenisation was done by 
carefully vortex-mixing the cell pellet in the homogenisation buffer and then passing the 
homogenate several times through a 23-gauge needle until the cell lysate was no longer viscous.
After homogenisation, sodium lauryl sarcosinate was added to the preparation to a final 
concentration of 0.5% and mixed thoroughly. The mixture was centrifuged at 5000 g  for 10 min 
at room temperature and the supernatant transferred to a fresh tube leaving behind any cellular 
debris. Using a hypodermic syringe fitted with a 23-gauge needle, 6 ml of the cell lysate was 
carefully layered onto a 7 ml cushion of 5.7 M CsCl, 0.01 M ethylenediamine tetraacetic acid 
(pH 7.5) in a 13 ml pollyalomer ultracentrifuge tube. The tubes were weighed and balanced by 
the addition of more guanidinium thiocyanate whenever necessary.
RNA was pelleted by ultracentrifugation at 125,000 £ for 16 h, at room temperature in a 
swinging-bucket rotor with the brakes turned off. To achieve this a TH641 rotor was used at the 
speed of 32,000 rpm. At the end of centrifugation the fluid above the caesium chloride cushion 
was carefully removed with a pasteur pipette stopping as soon as the DNA band had been 
removed. This usually presents as a white visible band. The remaining fluid was then carefully 
decanted, and the tubes inverted to drain on paper towels for 5 min, taking care not to disturb or 
drop the RNA pellets. Using a red-hot sterile scalpel, the tubes were cut off approximately 1 cm 
from the bottom forming small cups which were placed on ice. The RNA pellets were then 
dissolved in 100 ul of TE buffer (10 mM Tris.HCl, 1 mM ethylenediamine tetraacetic acid pH
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7.6) with repeated pumping of the pipette and the RNA solution transferred to a fresh microfuge 
tube. This was repeated with another 100 ul aliquot of TE buffer. The tubes were finally rinsed 
with 50 ul of TE buffer and the aliquots combined in a sterile microcentrifuge tube giving 250 ul 
of RNA solution. To ensure that the RNA was completely dissolved, the mixture was thoroughly 
vortexed then incubated in a water bath at 65°C for 10 min and finally vortexed once again. To 
the RNA solution 0.1 volume of 2 M potassium acetate and 2.5 volumes of ice-cold ethanol was 
added, mixed and chilled at -20°C for a minimum of 2 h. After precipitation the RNA was 
collected by centrifugation at 5,000 £ for 20 min and carefully decanting the supernatant. The 
pellets were briefly dried and redissolved in 200 ul of TE buffer (pH 7.6) and divided into 100 ul 
aliquots. To one aliquot, 0.1 volume of 2 M potassium acetate and 2.5 volume of ethanol was 
added and the RNA solution kept at —80°C for long term storage. 10 ul was taken from the 
remaining aliquot to determine the RNA concentration and the rest stored at —20°C for daily use.
3.2.3.1. RNA extraction with guanidine HC1 and organic solvents.
To a cell pellet, 10 volumes of guanidine HC1 homogenisation buffer I (8 M guanidium HC1, 0.1 
sodium acetate pH 5.2, 5 mM dithiothreitol, 0.5% sodium lauryl sarcosinate) were added and the 
pellet homogenised by drawing and passing through a 23-gauge needle several times until the 
lysate was no longer viscous. The homogenate was centrifuged at 5000 g  for 10 min at room 
temperature and the supernatant transferred to a fresh tube, then 0.1 volume 3 M sodium acetate 
(pH 5.2) added and mixed well. To this 0.5 volume of ice-cold ethanol was added and thoroughly 
mixed. The mixture was then stored for at least 2 h at 0°C.
The RNA was pelleted by centrifugation at 5000 g  for 10 min at room temperature and 
recovered by discarding the supernatant. After drying, the RNA pellet was dissolved in guanidine 
HC1 homogenisation buffer II (8 M guanidine HC1, 0.1 M sodium acetate pH 7.0,1 mM 
dithiothreitol, 20 mM ethelenediaminetetraacetic acid pH 8.0). To this, 0.5 volume of ice-cold 
ethanol was added, mixed and the solution kept at -20°C for at least 2 h. The RNA was 
recovered by centrifugation at 5000 g  for 10 min, discarding the supernatant and allowing the
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pellet to dry in air. The ethanol precipitation was repeated twice more. After the third 
precipitation, the pellet was dissolved by adding 2.5 ml of 0.02 M ethelenediaminetetraacetic 
acid (pH 8.0) and thoroughly vortexed. The mixture was then centrifuged at 3000 g  and the 
supernatant saved. This was repeated with another 2.5 ml of ethelenediaminetetraacetic acid 
(EDTA) and the supernatants pooled. To this an equal volume of chloroform:1-butanol (4:1) was 
added, vortex-mixed and the mixture centrifuged at 5000 g for 10 min at room temperature. The 
aqueous (upper) phase was then transferred to a fresh tube and the chloroform :1-butanol 
extraction repeated. After the second extraction, the aqueous phase was transferred to a fresh 
tube and 3 volumes of 4 M sodium acetate added. The mixture was then stored for at least 1 h at 
—20°C and the RNA recovered by centrifugation at 5000 g for 20 min at 0°C after removing the 
supernatant. The RNA pellet was washed once with 3 M sodium acetate (pH 7.0) at 4°C and 
centrifuged at 5000 g  for 20 min at 0°C. After centrifugation, as much as possible of the 
supernatant was removed and the pellet dissolved in 500 ul of 0.2% sodium dodecyl sulphate 
(SDS), 0.05 M EDTA (pH 8.0). To this, 2 volumes of ice-cold ethanol was added and the mixture 
kept at 0°C for at least 2 h. The RNA was finally recovered by centrifugation at 5000 g  for 10 
min at 4°C and the pellet washed with 70% ethanol, then allowed to dry in air. After drying, the 
pellet was dissolved in 200 ul of TE buffer and divided into 100 ul aliquots. To one of the 
aliquots, 3 volumes of ethanol was added and the RNA stored at -70°C for later use. 10 ul were 
removed from the second aliquot for estimation of the RNA concentration and the rest stored at 
-20°C as described previously.
3.2.4. Determination of RNA concentration.
The RNA quantitation was done by spectrophotometry at wave lengths of 260 and 280 nm. To 
do this, 10 ul of RNA solution was diluted in 990 ul of TE buffer in 1 ml cuvettes and the optical 
density (OD) determined. An OD of 1 at 260 nm corresponds to approximately 40 ug/ml of 
RNA. The ratio between readings at 260 and 280 nm was used to determine the purity of the 
RNA solution, whereby a pure RNA solution was expected to have an OD26o/OD28o value of 2.
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3.2.5.. Qualitative assessment of RNA.
The quality of RNA was assessed by agarose gel electrophoresis. A 30 ml mini-gel was 
prepared by weighing out 0.45 g of agarose and adding 22 ml of water in a flask. The flask and 
contents were weighed and the agarose boiled until fully dissolved. The flask was then re­
weighed, evaporated water replaced and the gel allowed to cool to 5f? C. After cooling, 5 ml of 
formaldehyde and 3 ml of 10X 3- (/V-morpholino) ethanesulfonic acid (MOPS) were mixed and 
quickly poured before setting. Meanwhile, the RNA samples were prepared by mixing 1 ul of 
RNA solution with 5 ul of formamide, 1.65 ul of formaldehyde, 1 ul of 10X MOPS and 1.3 ul of 
dH20. The mixture was heated to 55°C for 10 min, quenched on ice and to it 2 ul of gel loading 
buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 40% sucrose in water) added. The 
samples were then immediately loaded and electrophoresed at 75 V until bromophenol blue 
reached the bottom of the gel. After electrophoresis, the gel was soaked in water for 1 h, 
changing the water twice or thrice to wash out formaldehyde. The gel was stained for 5 min in a 
0.5 ug/ml solution of ethidium bromide in running buffer, then destained for 2 hr or when 
necessary overnight and viewed under U. V. light to check for the integrity of ribosomal bands. 
As a marker the samples were run alongside 1 ug of Escherichia coli ribosomal RNA 
(Boehringer) treated in the same way as the RNA samples.
3.3. Polymerase chain reactions.
To develop a method of direct sequencing, PCR amplifications were done on various templates. 
These included DNA and RNA fragments from the plasmid pBR322, bacteriophage lambda 
DNA, Duchenne muscular dystrophy gene, cystic fibrosis gene, chorionic RNA, placental RNA, 
HeLa cell RNA and porphobilinogen deaminase gene. All PCRs were done on a Tecline PHC 1 
thermal cycler.
3.3.1. PCR amplification of pBR322.
Primers flanking a 500 bp region of pBR322 DNA were constructed and used in amplification 
of this region by PCR. Both coiled and linear pBR322 DNA were used in these experiments. To 
linearise pBR322 DNA, the plasmid was digested to completion with ZscoRI. The digestion was 
carried out by incubating at 37°C for 2 h, 5 ug of plasmid DNA with 50 u of EcoRl in a reaction 
mixture containing 50 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 100 mM NaCl and 5 mM 
spermidine. At the end of the digestion the digests were ethanol precipitated in the presence of 
0.3 M sodium acetate (pH 5.2). This was done by adding to the digests, 0.1 volume of 3 M 
sodium acetate (pH 5.2), mixing well and then adding 2 volumes of ice-cold ethanol. The 
mixture was stored on ice at 0°C for 30 min, then centrifuged at 12,00Qg for 10 min to recover 
the DNA pellet. The pellet was washed once in 70% ethanol by adding 500 ul of ethanol and 
recentrifuging at 12,000^ for 2 min. After removal of the supernatant the pellet was dried and 
dissolved in 10 ul of TE buffer.
Amplification was performed by addding 1 ug of the plasmid DNA to a 100 ul reaction mixture 
containing 50 mM KC1,10 mM Tris.HCl (pH 8.4), 1.5 mM MgCl2, 100 ug/ml gelatine, 200 uM 
of each dNTP (dATP, dCTP, dGTP, dTTP) and 0.5 uM of each primer. To this, 2.5 u of Taq 
DNA Polymerase was added, the mixture overlaid with 100 ul of light mineral oil and amplified 
for 30 cycles. Usually a master mix of reagents was prepared whereby to a 1.0 ul microfuge tube 
were added all components for PCR except DNA and the enzyme. The mixture was then put in a 
U.V. box (Amplirad II) for 10 min. After U.V. treatment, DNA was added and thoroughly mixed 
by vortexing, following which Taq DNA polymerase was added and briefly vortexed. The 
reaction mixture was overlaid with light mineral oil and briefly centrifuged to bring down any 
droplets so formed to the bottom of the tube. The first denaturation was done at 93°C for 3 min 
and thereafter for 1 min in the remaining cycles. Annealing was performed at 55°C for 2 min and 
extension at 72°C for 1.5 min except for the last extension which was carried out for 7 min. At 
the end of PCR, samples were briefly centrifuged and 5 ul of each reaction mixture taken from 
below the oil and resolved in a 1.4% SeaKam agarose gel in 0.5X TBE buffer (44.5 mM Tris-
borate, 1 mM). Electrophoresis was done at 10-15 V/cm until bromophenol blue migrated two 
thirds the distance of the gel. The gel was stained by soaking for 30 min at room temperature in 
the running buffer containing 0.5 ug/ml of ethidium bromide. When necessary the gel was 
destained for 20 min before visualisation under U.V. light.
3.3.2. PCR amplification of bacteriophage lambda DNA.
A 500 bp segment of bacteriophage lambda DNA supplied in the GeneAmp™ DNA 
amplification kit (Perkin Elmer Cetus) was amplified using the supplied control amplification 
primers. The sequences of primers complementary to the sense and antisense strands were: 5’- 
GGTTATCGAAATCAGCCACAGCGCC-3’ and 5’-GATGAGTTCGTGTCCGTACAACIGG-3’ 
respectively. 1 ng of the target DNA fragment and 1 uM of each primer was used in PCR using 
otherwise the same conditions as those described for the amplification of pBR322 DNA. 
Similarly, analysis of the amplified products was done in the same way.
In attempts to produce single-stranded templates for direct sequencing, asymmetric PCR was 
performed on bacteriophage lambda DNA. In asymmetric PCR, similar parameters as those for 
standard PCR were followed, except that the number of PCR cycles performed and the amounts 
of dNTPs and amplification primers used were changed. The asymmetric PCRs were performed 
with a reduced concentration of each dNTP to 50 uM instead of 200 uM. To produce the sense 
strand, 50 pmol of its complementary primer were used along with 0.5 pmol of the primer 
complementary to the opposite strand, whereas the antisense strand was produced by reversing 
the ratio of the primers used. Another departure from the standard PCR was that 40 cycles were 
done instead of 30.
3.3.3. Asymmetric PCR amplification of cystic fibrosis gene.
A DNA fragment consisting of 493 bp, spanning across the G1784->A (G551D) mutation on the 
cystic fibrosis gene was amplified by asymmetric PCR to produce templates for sequencing. 
Sequences of the forward and reverse primers used were, 5’-
TTCAGC AATGTTGTTTTGACC AAC-3 ’ and 5 ’ -C AC AG ATTCTG AGTAACC ATA ATC-3 ’ 
respectively. Amplifications were performed on genomic DNA in 100 ul volumes containing 50 
mM KC1,10 mM Tris.HCl (pH 8.4), 2.5 mM MgCl2, 100 ug/ml gelatine, 50 uM of each dNTP, 
0.5 uM of the forward primer, 0.05 uM of the reverse primer, 1 ug of DNA and 3.5 u of Taq 
DNA polymerase. To produce the opposite strand, a second set of reaction mixtures was 
prepared in which the amounts of the primers were reversed to contain 0.05 uM of forward and 
0.5 uM of reverse primer.The actual procedure followed in the preparation of the reactions, was 
as described previously above. Amplification was performed by initially heating the mixture to 
95°C for 10 min prior to the addition of Taq DNA polymerase. The samples were then denatured 
at 91°C for 0.5 min, annealed at 52°C for 1 min and extended at 72°C for 0.5 min. 40 cycles were 
performed in which the last extension step was done for 10 min. At the end of the PCR, the 
amplification products were briefly centrifuged and 5 ul removed under the oil cap to be analysed 
as described previously.
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3.3.4. Reverse-transcriptase PCR.
Reverse-transcriptase PCR amplifications of the PBG-D cDNA were performed on various RNA 
samples e.g. from placenta, chorion, HeLa cells, buccal epithelial cells and from total cellular 
RNA extracted from human lymphocytes. In doing R-T PCR, two main approaches were used in 
the synthesis of first strand cDNA. In the first approach, a forward (upstream) primer was used 
whereas in the second, oligo(dT) was used. In both cases, reverse transcriptase and the PCR were 
performed in the same tube. Oligonucleotide primers used in the amplification and subsequent 
sequencing of the PBG-D gene and their relative positions along the PBG-D cDNA are as as 
shown in figure 5. The oligonucleotide primers were synthesised on an Applied Biosystem 
Incorporation (ABI) 380B DNA synthesiser at small scale cycle, using ABI cyanolethyl 
phosphoramidites. After synthesis, all primers were deprotected with ammonia, purified by 
reverse-high pressure liquid chromatography (HPLC) and dissolved in 1 ml of dH20. The 
oligonucleotide primers were quantified by measuring their OD at 260 nm.
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FI: 5’- ACT TTC CAA GCG GAG CCA TG -3’
F2: 5’- CAT GTC TGG TAA CGG CAA TGC GG -3’ 
F3: 5’- GAT TCG CGT GGG TAC CCG CA -3’
R6: 5’- GAG GCT TTC AAT GTT GCC AC -3’
F4: 5’- ATG CCC TGG AGA AGA ATG A -3’
F5: 5’- GGA AGC TTG ACG AGC AGC AGG A -3’ 
R5: 5’- AGC ATA CAT GCA TTT CTC A -3’
R4: 5’- CTA CTG GCA CAC CTG CAG CCT C -3’ 
R3: 5’- CAT GGT AGC CTG CAT GGT CT -3’
R2: 5’- CTG TGC CCC ACA AAC CAG TTA AT -3’ 
Rl: 5’- TAG GCA CTG GAC AGC AGC A A -3’
5’ El E3 E4
FI -> F2 -> 
E5
F3 -> <- R6 
E6 E7
E8
F4->
E9 E10
E ll E12
F5->
E13
<- R5
E14
<- R4
E15 T 3’
<- R3 <- R2 <- Rl
Figure 5: Oligonucleotide primers used in PCR amplification and sequencing and their relative positions on the PBG-D cDNA.
Sequences of oligonucleotide primers used in PCR amplifications and sequencing reactions. All 
primers were fully deprotected by ammonium treatment and purified by reverse-HPLC. F and R 
represents forward and reverse primers respectively. E stands for exon and T the termination 
codon. The PBG-D map is not drawn to scale.
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3.3.4.1. Reverse-transcriptase PCR using forward (upstream) primers.
RNA isolated from one of the above described methods was reverse transcribed by using with a 
forward (upstream) primer complementary to mRNA and the cDNA thus synthesised amplified 
directly by PCR. To accomplish this, 1 ug of RNA was heated to 65°C for 10 min, quenched on 
ice and then reverse transcribed for 1 hr at 37°C in a 20 ul reaction mixture containing 200 uM 
each dNTP (dATP, dCTP, dGTP, dTTP), 10 mM DTT, 75 mM KC1, 50 mM Tris.HCl (pH 8.3), 3 
mM MgCl2, 100 ug/ml bovine serum albumin, 0.5 uM forward primer and 200 u of murine 
malony leukaemia virus-reverse transcriptase. At the end of the reverse transcription the mixture 
was heated to 95°C for 5 min, quenched on ice and the reverse (downstream) primer added to the 
final concentration of 0.5 uM. The volume of the reaction mixture was adjusted to 100 ul and 2.5 
u of Taq DNA polymerase added. The samples were then briefly vortexed and capped with 100 
ul of light mineral oil. Finally after a brief centrifugation, the cDNA was amplified during 30 
cycles of PCR. The initial denaturation was done at 95°C for 3 min and thereafter at the same 
temperature for 1 min. Annealing was performed at 60°C for 1 min and extension at 72°C for 1.5 
min except for the last extension step which was increased to 7 min.
At the end of amplification the samples were drawn below the oil cap and resolved in 1.4% 
SeaKem agarose gels and visualise under U.V. light as described previously. The appropriate 
band was excised and the cDNA eluted by soaking for 3 h in 100 ul of TE buffer. The cDNA in 
solution was removed from the agarose by pipetting and stored at -20°C or used directly in 
asymmetric PCR without further purification.
3.3.4.2. Reverse-transcriptase PCR using Oligo (dT).
The R-T PCR was performed in a similar way as above, except 0.2 ug oligo (dT)12.18 was used 
instead of a forward primer in the synthesis of the first strand cDNA. At the end of the reverse 
transcription, forward and reverse primers were added to a final concentration of 0.5 uM of each 
and amplification carried out as described above.
A modification of this was also performed using unequal amounts of primers as in asymmetric 
PCR designed to directly synthesise single-stranded cDNA. In ‘asymmetric’ R-T PCR the 
amplification was carried out with 50 pmol of one primer and 0.5 pmol of the second primer.
In another modification, total cellular RNA was first treated with RNAase-free DNAase I, 
before being amplified in R-T PCR. 89 ul of RNA solution at 500 ug/ml were mixed with 1 ng of 
RNAase-free DNAase in a reaction mixture containing 50 mM Tris.HCl (pH 7.6), 10 mM 
MnCl2, 0.1 mg/ml bovine serum albumin and incubating at 37°C for 20 min. After incubation, 
the reaction mixture was extracted once with 200 ul phenol:chloroform and the aqueous phase 
removed to a fresh microfuge tube. The RNA was precipitated by adding 0.1 volume of 3 M 
sodium acetate and 2.5 volumes of ethanol, chilled on ice for 15 min, then recovered by 
centrifuging at 12,000 £ for 15 min. The RNA pellet was washed once in 70% ethanol, 
resuspended in 90 ul dH20  and 3 ul used in each R-T PCR as described before.
3.3.5. Asymmetric PCR of PBG-D cDNA.
Porphobilinogen deaminase cDNA synthesised by R-T PCR was reamplified by asymmetric 
PCR to produce templates suitable for direct sequencing. Conditions for the asymmetric PCR 
were modified in such a way that a minimum amount of dNTPs were used. 5 ul of PBG-D cDNA 
estimated to be 0.5-1.0 ug by ethidium bromide fluorescence intensity, was amplified in a 100 ul 
reaction mixture containing 50 mM KC1, 10 mM Tris.HCl (pH 8.4), 1.5 mM MgCl2, 100 ug/ml 
gelatine, 50 uM of each dNTP (dATP, dCTP, dGTP, dTTP), 0.5 uM forward primer and 0.05 uM 
reverse primer. To synthesise the opposite strand, the primer concentrations were reversed. As 
before master mixes were prepared by adding all components except for the cDNA and the 
enzyme. The mixture was then irradiated in a U.V. box (Amplirad II) for 10 min. After 
irradiation, cDNA was added and the mixture thoroughly vortexed. Finally, 2.5 u of Taq DNA 
polymerase were added and after vortexing briefly, the reaction mix was capped with 100 ul of 
mineral oil. PCR was done using the same parameters as in the standard PCR except that 40 
instead of 30 cycles were performeed.
3.4. Purification of PCR products.
At the end of PCR, the amplified DNA or cDNA was concentrated and purified by removing 
excess primers, dNTPs and salts. Various methods were used and compared. These included 
Sephadex™ spun-column chomatography (Sambrook et al., 1989b), agarose gel purification 
followed by nucleic acid chromatography system (NACS) purification (BRL), Geneclean 
purification (Vogelstein and Gillespie, 1979), centrifuge-driven dialysis (Saiki et al.,1988a; 
Sambrook et al., 1989a), selective alcohol precipitation (Gyllensten, 1989; Brow M-A D, 1990) 
and acrylamide gel purification.
3.4.1. Spun-column chromatography.
At the end of PCR, 5 ul of the PCR products were removed below the oil cap and analysed as 
mentioned before. On finding that the appropriate products had been amplified, the rest of the 
sample was removed and extracted once with chloroform to remove the mineral oil. This was 
effected by mixing the PCR products with 150 ul of chloroform and centrifuging the mixture at 
12,000 £  for 15 seconds. The aqueous phase was removed and re-extracted in butanol and this 
time the lower (aqueous) phase retained. The remaining butanol was driven off by immersing the 
tubes in a 37°C water bath with the caps off for 5 to 10 min. The DNA or cDNA was then 
precipitated by addition of 0.1 volume of 3 M sodium acetate and 2.5 volumes of ethanol as 
described before. After recovery by centrifugation the DNA pellet was resuspended in 100 ul of 
0.5X TE buffer pH (8.0).
In the meantime, spun columns were prepared by plugging the bottom of 1 ml disposable 
syringes with a small amount of sterile glass wool and completely filling them with Sephadex 
G-50 (DNA grade) equilibrated in 0.5X TE buffer. The syringes were then inserted onto 20 ml 
universal containers and centrifuged at 1600 £ for 4 min at room temperature in a swinging 
bucket rotor. More Sephadex G-50 was added and the centrifugation repeated until the volume of 
the packed columns was approximately 0.9 ml and remained unchanged on further 
centrifugation. 100 ul of 0.5X TE buffer was then carefully applied to the top of each column
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which was subsequently centrifuged at 1600 g for 4 min and repeated twice. At the end of the 
third wash, the PCR amplified DNA samples in 100 ul 0.5X TE buffer were applied to the top of 
the columns. The columns were then inserted into decapped 1 ml microfuge tubes, placed in 
fresh universal containers as shown in figure 6, and centrifuged at 1600 g  for 4 min at room 
temperature to collect 100 ul of the effluent. The eluted cDNA was concentrated by precipitating 
in 0.1 volume of 3 M sodium acetate and 2 volumes of ethanol, then washed once in 70% ethanol 
as described earlier. After drying, the cDNA pellet was dissolved in 14 ul of TE buffer (pH 7.4) 
for use in sequencing reactions.
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Figure 6: Spun-column chromatography.
(From Sambrook et al., 1989b).
Spun columns are prepared by packing 1 ml disposable syringes with Sephadex G-50™ beads 
(DNA grade) and equilibrating them with 0.5X TE. Such prepared spun-columns, can be stored 
in upright position at 4°C for up to one month or more before use. They should, however, be 
rehydrated with 0.5X TE just before use. Samples are purify by carefully applying them at the 
top of the Sephadex columns and centrifuging in a swinging bucket rotor, collecting the eluates 
in decapped 1 ml microfuge tubes.
- 5 8 -
3.4.2. Agarose gel fractionation followed by NACS column chromatography.
At the end of PCR amplification, the products were electrophoresed in a 1.5% low melting 
NuSieve agarose gel and the appropriate band excised. The gel slice was placed in a microfuge 
tube and completely melted by placing in a water bath at 70°C. The volume of the molten gel 
was determined and 4 volumes of 0.25 M NaCl in TE buffer (pH 7.2) added. The diluted molten 
gel was then incubated at 70°C for 10 min. In the meantime the resin in NACS columns was 
hydrated by being washed thrice with 2.0 M NaCl in TE buffer (pH 7.2) and equilibrated with 
0.2 M NaCl in TE buffer (pH 7.2). The diluted molten gel was then loaded onto NACS colums 
and the bound cDNA washed with warm 0.2 M NaCl in TE buffer (pH 7.2) heated to 42°C, to 
remove gel impurities. The cDNA was eluted by adding 100 ul of 1.0 M NaCl in TE buffer (pH
7.2) and collecting the effluent by gravity. This was repeated twice more and the three effluents 
pooled. The cDNA was precipitated by mixing with 10 ug of tRNA and 600 ul of 95% cold 
ethanol (-20°C) and freezing the mixture at -70° C for 10 min. At the end of the precipitation, the 
cDNA was recovered by centrifugation at 12,000 g  for 15 min and the pellet washed once in 
80% ethanol, dried and resuspended in 14 ul of TE buffer (pH 7.4).
Alternatively the PCR products were directly purified in the NACS columns without any prior 
gel purification. Using this alternative method, the PCR products were extracted once in 
chloroform as described previously and loaded directly onto the equilibrated NACS columns to 
be processed as above.
3.4.3. Geneclean™ purification.
Agarose gel electrophoresis followed by Geneclean™II (BIO 101 Inc) purification was also 
used to clean up PCR products prior to sequencing. At the end of PCR amplification, the 
products were resolved in 1.5% low melting NuSieve agarose gel as mentioned before. The 
appropriate band was excised and DNA eluted using geneclean according to the manufacturer’s 
recommendations. Briefly, the excised gel slice was weighed and assuming 1 g is equivalent to 1 
ml, 0.5 volume of ‘TBE modifier’ and 4.5 volumes of the supplied stock solution of Nal were
- 5 9 -
added giving a final concentration of at least 4 M. The mixture was incubated at 50°C for 5 min 
to dissolve the agarose gel. At the end of incubation, 5 ul of the provided ‘glassmilk’ suspension 
was added, mixed and the mixture kept on ice for 5 minutes to bind the DNA molecules. The 
mixture was then centrifuged in a microcentrifuge for 5 seconds and the supernatant removed. To 
ensure that most of the liquid had been removed, the tubes were recentrifuged and as much as 
possible of the supernatant removed. The pellet was then resuspended in 10-50 volumes of the 
‘NEW WASH’ provided, centrifuged for 5 seconds and the supernatant discarded. This washing 
was repeated twice more and after the third wash the pellet was resuspended in 7 ul of TE buffer 
and incubated at 50°C for 3 min. The mixture was then centrifuged for 30 seconds and the 
supernatant containing eluted DNA was transferred to a fresh microfuge tube. This was repeated 
once and the two eluates pooled to be used in sequencing reactions.
3.4.4. Centrifuge-driven dialysis method.
After removing 5 ul for checking, the remaining 95 ul of the PCR products were extracted once 
with 150 ul of chloroform to remove mineral oil. The aqueous layer was transferred to a fresh 
tube and 2 ml of dH20  added. This was then loaded to the reservoir chamber of a Centricon 30 
microconcentrator as shown in figure 7 and centrifuged at 3000 £  (6500 rpm in a Sorvall SA 600 
rotor) for 30 min at room temperature. At the end of centifugation the filtrate was discarded and 
the unit inverted with the retentate cup placed at the bottom of the rotor. The sample was then 
centrifuged at 1000 g  (3000 rpm in a Sorvall SA 600 rotor) to collect the concentrated products. 
The amplified cDNA was recovered by ethanol precipitation and after washing once with 70% 
ethanol was dried and dissolved in 14 ul of TE buffer (pH 7.4).
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Figure 7: Centrifuge-driven dialysis using microconccntrators.
(From Amicon publication number 1-259G).
The microconcentrator device consists of two chambers, a filtrate cup and a sample reservoir 
separated by a filtration membrane. Samples are desalted and concentrated by centrifuging, after 
their dilution and application into the sample reservoir. The filtrate collects in the filtrate cup 
which can be used for storage. This is useful for checking sample losses if necessary, as for 
instance when dealing with precious material. The retentate cup is then attached to the sample 
reservoir and the device inverted to collect the sample by centrifugation.
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3.4.5. Selective alcohol precipitation.
Two methods were used, based on the fact that 2.0-2.5 M ammonium acetate reduces the 
coprecipitation of dNTPs with DNA (Okayama and Berg, 1982). At the end of PCR 
amplification, the samples were analysed and mineral oil extracted as described before. An equal 
volume of 4 M ammonium acetate (pH 5.2) was then added, mixed and to this, 3 volumes of 
ethanol added and again mixed. The mixture was left at room temperature for 5 min, then 
centrifuged at 12,000 g for 10 min to recover the DNA. The DNA pellet was finally washed in 
70% alcohol, dried in air and dissolved in 14 ul of TE buffer (pH 7.4).
Alternatively, the PCR products were mixed with an equal volume of 4 M ammonium acetate 
(pH 5.2), and precipitated in 2 volumes of propan-2-ol for 10 min at room temperature and the 
cDNA recovered by centrifuging at 12,000 g  for 10 min. The cDNA pellet was then washed in 
70% alcohol, dried and dissolved in 14 ul of TE buffer (pH 7.4) as described before.
3.4.6. Purification and strand separation in acrylamide gel.
Simultaneous purification and strand separation of PCR products was performed on 5% 
acrylamide gels. The gels were prepared by dissolving 2.5 g of acrylamide and 0.05 g of N,N’- 
methylene bisacrylamide in IX TBE buffer (89 mM Tris-borate, 2 mM EDTA, pH 8.0). The gel 
was polymerised by adding 90 ul 25% ammonium persulphate (APS) and mixed by swirling 
followed by addition of 25 ul N,N,N’, A'-tetramethyethylenediamine (TEMED) which was mixed 
in the same manner. The gel solution was allowed to stay for a period of 2 h, to ensure complete 
polymerisation of acrylamide. The polymerised gel was then pre-run for 2 h at 10 V/cm.
After standard PCR amplification of PBG-D cDNA as described earlier, dsPCR products were 
removed under the mineral oil, checked and extracted once with chloroform. The aqueous phase 
was then precipitated with ethanol and washed twice in 70% ethanol. After the second washing 
the cDNA pellet was dissolved in 40 ul of strand separation buffer containg, 30% dimethyl 
sulphoxide (DMSO), 1 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF and 
heated to 90°C for 2 min. After heating, the samples were quickly chilled on ice and immediately
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applied to the gel. Electrophoresis was carried out until bromophenol blue reached the bottom of 
the gel. The gel was stained with ethidium bromide and appropriate bands excised. The separated 
strands were recovered using NACS columns as described above.
3.5. Genomic sequencing.
The PCR amplified DNA and cDNA were directly sequenced using both double- and single­
stranded templates involving various sequencing protocols.
3.5.1. Sequencing of dsPCR products with end-labelled primers.
Double-stranded PCR products were purified using one of the described methods above and 
used directly in sequencing reactions without cloning. Sequencing reactions were done with 
either 32P end-labelled primers or uniformly 35S-labelled templates by the dideoxy method of 
Sanger (1977) using Sequenase T7 DNA polymerase or Taq DNA polymerase enzymes. 
Sequencing primers were (32P) 5’ end-labelled using 5.3 u of T4 polynucleotide kinase by 
mixing 20 pmol of the primer with 25 pmol of (gamma-32P) ATP (3000 Ci/mmol) in a 20 ul 
reaction mixture containing 50 mM Tris.HCl, 10 mM MgCl2, 5 mM dithiothreitol, 0.1 mM 
spermidine HC1 and 0.1 mM EDTA (pH 8.0). The reaction mixture was incubated at 37°C for 30 
min. In practice, the reaction mixtures were mixed, briefly centrifuged and incubated at 37°C for 
15 min. After 15 min the samples were again mixed, recentrifuged and incubated for another 15 
min. At the end of incubation the T4 polynucleotide kinase was inactivated by heating the 
samples to 90°C for 10 min. The amount of radioactivity incorporated into the primers was 
checked by diluting 0.5 ul of the reaction mixture in 4.5 ul of water and spotting 2 ul onto two 
DE-81 filters. The filters were allowed to dry and one of them washed four times by swirling in 
250 ml of 0.5 M Na2HP04 (pH 7.0), each wash lasting for 5 min. This was followed by two, 1 
min washes in water and a final 1 min wash in 95% ethanol. The filter was allowed to dry and 
then both the washed and unwashed filters were placed in scintillation vials and 5 ml of toluene- 
based scintillation fluid added. The amount of the radioactivity was determined and the
proportion of the incorporated radioactivity calculated by the following formula: cpm in washed 
filter/cpm in unwashed filter = proportion of the radioactivity incorporated. Incorporation rate of 
20% or more was usable for the subsequent sequencing reactions.
The double stranded templates had to be denatured before being used in sequencing reactions. 
This was done either by alkaline treatment or by boiling at 100°C. In the alkaline denaturation 
method, 17 ul of the purified PCR products were denatured in 0.2 M NaOH, 0.2 mM EDTA at 
37°C for 30 min and the mixture neutralised by adding 0.1 volume of 3 M sodium acetate (pH
5.2). The DNA was then precipitated by adding 2 volumes of ethanol and stored at -70°C for 15 
min. After precipitation, the DNA was recovered by centrifugation and washed in 70% ethanol 
as described before. In Sequenase T7 DNA polymerase mediated sequencing, the denatured 
DNA was redissolved in 14 ul of water and 7 ul used in each sequencing reaction, whereas in 
Taq DNA polymerase sequencing, the pellet was resuspended in 20 ul and 10 ul used the 
sequencing reaction.
In the Sequenase T7 DNA polymerase sequencing reactions, template-primer annealing was 
done by adding 1 pmol (1 ul) of the 32P end-labelled sequencing primer to 5 ul of the alkaline 
denatured template in a 10 ul reaction mixture containing 40 mM Tris.HCl, 20 mM MgCl2, 50 
mM NaCl (pH 7.5) and heating the mixture to 65°C for 2 min then cooling slowly to below 30°C 
over a period of 20 min. The annealed template-primer mixture was briefly centrifuged and 
immediately kept on ice. As sequencing primer, one of the amplification primers or a nested 
primer complementary to the strand to be sequenced was used.
Alternatively dsPCR templates and sequencing primers in the reaction mixture described above, 
were denatured and annealed by melting at 100°C for 5 min, then snap quenched in dry ice- 
ethanol bath at-70°C for 30 seconds and immediately thawed by a 15 s centrifugation. The 
annealed template-primer mixture was then placed on ice and immediately used in extension- 
termination reactions for sequencing.
To the ice-cold annealed template-primer mixture were added 1 ul 0.1 M dithiothreitol (DTT),
2.5 ul dH20 , and 2 ul (1.5 u) of a 1:8 dilution of Sequenase T7 DNA polymerase enzyme in TE
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buffer. 3.5 ul of this mixture were immediately added to 2.5 ul of dideoxy A, C, G, and T 
termination mixes which had been pre-warmed to 37°C for at least 1 min. Dideoxy A termination 
mix contains 80 uM dATP, 80 uM dCTP, 80 uM dGTP, 80 uM dTTP, 8 uM ddATP and 50 mM 
NaCl. Dideoxy C, G and T termination mixes are similarly constructed with the appropriate 
ddNTPs; ddCTP, ddGTP, ddTTP respectively. The mixtures were incubated at 37°C for 5 min 
and the reactions terminated by adding 4 ul of a stop mix containing 95% formamide, 20 mM 
EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF.
3.5.2. Sequencing of dsPCR products by incorporation labelling.
Double-stranded PCR amplified templates were prepared and annealed to the sequencing 
primers as described above. To 10 ul of the annealed template-primer mixture on ice, were added
1 ul 0.1 M DTT, 2 ul 1.5 uM each dCTP, dGTP, dTTP, 0.5 ul (ct-35S)dATP (1000 Ci/mmol) and
2 ul (1.5 u) of a 1:8 dilution of Sequenase T7 DNA polymerase version 2.0, diluted in 10 mM 
Tris.HCl (pH 7.5), 5 mM DTT and 0.5 mg/ml bovine serum albumin. The solution was mixed 
thoroughly avoiding formation of bubbles, then briefly centrifuged and kept at room temperature 
for 3 min. Finally 3.5 ul of the labelled mixture were transferred to the termination mixtures and 
the reactions performed as described above.
3.5.3. Sequencing of ssPCR products by incorporation labelling.
Single-stranded templates were synthesised by asymmetric PCR amplification and purified by 
one of the methods previously described. Sequencing reactions were performed using either 
Sequenase T7 DNA polymerase or Taq DNA polymerase enzymes. In the Sequenase T7 DNA 
polymerase based reactions, 7 ul of the purified PCR products and 1 pmol of sequencing primer 
in a 10 ul reaction mixture containing 40 mM Tris.HCl (pH 7.5), 20 mM MgCl2 and 50 mM 
NaCl were annealed by heating to 65°C for 2 min and then allowed to cool down to below 30°C 
over a period of 20 min. Thereafter the rest of the reactions were carried out as described above 
in the sequencing of the double-stranded templates.
When using Taq DNA polymerase, the purified PCR products were resuspended in 20 ul dH20  
and 10 ul of which were mixed with 1 pmol of a sequencing primer in a 13 ul reaction mixture 
containing 50 mM Tris.HCl, 7 mM MgCl2 (pH 8.8). Annealing was accomplished by heating the 
mixture at 70°C for 2 min, then cooled to below 30°C over a period of 20 min. The annealed 
template-primer was briefly centrifuged, put on ice, and to it were added 2 ul of 1.5 uM each 
dCTP, dGTP, dTTP, 0.5 ul (a-35S)d ATP (1000 Ci/mmol) and 2 ul (2 u) of Taq DNA polymerase 
diluted from 5 u/ul to lu/ul in 25 mM Tris.HCl (pH 8.8), 0.1 mM EDTA, 0.15% Tween 20 and 
0.15% Nodidet P-40. The mixture was mixed thoroughly and then incubated at 45°C for 5 min to 
label the template. At the end of the labelling incubation, 4 ul of the labelled reactions were 
transferred to 4 ul of dideoxy termination mixtures and incubated at 70° C for 5 min. The dideoxy 
termination mixes all contain 50 mM Tris.HCl (pH 8.8), 7 mM MgCl2, and 20 mM of each 
dNTP (dATP, dCTP, dGTP and dTTP). In addition, individual mixes contain the following: A- 
mix 800 mM ddATP, C-mix 400 mM ddCTP, G-mix 60 mM ddGTP and T-mix 800 dTTP. After 
5 min at 70°C, the samples were cooled to room temperature and the reactions stopped by adding 
4 ul of 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol FF 
and mixing thoroughly. The samples were then briefly centrifuged and denatured at 70°C for 5 
min. After denaturation the samples were quickly placed on ice and immediately loaded and 
electrophoresed on polyacrylamide sequencing gels. Samples labelled with 35S can be stored at 
-20°C for up to one week with little degradation.
Sequencing gels contained 7 M urea, 8% acrylamide and were prepared by dissolving 25.3 g 
urea and 16 ml of 30% acrylamide solution (acrylamide: N, /V’-methylenebisacrylamide at 19:1) 
in IX TBE buffer (89 mM Tris, 89 mM borate, 2 mM EDTA pH 8.3) to a final volume of 60 ml. 
The urea was dissolved by stirring at room temperature or by briefly warming in a water bath at 
50°C in a fume hood. The gel solution was then filtered through a 0.45 micron mesh (millipore) 
filter and degassed under strong vacuum for 10 min. The gel was moulded in a Sequi-Gen^ 
nucleic acid sequencing cell (Bio-Rad) consisting of an upper buffer chamber and a glass plate 
bound together with a permanent adhesive at the sides and the bottom edges, an outer plate and a
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pair of clamps, thus obviating the need of using tape for sealing. Prior to casting the gel, both the 
bound and the outer plates were cleaned with warm soapy water and rinsed with deionised water. 
The plates were then dried and polished with ethanol. The bound glass plate was siliconised in a 
fume hood and allowed to dry. On drying, spacers were inserted between the two plates and held 
together by the side clamps. The bottom of the sequencing cell was sealed by pouring 10 ml of 
the gel solution into a beaker and adding 50 ul each of 25% APS and TEMED in that order. This 
was mixed by swirling and quickly poured onto and completely saturating the sealing paper strip 
in a provided casting tray. The sequencing cell was then immediately placed on the paper strip 
allowing the gel solution to move up between the glass plates by capillary action. The 
sequencing apparatus was held upright in this position for 2 min until the thin film of gel at the 
bottom completely polymerised thus sealing the squencing cell. To the remaining gel solution 
were added 90 ul of 25% APS and 90 ul TEMED, then mixed and poured between the sealed 
plates of the sequencing cell. After inserting a comb the sequencing cell was rested inclined at an 
angle of about 5° and the gel allowed to polymerise over a period of 30 min, when the comb was 
removed and the wells immediately washed with IX TBE buffer using a pasteur pipette. The 
casting tray and sealing paper strip were removed and the gel left to age for at least 3 h. In most 
cases the gels were conveniently prepared in the evening and left to age in running buffer 
overnight, covered with Saran wrap to prevent drying. Such gels can be kept for up to 20 hr 
before running.
Prior to loading of the samples, the gels were pre-run at approximately 2000 V for 30 min to 
stabilise the gel temperature at 55°C, or alternatively the pre-run was done for 1-2 hr at a gel 
temperature of 45°C, monitored by gel temperature indicator strips placed on the outer glass 
plate of the sequencing cell. The sequencing samples were then denatured at 70°C for 5 min. 
Immediately before the end of the denaturation the wells were once again cleaned with IX TBE 
buffer to get rid of leached urea. At the end of denaturation the samples were placed on ice and
1.5 ul of each were immediately applied on the hot gel in the order of T, C, G and A. The 
electrophoresis was conducted at a gel temperature of 50°C for 2-4 h depending on the size of the
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DNA fragment to be sequenced. Routinely for convenience, staggered loading was performed, 
whereby the samples were loaded at different intervals such that one batch was run for 2 hr and 
the other for 4 hr on the same gel.
At the end of electrophoresis the glass plates were gently prised apart with a blade and the gel, 
usually stuck to the outer glass plate, was fixed for 10 min in 1 L 10% methanol/10% acetic acid. 
After 15 min the gel on the glass plate was gently removed from the fixative and the excess 
fixative drained or carefully wiped with paper towels. The gel was then lifted off the plate using 
Whatman 3MM paper and covered with Saran wrap. Air bubbles and wrinkles were smoothed 
out by gently rolling with a 10 ml plastic pipette. The edges were then trimmed with a scalpel to 
fit the slab gel drier and the gel dried at 80° C for 30 min with the Saran wrap side up. When dry, 
the Saran wrap was removed and the gel directly exposed to Kodak X-Omat XAR5 film for 
16-18 hr at -70°C with an intensifying screen.
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3.5.4. Variations in sequencing protocols.
Depending on the need, the sequencing protocols and gel running conditions mentioned above 
were modified from time to time. This depended on factors like the need to sequence closer or 
further from the sequencing primers or on encountering regions with strong secondary structures 
leading to unresolved compressions on sequencing gels.
To emphasise and read sequences close to sequencing primers with Sequenase T7 DNA 
polymerase, two approaches were used. Li the first method, the labelling reaction was done in the 
presence of reduced concentrations of dNTPs (0.75 mM instead of 1.5 mM each dCTP, dGTP 
and dTTP) and its duration strictly limited to 3 min. In addition, the quantity of the templates was 
doubled, thus in this case the purified PCR templates were resuspended in 10 ul and the whole 
amount used in the sequencing reactions. Alternatively, the sequencing reactions were done in 
the usual manner except that in addition, 1 ul of Mn++ buffer (0.15 M sodium isocitrate, 0.1 M 
MnCl2) was added just before the addition of Sequenase T7 DNA polymerase (Tabor and 
Richardson, 1989). The gels were run for 2.5 h under the same conditions described above.
These methods highlight 200 nucleotides or less from the sequencing primers. To read sequences 
of about 400 nucleotides beyond sequencing primers, the concentration of dNTPs was increased 
to 7.5 uM for each dNTP and 2 ul of (a-35S)dATP (1000 Ci/mmol) were used in the labelling 
reaction. In addition, the labelling reactions were increased to 5 min. The samples were resolved 
in wedge gels using spacers that were thin at the top (0.25 mm) and thicker at the bottom (0.4 
mm). Such gels were run at a gel temperature of 40°C for 6.5 h, fixed in 10% acetic acid/10% 
methanol for 20 min and dried for 45 min.
Compressions were resolved by at first doing termination reactions at 45-50°C with Sequenase 
T7 DNA polymerase and when still unresolved, switching to Taq DNA polymerase. Rarely it 
was necessary to resort to the dNTP analogues dITP and 7-deaza-dGTP. The former was used 
with Sequenase T7 DNA polymerase and the later with Taq DNA polymerase. These analogues 
were used in place of the regular dGTP.
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Another variation was the use of pyrophosphatase in sequencing reactions. Pyrophosphatase 
improves the intensity of the sequencing ladder by preventing pyrophosphorolysis which occurs 
naturally with Sequenase T7 DNA polymerase (Tabor and Richardson, 1990). To prevent this 
0.0003 u of pyrophosphatase was added for every unit of Sequenase T7 DNA polymerase. This 
was either added immediately before the addition of Sequenase T7 DNA polymerase enzyme or 
by directly mixing 0.33 ul of pyrophosphatase in 10 mM Tris.HCl, 0.1 mM EDTA and 50% 
glycerol with every 1 ul of the Sequenase T7 DNA polymerase stock solution.
3.6. Secondary structure analysis.
PEPTIDESTRUCTURE and PLOTSTRUCTURE computer programmes were used to predict 
for alterations in secondary structure and hydropathy likely to be caused by the detected 
mutations (Wolf et al., 1988). Changes in the secondary structure were determined from analyses 
of two-dimensional plots of the mutant protein against the normal PBG-D. Hydrophilicity 
changes were determined for each mutation by comparing the mean hydrophilic value at and 
around the substituted amino acid with normal values (Chou and Fasman, 1978). 
Crystallographic studies were kindly performed by Professor Blundell after aligning the 
sequences of the PBG-D from various species including the human and Escherichia coli. Highly 
conserved amino acids were defined as those amino acids that were present at the same residue 
position in all species for which their sequence has been described. These include, Escherichia 
coli (Jordan et al., 1988), rat, (Beaumont et al., 1988; Blundell, 1991; personal communication) 
mouse (Beaumont et al., 1989) bacillus ( Blundell, 1991; personal communication) Euglina 
glacilis (Sharif et al., 1989) and human (Raich et al., 1886; Grandchamp et al., 1987; Chretien et 
al., 1988).
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CHAPTER FOUR: RESULTS.
4. RESULTS.
4.1. Direct sequencing of dsPCR amplified DNA templates.
4.1.1. Sequencing with 32P end-labelled primers.
Before its application on clinical cases, the direct sequencing of PCR amplified products was first 
performed on various templates including DNA fragments of the plasmid pBR322, the 
dystrophin gene, bacteriophage lambda and the gene responsible for cystic fibrosis. This was 
necessary for the establishment, development and optimisation of various procedures used in the 
detection of mutations. Initially the study concentrated on the amplification and sequencing of 
double stranded DNA templates. Early experiments were performed on plasmid, where a 500 bp 
pBR322 DNA fragment was amplified through a standard polymerase chain reaction and the 
dsPCR products directly sequenced using one of the amplification primers, 5’ end-labelled with 
32P. Purification of the templates prior to sequencing was carried out by spun-column 
chromatography. In the sequencing reactions, template-primer annealing was performed by 
denaturing the template-primer mixture at 100°C for 2 min and then snap-freezing at -70°C for 
30 s. Using either linearised or supercoiled pBR322 the expected 500 bp PCR product was 
obtained as shown in figure 8a.
Purification of the PCR products with spun column chromatography gave inconsistent results in 
terms of DNA recovery and primer removal. For instance when using spun column 
chromatography for desalting and separation of primers from DNA templates, it is recommended 
to collect the first eluate (Sambrook et al., 1989b). hi the current study, however, the appropriate 
products were sometimes recovered in the second or even the third eluate. The template- 
primer separation was also not always effective as in some cases the products were eluted along 
with the amplification primers even in the first eluate. Moreover, on some occasions the 
sephadex columns collapsed with the subsequent loss of the entire samples. Figure 8b shows 500 
bp fragments of spun column purified PCR amplified DNA of pBR322 and dystrophin gene after 
two, three and four rounds of elution.
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Sequencing of dsPCR amplified pBR322 DNA purified by spun columns persistently failed. In 
most cases the results showed only a dark background without any sequencing ladder. To 
circumvent this, attempts were made at producing single-stranded templates by gel separation as 
shown in figure 9a and 9b.
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F igure 8: Spun-column chromatography in the purification of PCR products.
8a: Lane 1,1 kb DNA ladder, lanes 2-5, pBR322 and 6-8, 500 bp fragment of the dystrophin 
gene. Lanes 9 and 10, negative control and 123 bp DNA ladder respectively.
8b: Lanes 1,11 and 12,1 kb DNA ladder, lanes 2 and 3, purified PCR amplified products of 
dystrophin DNA collected as second spun column eluates. Lane 4, purified PCR amplified 
pBR322 DNA also collected as a second spun column eluate. Lanes 5-6 and 8-9, third and fourth 
eluates collected from purified PCR amplified dystrophin products whereas lanes 7 and 10 are 
third and fourth pBR322 eluates. In lane 10 amplification primers (p) can be seen as well.
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Figure 9: Strand separation gel electrophoresis.
9a: PCR amplified DNA fragments. Lanes 1 and 2, from dystrophin gene and 3-6, pBR322. Lane 
7,1 kb DNA ladder.
9b shows that following strand separation gel electrophoresis, three main bands were visualised. 
The bottom band was presumably due to the undenatured DNA and the top two bands 
represented the separated DNA strands.
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4.1.2. Incorporation sequencing using 35S.
Following the failure of sequencing dsPCR products using 32P end-labelled primers, internal 
labelling was attempted. To achieve this, a 500 bp long segment of bacteriophage lambda DNA 
was amplified and sequenced using two different approaches. In the first approach, the dsDNA 
templates and sequencing primers were annealed after the templates were denatured by boiling at 
100°C for 2 min in the presence of the primers and immediately frozen at -70°C for 30 s to 
prevent renaturation. In the second approach, template denaturation was performed by alkaline 
treatment and the template-primer annealing carried out by heating the mixture to 65°C and 
slowly cooling to below 30°C. Prior to sequencing reactions, the PCR products were purified by 
NACS columns either directly or after an initial fractionation in agarose gels. In order to 
determine the optimal template :primer ratio, different quantities of DNA were used as 
sequencing templates. This ranged from 50% of a PCR mixture to two reactions. Figure 10a 
shows dsPCR amplified products of bacteriophage lambda DNA and 10b and 10c sequencing 
ladders generated from these products.
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Figure 10: Sequences from bacteriophage lambda dsDN A templates.
10a: Double-stranded PCR products derived from amplification of bacteriophage lambda DNA. 
10b: Sequence set 1, sequencing ladder derived from products combined from two polymerase 
chain reactions (200 ul), purified directly by NACS columns. Set 2, sequencing ladder derived 
from one PCR (100 ul) after both gel and NACS column separations and 3, from one PCR (100 
ul) directly purified by NACS column chromatography. Sequence set 4, sequencing ladder of the 
control M13mpl8 cloned DNA.
10c: Sequence set 1, sequence ladder generated from 50% of PCR products purified directly 
using NACS column and set 2 from M13mpl8 DNA.
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4.2. Direct sequencing of ssPCR amplified DNA templates.
Single-stranded PCR products were generated through asymmetric polymerase chain reaction 
by amplifying a 493 bp fragment of cystic fibrosis gene spanning across the G2 784->A (G551D 
or Gly 551 to Asp) mutation. This was performed on an individual with a heterozygous G551D 
mutation and on a known normal control. The PCR products were purified by selective 
precipitation in 2 M ammonium acetate and propan-2-ol. Sequencing was performed with Taq 
DNA polymerase using 50% of each purified PCR product and 1 pmol of the limiting primer as a 
sequencing primer. The sequencing reactions were stagger loaded and electrophoresed for 2 and 
3 h. Both the sense and anti-sense strands were generated and sequenced. It was possible to 
unequivocally demonstrate the putative mutation in the cystic fibrosis carrier as shown in figure 
11.
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T C G A T C G  AT C G A T C G A
Figure 11: Partial sequences o f cystic fibrosis gene demostrating the G1,784->A mutation.
11a: Lane 1,1 kb DNA ladder, lanes 2-5, top row PCR products with forward primer limiting 
and bottom row with reverse primer limiting. Asymmetric PCR tends to generate a lot of 
spurious products as seen here. These are presumably drop-off products, homologous to the 
target products and do not interfere with sequencing reactions.
lib : Sets 1 and 2, sequencing ladders from a cystic fibrosis carrier of a G1)784->A mutation and 3 
and 4 from a normal control. Sets 1 and 4 were run for 2 h whereas 2 and 3 for 3 h.
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The generated sequences of the individual heterozygous for the G551D mutation (with the 
lower case letters representing intronic and the capitals exonic sequences) is as follows:
5’- aatgcagatg caatgttcaa aatttcaact gtggttaaag caatagtgtg
atatgattac attgcaagga agatgtcctt tcaaattcag attgagcata
ataaaagtga ctctctaatt ttctattttt gctaatagGA CATCTCCAAG 
1730 TTTGCAGAGA a a g a c a a t a t  a t t c t t g g a g  a a g g t g g a a t  c a c a c t g a g t  
1780 GGAGG/ATCAAC GAGCAAGAAT TTCTTTAGCA AGgt
4.3. Application of direct sequencing of PCR products in the detection of PBG-D gene 
mutations.
4.3.1. PCR amplification and ‘one-step’ direct sequencing of PBG-D cDNA.
Prior to the handling of the clinical samples from AIP patients, experiments were performed to 
determine the optimal conditions required for the synthesis, PCR amplification and direct 
sequencing of PBG-D cDNA. These optimisation experiments were carried out on various 
sources of RNA including human chorionic and placental RNA, HeLa cell RNA, and total 
cellular RNA from lymphocytes of normal subjects. Both double- and single-stranded PCR 
amplified cDNA were produced and sequenced. Using primers F2 and R2 which flank a 1,108 bp 
region including the entire PBG-D cDNA, reverse transcription and PCR amplification was 
performed according to Grandchamp et al (1989c) whom had kindly supplied us with the 
primers. On following the recommended conditions a 500 bp PCR product was obtained instead 
of the expected product measuring 1,108 bp. The amplification of this 500 bp product was 
persistent and was seen in all samples irrespective of the RNA source. This 500 bp product was 
amplified from human chorionic, placental and blood lymphocyte RNA as well as from HeLa 
cell RNA. In addition it was obtained from both crude and caesium chloride grade RNA 
preparations. Furthermore, this product was also persistently amplified when PBG-D cDNA
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synthesis and amplification was performed through RT-PCR primed with either oligo(dT)12.18 or 
F2 (forward primer) as described under methods.
Single-stranded cDNA was produced by ‘asymmetric’ R-T PCR whereby synthesis of the first 
strand cDNA was performed by priming with 50 pmol of F2, a forward primer complementary to 
the PBG-D m RNA. After reverse transcription, different PCR amplifications were performed by 
the addition of 0.5 pmol, 0.66 pmol and 1 pmol of R2, a reverse primer complementary to the 
PBG-D cDNA, giving F2:R2 ratios of 100:1, 75:1 and 50:1 respectively and 40 amplification 
cycles performed. Results of both asymmetric and standard PCR with the amplification of the 
500 bp product are shown in figure 12a. Both the single- and double-stranded products were 
subsequently directly sequenced.
A ‘One-step’ direct sequencing was performed at first on purified double-stranded PCR 
products. Following R-T PCR amplification, the PCR products were desalted and concentrated 
by centrifuge-driven dialysis method using Centricon 30 (Amicon). The purified products were 
then annealed to the sequencing primers F3 and R3 by heating to 100°C for 2 min and 
immediately placing on dry-ice ethanol bath at -70°C for 30 s. Sequencing was performed with 
Sequenase T7 DNA polymerase, whereby termination reactions were carried out at 50°C, instead 
of being done at the usual temperature of 37°C. Sequencing ladder obtained from this experiment 
was faint and at some places ambiguous as shown in figure 12b. Partial sequence of the open 
reading frame read as follows:
3 ’-ATCACCCTTC TAAATATCCA TCTCCGCTGT TTGGAATGGC TCGGACCACT 
ATCGCCAACA GGTTCTATCT TAGAATCAAG TTGAAATTTA AACGTGTTC -5 ’.
This as well, did not correspond to the already published sequences of either the erythroid or the 
non-eiythroid PBG-D cDNA (Raich et al., 1986; Grandchamp et al., 1987).
To improve the results obtained from sequencing of dsPCR amplified templates, single-stranded 
products were used instead. Samples were purified by centrifuge-driven dialysis method using 
Centricon 30 (Amicon) microconcentrators. Sequencing was done with 1 pmol of the limiting
primer R2, using Sequenase T7 DNA polymerase and carrying out termintion reactions at 37°C. 
To determine the optimal template:primer ratio for the annealing reaction, 30,40, 50 and 75% of 
the PCR products were sequenced with 1 pmol of the sequencing primer. The results of these 
sequencing reactions are shown in figure 13.
b( 1 ) ( 2 ) (  3 )
T C G A T C G A T C G A
Figure 12: ‘One step’ direct sequencing of dsPBG-D cD N A
12a top row: lane 1,1 kb ladder, lanes 2 and 8, R-T PCR performed with an F2:R2 ratio of 
100:1, lanes 4 and 7 with an F2:R2 ratio of 75:1 and lanes 5 and 6 with an F2:R2 ratio of 50:1. In 
all these cases the first strand cDNA synthesis was carried out by priming with F2. Lane 3, R-T 
PCR amplification using oligo(dT)12.18 with an R2:F2 ratio of 100:1 whereas lane 9 with equal 
amounts of F2 and R2 and lane 10, negative control.
12a bottom row: Lane 1,1 kb ladder and lanes 2-10, standard R-T PCR of PBG-D cDNA.
12b: Sequence set 1 and 2, PBG-D cDNA sequenced with nested primers F3 (5 pmol) and R3 
(10 p mol) respectively. Sequence set 3, M13mpl8 control DNA.
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T C G A T C G A T C G A T C G A
Figure 13: One step direct sequencing of ssPBG-D cDNA.
13: Sequence sets 1-4, Single-stranded PBG-D cDNA sequenced with 1 pmol of the limiting 
primer R2, using 30, 40, 50 and 75% of PCR products respectively. Sequencing reactions were 
performed in the presence of Sequenase T7 DNA polymerase. The sequence ladders generated 
from this and the previous experiment were rather faint, implying inadequate DNA templates in 
the one step direct sequencing of PCR amplified products.
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Sequencing ladders generated from direct sequencing of ssPCR products were much improved 
and easier to read than those from dsPCR. Despite these improvements, there were however, still 
some regions in the sequencing ladders with bands appearing in all four lanes, albeit to a lesser 
extent when compared with sequencing of dsPCR products. The sequence obtained from this one 
step direct sequencing method using single-stranded templates was similar to that produced from 
double-stranded PCR products shown above and read as follows:
3’------------ AT ACATCGTTTT ATCACCCTTC TAAATATCCA TCTCCGCTGT
TTGGAATGGC TCGGACCACT ATCGACCAAC AGGTTCTACT TTAGAATCAA 
GTTGAAATTT AAACGTGTCT CTGGAGA -5 ’
R-T PCR was repeated using total cellular RNA which had been previously treated with 
RNAase free DNAase. This still yielded a 500 bp product and on sequencing with an internal 
sequencing primer R3, the same results as above were obtained. To circumvent this the annealing 
step in PCR was raised to 60°C and the amplification and subsequent sequencing of the products 
were performed in two steps. At first RT-PCR was performed to synthesise cDNA which was 
then reamplified to produce single-stranded templates suitable for sequencing.
- 8 4 -
4.3.2. Asymmetric reamplification and sequencing of PBG-D cDNA.
Optimisation experiments were done using HeLa cell and human placental RNA by altering 
various conditions starting from the reverse transcriptase reaction to the eventual PCR. PCR 
amplified products of expected size, were eventually obtained by using new primers (FI and Rl) 
and raising the annealing step to 60°C as described under methodology. Primers Rl and FI flank 
a region 1,150 bp in length which includes the non-coding region of the PBG-D gene thus 
enabling amplification of the entire cDNA. Even under these new conditions there was still, in 
some cases amplification of the 500 bp band. The products were therefore, fractionated in 
agarose gels and the appropriate band excised. The cDNA was then eluted and reamplified by 
asymmetric PCR. Alternatively, amplification of the right sized products was possible by 
amplifying the cDNA with primers F3 and R2 or with primers F2 and R3. These primers amplify 
overlapping cDNA products and therefore span the entire PBG-D cDNA. Figures 14a to 14d 
show results of these PCR optimisation experiments.
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Figure 14: Optimisation for PCR conditions.
14a: Lanes 1,1 kb ladder, Lanes 2-6, R-T PCR amplification with primers F2 and R2 and lanes 
7-10 with primers F2 and R3. The amplification conditions were as described in the methodology 
with the annealing temperature being at 60°C.
14b: Lane 1,1 kb ladder, lanes 2-5, R-T PCR amplification with primers R2 and F2. In lanes 2 
and 3 the amplication was done by an asymmetric PCR, whereas in 4 and 5 by a standard PCR. 
Lanes 6 and 7, standard R-T PCR with primers FI and Rl. In lanes 1-5 annealing was performed 
at 55°C and 6 and 7 at 60°C.
14c: R-T PCR amplification with primers FI and Rl in which annealing was performed at 55°C. 
14d: Asymmetric reamplification of products in figure 14b lanes 6 and 7, using internal primers 
F2 and R3 demonstrating presence of single-stranded cDNA.
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Having optimised for the PCR conditions, RT-PCR was performed on various templates 
including HeLa cells, human placenta cells, lymphocytes and lymphoblastoid cells of normal 
individuals. The R-T PCR was done with primers FI and Rl and the cDNA eluted as described 
previously. The eluted cDNA was then reamplified with internal primers F2 and R3 in an 
asymmetric PCR and the products purified by different methods to compare their efficacy. Figure 
15a demonstrates PCR products obtained from R-T PCR using primers FI and R l and figure 
15b, the results of asymmetrical reamplification of these products with internal primers F2 and 
R3. The single-stranded PCR products obtained from the reamplification of the PBG-D cDNA 
were purified either by selective precipitation in 2 M ammonium acetate and propan-2-ol or by 
centrifuge-driven dialysis using Centricon 30 (Amicon). After purification, 50% of each PCR 
was sequenced with either the limiting primer F2 or the internal primer F3, using Sequenase T7 
DNA polymerase. Sequences obtained from this experiment are shown in figure 15c. These 
sequences correspond with the published sequences of the PBG-D cDNA.
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t c g a t c g a t c g a t c g a
F igure 15: A  two step amplification and sequencing of PBG-D cD N A .
15a: Double-stranded PCR products obtained from amplification with primers FI and Rl.
15b: Products of asymmetric PCR amplification of PBG-D cDNA. The original products in 
figure 15a above, were reamplified with nested primers F2 and R3. Top row, are products 
produced with F3 as the limiting primers whereas, in the bottom row, the limiting primer was R3. 
15c: Sequence sets 1 and 3, sequences of PBG-D cDNA from HeLa cell RNA and lymphocytes 
of a normal control respectively, following Centricon 30 microconcentrator purification.
Sequence sets 2 and 4, sequences obtained from HeLa cells and normal lymphocytes after the 
purification of PCR products by selective precipitation with ammonium acetate and propan-2-ol.
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Set 1 and 3 were sequenced with the limiting primer F2 whereas sets 2 and 4 with the internal 
primer F3.
Sequencing of PCR products from 15b above, was repeated using Tag DNA polymerase as a 
sequencing enzyme. Sequencing was done with primer F3 following the purification of PCR 
products by selective precipitation in 2 M ammonium acetate and propan-2-ol. Sequences 
generated from this experiment are shown in figure 16. These experiments in principle 
established and standardised the protocol that was used for the detection of mutations of PBG-D 
gene in patients with AIP.
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T C G A T C G A  T C G A T C G  A
Figure 16: Sequencing of PBG-D cD N A  with Taq D N A  polymerase.
Set 1-3, Sequences of PCR amplified PBG-D cDNA from human placental RNA, normal control 
lymphocyte RNA and HeLa cell RNA respectively. Set 4, M13mpl8 control DNA. The products 
were all purified by precipitation in ammonium acetate and propano-2-ol and sequenced with 
primer F3 in a Taq DNA polymerase mediated reaction.
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4.3.3 Direct sequencing of PBG-D cDNA from crude cell lysate preparations.
Following the successful sequencing of PBG-D cDNA, modifications were introduced in order 
to simplify the protocol used for the detection of mutations. These included the use of crude 
preparations of buccal cells and fresh blood lymphocytes as sources of RNA. Crude RNA 
preparations were made by lysing buccal cells from mouth washings and direct amplification of 
PBG-D cDNA attempted from the cell lysates. This approach was however, unsuccessful despite 
several attempts. 20 ml of venous blood were then collected from volunteers and lymphocytes 
separated. The lymphocytes were lysed and PBG-D cDNA amplified from crude RNA 
preparations using primers FI and Rl as described before. Asymmetric reamplification of the 
cDNA with internal primers, provided templates suitable for sequencing. In addition asymmetric 
R-T PCR was performed directly on the cell lysate using primers FI and R l and sequenced 
successfully with internal primers as shown in figure 20.
Figure 17: Direct sequencing of PBG-D cD N A  derived from uncultured cells.
17a: Asymmetric PCR of PBG-D cDNA derived from uncultured lymphocytes amplified with 
primers F3 and R3. The top row is with F3 limiting and the bottom row with R3 limiting.
17b: Asymmetric PCR products amplified directly in a R-T PCR using primers FI and Rl.
17c: Sequence sets 1-3, sequences generated from uncultured lymphocytes as shown in figure 
17a bottom row, in which sets 1 and 2 were sequenced with primer R4 and set 3 with R5. 
Sequence set 4, one step sequencing of PCR products amplified by asymmetric R-T PCR and 
sequenced with a nested primer F3 without reamplification of the cDNA. Sets 5-8, sequences 
generated from lymphoblastoid cell lines, in which set 5 was sequenced with F3 and the rest with 
R3.
- 9 2 -
4.3.4. Problems associated with direct sequencing of PBG-D cDNA.
In the course of the development and optimisation of the protocol for PCR amplification and 
direct sequencing of PBG-D cDNA, several problems worth mentioning were encountered.
Some of these problems would occur from time to time even after the establishment and 
standardisation of the protocol, mainly during the sequencing reactions. The most commonly 
encountered problems were the inability to amplify and sequence a particular strand of cDNA 
and the inability to accurately interpret some results due to the presence of ambiguous 
sequencing ladders caused by the appearance of the same sequencing bands in all four lanes.
In some cases asymmetric PCR amplification seemed to work for one strand and not the other, 
making it difficult to sequence a particular cDNA strand even after optimal conditions had been 
defined. On the other hand, sequencing of a particular cDNA strand was occasionally found to be 
poor even after what appeared to have been a very successful PCR amplification. These problems 
are illustrated in figures 18a to 18c.
Sequence ambiguity due to the presence of the same bands appearing in all lanes was 
encountered in several templates. There were two main types of such bands as shown in figures 
19 and 20.
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T C G A  T C G A
F igure 18: Strand specific problems associated with direct sequencing o f PCR amplified products.
18a: Lane 1, 1 kb DNA ladder. Lanes 2-5, asymmertic PCR products amplified with primers F2 
and R3 in which R3 was the limiting primer and in lanes 6-9 the limiting primer was F2. PCR 
amplification in lanes 2-5 is very much inferior when compared with that in lanes 6-9 though 
they were from the same individual and performed at the same time using the same conditions. 
18b: Lanes 1 top and bottom rows, 1 kb DNA ladder and lanes 2-9 top row, asymmetric PCR 
products amplified with primers F2 and R2 in which F2 was limiting, whereas in the bottom row 
R2 was limiting. Lanes 6-9 bottom row show the presence of more single stranded products then 
6-9 in the top row. This is confirmed in the sequencing ladders shown in 18c.
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18c: Sequencing set 1, sequence of PBG-D cDNA in figure 18b bottom row lane 6, sequenced 
with primer R2. Set 2, sequencing of products from lane 6 of the top row, sequenced with F2. In 
both cases the sequencing primers were the limiting primers used in asymmetric PCR 
amplifications. Set 1 also depicts ambiguous sequences due to the presence of multiple bands in 
several lanes.
( 1 > < 2 ) < 3 ) ( 4 )  
TCGA TCGATCGATCGA
Figure 19: Sequencing artefacts.
Sequence sets 1 and 2, AIP patient and a normal control respectively, sequenced with primer F3. 
Set 3 and 4, the same individuals sequenced with primer F5. Arrows (a) point out bands which 
appeared in all tracks  ^ whereas (b) bands were unique to those templates sequenced with 
primer F5. The gel was run for 3 h at the temperature of 50°C.
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F igure 20: Effect o f gel temperature on sequencing artefacts.
Sequencing products in figure 19, were run in a different gel at a running temperature of 60°C. 
Sets 1-4 were run for 4 and sets 5-8 for 2 h. Sets 1 and 2, AIP patient and normal control 
respectively, sequenced with primer F3, whereas 3 and 4, were sequenced with primer F5. Sets 
5-8, sequencing products from sets 1-4 respectively, electrophoresed for 2 h. Both types of 
artefacts (a and b) were persistent in this case, even when the gel was nm at a higher temperature 
of 60°C. A substitution of G to T at nucleotide position 606 is seen in set 7.
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4.3.5. Detection of mutations in PBG-D gene in patients with AIP.
4.3.5.1. RNA extraction and quantitation.
Total cellular RNA was extracted from lymphoblastoid cell lines of 30 patients with AIP and 10 
controls. In the clinical cases and controls, total cellular RNA was prepared by extraction with 
guanidium thiocyanate and equilibrium centrifugation through caesium chloride. The 
preparations were run in RNA checker gels to determine the integrity of the RNA whereas 
concentration and purity were determined by spectrophotometry. The mean total cellular RNA 
concentration was 650 ug/ml and the range 128-1400 ug/ml. The purity as determined by the 
mean value of OD26o/OD28o was 1.98. Results of fractionation of the RNA preparations are 
shown in figures 21a and 21b.
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F igure 21: RNA electrophoresis o f AIP patients and controls.
21a and 21b: Lane 1,1 ug of Escherichia coli ribosomal RNA used as a marker whereas the 
remaining lanes in 21a, are RNA samples from AIP patients and 21b from normal controls. The 
top band in the samples from patients and controls represent 28S rRNA and the bottom one 18S 
rRNA while the smear denotes the presence of mRNA.
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4.3.5.2. Delineation of molecular pathology in AIP.
Total cellular RNA from affected individuals and control subjects were amplified with primers 
FI and Rl in a R-T PCR to produce cDNA. In all cases the correct sized fragments were 
amplified thus excluding any major deletions or truncated mRNA products. The cDNA was then 
reamplified in asymmetric PCR using primers F2 and R2. Sequencing was done with limiting or 
nested primers as described in the methods. Sequence changes were determined by comparing 
with normal control sequencing ladders and confirmed by showing the same change in the 
opposite strand.
To sequence the entire PBG-D cDNA, at least four different sequencing primers were used in 
addition to the application of various techniques which highlight different regions of the 
sequencing ladder. Highlighting of sequences close to the sequencing primers was achieved by 
using manganese buffer whereas to facilitate sequencing of regions distant from the primers, the 
concentrations of dNTPs used in the labelling reactions were increased. Figure 22, demonstrates 
sequencing of the entire PBG-D cDNA in a single experiment, where sequence sets 3,4, 5 and 8 
where from the same individual.
1 2 3 4 5 6 7 8
l _
F igure 22: Sequencing of the entire PBG-D cD N A  in one experiment.
Sequence set 3 was sequenced with primer R4 using a labelling mix containing 7.5 uM each of 
dCTP, dGTP and dTTP and 20 uCi of (a-32P)dATP. The reactions were electrophoresed for 4 h. 
Sequence set 8 was also sequenced with primer R4, except that standard concentrations of 
dNTPs in the labelling mix were used as described in the methods, hi addition, the sequencing
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reactions were performed in the presence of manganese buffer and electrophoresed for 2 h only. 
Sets 4 and 5, were sequenced with primers R5 and F4 respectively and electrophoresis carried 
out for 4 h. In this screening experiment, Set 3 shows the G606->T mutation in the anti-sense 
strand.
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Using the above method, the PBG-D cDNA was rapidly scanned in both AIP patients and 
normal controls. Seven mutations summarised in table 1 and shown in figures 23-29 were 
demonstrated in nine patients with AIP and none in the control subjects. The Q34K and L177R 
mutations were each seen in two individuals whereas, H256N, R167Q, L42L and S45S were 
noted in one individual each and V202V in four. All mutations were due to single base 
substitutions. Four mutations namely Q34K, R167Q, L177R and H256N were associated with 
amino acid substitutions whereas in the remaining three (L42L, S45S and V202V) there were no 
changes. Three of the mutation namely L177R, H256N and S45S were associated with alteration 
in the recognition sites for restriction enzymes. Mutations L117R and H256N lead to the 
abolishing of recognition sites for the enzymes Alul and Banl respectively whereas the silent 
mutation S45S abolishes the recognition site for Rsal.
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Table 1: Mutations of the PBG-D gene, detected in AIP patients in the current study.
Mutation Exon Amino acid change
C100->A (Q34K) 4 Glutamine to lysine.
G500->A (R167Q) 10 Arginine to glutamine.
T530->G (L177R) 10 Leucine to arginine.
C766->A (H256N 12 Histidine to asparagine.
G117->A (L42L) 4 None.
G135->A (S45S) 4 None.
G606">T (V202V) 10 None.
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F igure 23: Q34K mutation causing the substitution of glutamine to lysine.
Partial sequencing ladders of the sense strands, comparing sequences from a normal control on 
the left and a patient with acute intermittent porphyria on the right. The wild-type sequence 
reads, ATACAGAC, whereas the mutant sequence is, ATAC/AAGAC, denoting a C to A 
transversion at nucleotide position 100 in exon 4. This is demonstrated by the appearance of both 
alleles i.e. bands C and A at the same position. The mutation leads to the substitution of a highly 
conserved amino acid glutamine to lysine at the amino acid residue position 34 (Q34K). In 
addition, by using PEPTIDESTRUCTURE and PLOTSTRUCTURE computer programmes, it 
has been predicted that, this change is likely to cause a disruption of the PBG-D (3-strand. The 
mutation was observed in a mother and her daughter.
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F igure 24: R167Q mutation causing the substitution of arginine to glutamine.
Partial sequences of exon 10 of the PBG-D gene. Mutant sequences of the sense strands are 
shown on the left and the wild type on the right. In the section shown, the normal sequence reads, 
AACTCCAAAGGGGCTTACGA whilst the mutant reads, AACTCCAAAGGGG/ACTTCGA 
because of a G to A transition at nucleotide position 500. This change causes the substitution of 
the highly conserved amino acid arginine to glutamine at position 167 (R167Q) of the protein 
structure. In the figure, it can be observed that in the mutant sequence the mutated A band has 
greater intensity then the normal G band. To date this is the only mutation of PBG-D that has 
been reported separately by more than one investigator. This mutation was seen in one patient.
T530^ G
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F igure 25: L177R mutation causing the substitution of leucine to arginine.
The normal sequence, AGCAGGTCGAAGGCT shown on the left is part of exon 10 of the 
PBG-D gene. The mutant sequence, AGCAGGT/GCGAAGGCT on the right arises from a T to 
G transversion at position 530 as demonstrated in the figure, by the presence of both G and T 
bands at this position. This results in the substitution of a highly conserved amino acid, leucine to 
arginine at amino acid residue position 117. The change, which was observed in two unrelated 
AIP patients, also abolishes a recognition site for the restriction enzyme Alul which can be used 
to track this mutation within this family.
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F igure 26: H256N mutation causing the substitution of histidine to asparagine.
Partial sequences of exon 12 of the PBG-D gene. The sequence on the right is from a patient with 
AIP showing a C to A transversion at nucleotide position 766. The normal sequence on the left 
reads, GGTCCACGGAGTC whilst the mutant reads, GGTCCAC/AGGAGTC. This mutation 
substitutes the amino acid histidine for asparagine at the amino acid residue position 256, altering 
a conserved charge. In addition the change abolishes a recognition site for the restriction enzyme 
Banl which may be used to track this mutation in this family. The change was observed in one 
patient.
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F igure 27: Silent mutation L42L.
Partial sequences of exon 4 of the PBG-D gene, showing a silent mutation at nucleotide position 
117. The sequence on the left, GGTGGCAAC is from a normal control and the one on the right 
from an AIP patient. The mutant sequence reads, TGGTG/AGCAA. This mutation, which was 
observed in one individual, does not result in any change, either in the amino acid pattern or 
recognition sites for restriction enzymes.
- 1 0 9 -
135
TCGA
A
T
G - A
n
T
8
T C G A
B
M
» «
*•*
**
F igure 28: Silent mutation S45S.
The partial sequence on the left is from a patient with AIP with a G to A transition at position 
135 in exon 4. The wild-type sequence on the right reads, CCTCCCGTACCC, whereas the 
mutant is, CCTCG/ATACCC. This mutation which was observed in one subject abolishes a 
recognition site for the restriction enzyme Rsal, which may be useful in linkage studies for 
tracking gene carriers within this family. Since the mutation changes codon TCG (UCG) to TCA 
(UCA), both coding for the same amino acid serine, it does not cause any amino acid 
substitution.
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Figure 29: Silent mutation V 202V .
Partial sequences of exon 10. The sequencing ladder on the left is the normal and on the right a 
mutant sequence from a patient with AIP. The normal sequence is, 
CGTCCTAGACGGGGTGGGCCAACAC whereas the mutant sequence reads, 
CGTCCTAGACGGGG/TTGGGCCAACAC. This alters codon GTG (GUG) to GTT (GUU) 
both coding for the same amino acid valine. This mutation, therefore causes no change in the 
amino acid pattern, and moreover, does not alter any recognition sites for restriction enzymes. 
The mutation was seen in four patients with AIP.
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4 .3 .6 .  A n a ly s is  o f  s e c o n d a r y  s t r u c t u r e  a l t e r a t io n s  r e s u l t in g  f r o m  t h e  d e t e c t e d  P B G - D  
m u t a t io n s .
Alignment of the mutated amino acid sequences with normal sequences of other species 
revealed that three of the detected mutations affected highly conserved amino acids and one a 
conserved charge. In addition, crystallographic studies kindly performed by Prof. Blundell 
(Birbeck College, University of London) revealed that these mutations were likely to result in 
either, structural or functional aberrations. These results are summarised in table 2. In the table, 
due alignment of the human PBG-D with sequences of different deaminases from other species, 
the numbering of the amino acid residues differs from that reported by Grandchamp et al (1987). 
The number in brackets refer to the original amino acid residue position in the human non- 
erythroid PBG-D.
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Table 2: Analysis of the PBG-D structural and functional changes likely to arise from the detected mutations.
Residue
Glnl9(34)*
Structural environment
Located at base of active 
site cleft and involved 
in hydrogen bonding to 
conserved residues 
Ser81(96) and Argl76(191)
Argl49(167)* Forms direct salt bridge 
to acetyl side group of 
ring 2 of cofactor. The 
position occupied by 
this ring may become 
the binding site for 
the incoming PBG
Leul59(177)* Forms part of
hydrophobic core of the 
molecule
His237(256) In E. Coli protein, Arg237
forms a salt bridge to 
Glu292. His237(256) 
and Asn292(322) may 
form a corresponding 
hydrogen bond in the 
human PBG-D
’"Highly conserved amino acid.
Possible structural 
or functional change
Change to Lys 
disrupts hydrogen 
bonding network, 
especially in two 
nearby positively 
charged residues
Change to Gin 
results in loss of 
stabilising 
interaction to 
carboxylate group of 
the cofactor, and 
possibly of the 
substrate
Change to Arg 
introduces a 
destabilising effect 
of a charged group 
within the apolar 
core.
Change to Asn, 
results in a pair of 
Asn which may be 
less able to form 
hydorogem bond
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CHAPTER FIVE: DISCUSSION.
5. DISCUSSION.
During the course of developm ent and optimisation of direct sequencing of PCR amplified 
products in the characterisation of PBG-D mutations, it became clear that the two most important 
factors were the template quality and quantity. These were in turn, influenced mainly by the 
efficiency of PCR amplification and the subsequent purification of the templates. In the case of 
RNA amplification, the quality of the RNA as a starting material also mattered.
5.1. Direct sequencing of dsPCR amplified DNA templates with end-labelled primers.
Direct sequencing of PCR amplified products was first performed on ds templates. In these 
experiments DNA was amplified from 500 bp segments of the DMD gene, the plasmid pBR322 
and bacteriophage lambda. In all cases after optimisation for the PCR conditions, the correct 
sized products were amplified. The amount of DNA amplified as estimated by ethidium bromide 
fluorescence was judged to be adequate as shown in figure 8a. Prior to sequencing, the products 
were extracted in chloroform to remove traces of mineral oil used in the polymerase chain 
reactions, then passed through Sephadex G-50 (Pharmacia) spun columns for concentration and 
removal of salts, excess dNTPs and amplification primers. Sequencing was performed with the 
same amplification primers end-labelled with 32P. The primers were annealed to the templates by 
heating the primer-template mixture to 100°C for 2-5 min and snap freezing in a dry ice-ethanol 
bath for 30 s. In some cases following the heat denaturation, the templates were annealed on wet 
ice at 0°C for 30 s. The annealed primer-template mixture was then immediately used in 
sequencing reactions to discourage template renaturation. These early attempts at sequencing 
invariably failed but were useful in identifying the main pitfalls, which were template 
purification and primer-template annealing.
Purification of the PCR templates aims at removing the excess amplification primers, dNTPs 
and salts used in the amplification reactions because of their interference in sequencing reactions. 
The presence of the excess amplification primers interferes with the annealing and the extension 
steps in the sequencing reactions. This occurs because the unlabelled amplification primers may
either compete directly with the radiolabelled sequencing primers for binding sites on the 
template DNA or generate extension products that efficiently exclude the radiolabelled 
sequencing primers. It is also necessary to remove all dNTPs used in the PCR, so that they do not 
serve as substrates in the subsequent chain-termination reactions and hence interfere with 
sequencing reactions. The presence of salts also tend to interfere with sequencing reactions by 
inhibiting sequencing enzymes. Although the removal of excess dNTPs, amplification primers 
and salts have been attempted by separation through Sephadex G 50 (Pharmacia) spun columns 
(Newton et al., 1988), in the current study this method was found to be unsatisfactory. Both the 
separation of amplification primers from templates and the template recovery were found to be 
inconsistent. For example, when using spun-column chromatography, it is recommended that the 
eluted DNA be collected during the first round of centrifugation (Sambrook et al., 1989b), but it 
was found in the current study that this was not always applicable. The DNA recovery was 
variable from one experiment to another, and maximum recovery could be anywhere between the 
first and the the fourth round of elution as shown in figure 8b. Furthermore these experiments 
revealed that the method was associated with poor recovery of DNA as evidenced by its presence 
even during the fourth round of elution. Thus after collecting the first or even the second round 
eluate, there was still a significant amount of DNA trapped in the columns. In addition, primer 
removal was not always efficient, thus defeating the whole purpose of the purification. Another 
practical problem associated with this method of purification was the tendency of the columns to 
collapse, leading to loss of samples. Although this was infrequent, such losses can be 
catastrophic when precious samples are involved.
Despite of the fact that successful sequencing of dsPCR products has been reported by several 
authors (Wrischnick et al., 1977; Wong et al., 1987; Engelke et al.„ 1988; Higuchi et al., 1988a; 
Newton et al., 1988), this approach can still be problematical. This is due to the fact that the 
protocols currently available for preparation of double-stranded templates for sequencing were 
developed for covalently closed circular plasmids (Chen and Seeburg, 1985; Zagursky et al.,
1965; Lim and Pene, 1988). Although satisfactory results are obtained for supercoiled plasmid
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DNA, rapid reannealing of short, linear, dsDNA templates as produced by PCR is a significant 
obstacle to sequencing of DNA templates by this approach (Kretman and Landweber, 1989).
This problem is compounded by the fact that these protocols, adapted for sequencing of dsPCR 
products do vary considerably (Wong et al., 1987; Wrischnik et al., 1987; Newton et al., 1988; 
Higuchi et al., 1988; Saiki et al., 1988; Kretz et al., 1989; Winship, 1989; Bachmann et al.,
1990). For example in the direct sequencing of |3-globin gene, Wong et al., (1987) denatured the 
templates by heating at 95°C for 10 min and performed the primer-template annealing at 37°C 
for 2 min at a primer:template ratio of approximately 7:1, whereas Saiki et al. (1988) while 
investigating the same gene, performed the denaturing at 95°C for 10 min and annealing at 0°C 
for an unspecified duration. On the other hand Newton et al., (1988) while sequencing the a- 
antitrypsin gene denatured the templates by boiling at 100°C for 5 min and and immediately 
placed the primer-template mixture at -70°C for 5 min. In 1990, Casanova et al., determined the 
optimal set of conditions for the primer-template annealing. They found out that for best results, 
the primer-template mixture should be heated to 100°C and immediately placed at -70°C for 
15-45 s, using a primentemplate ratio of 20:1. Among these factors, the duration of the annealing 
reaction is probably the most crucial parameter. Casanova et al. (1990) were able to show that 
sequences were readable only when the duration of the annealing reaction was carried out for 
0-45 s and that within that range of time, sequencing band intensity increased with time. 
Sequences became unreadable when primer-template annealing was done for 60 s or more. 
Similarly sequences were difficult to read when the primentemplate ratio was 2:1 or less and 
non-specific sequencing bands appeared when the ratio exceeded 200:1.
In order to compare efficacy of different methods of denaturation of templates prior to the 
primer-template annealing, templates were also denatured by alkali treatment. The templates 
were denatured in 0.2 M NaOH for 5 min, either at room temperature or at 37°C, put on ice and 
the reaction neutralised with ammonium acetate as described in the methods section. The DNA 
was then immediately precipitated by addition of 2.5 vol of ethanol and resuspended in 10 ul of 
dH20  or TE buffer before being used in the sequencing reactions. The denatured DNA pellets
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prepared by this method can be stored in this form for several weeks and when required 
dissolved in dH20 or TE buffer just before use (Hattori and Sakaki, 1986). Despite the fact that 
alkali denaturation has proved to be superior to heat denaturation in the preparation of ds 
supercoiled plasmid templates for sequencing (Chen and Seeburg, 1985; Hsiao, 1991), it does 
not seem to be the preferred method in the sequencing of dsPCR amplified templates. Virtually 
all reports on successful sequencing of dsPCR products have been carried out using the heat 
denaturation method (Wong et al., 1978; Wrischnik et al., 1987; Newton et al., 1988; Higuchi et 
al., 1988; Kretz et al., 1989; Winship, 1989; Bachmann et al., 1990; Casanova et al, 1990). 
Nevertheless, the main problem associated with both approaches is the rapid reannealing of the 
templates following the denaturation.
To overcome this problem, Winship (1989) used DMSO. The addition of 10% DMSO in the 
sequencing reaction mixtures, not only improved the intensity of sequencing ladders but also 
reduced the background at specific positions. This reduction in the background is thought to be 
due to the prevention of secondary structure formation. Similar results have also been obtained 
by Bachmann et al. (1990) through the addition of the detergents nonidet P-40 (NP-40) and 
Tween 20. By denaturing templates in the presence of 0.5% NP-40 or Tween 20 or a 
combination of both and including the detergents in the sequencing reactions, the intensity of the 
sequencing ladders similarly increased and the background at specific positions decreased as 
well. These modifications, however, were not attempted in the current study.
Another way of improving the quality of sequences generated from dsPCR products is to end- 
label the sequencing primer with 32P, rather than have it incorporated as a nucleotide during the 
polymerase-mediated chain extension in the sequencing reactions (Engelke et al., 1987; Wong et 
al., 1987; Saiki et al.„ 1988). This approach unfortunately requires an additional enzymatic step 
in the kinasing reaction and more important, obviates the use of 35S with its superior base-ladder 
resolution (Kraitman and Landweber, 1989). In the current study, the application of spun-column 
purification and 32P end-labelled primers for sequencing of dsPCR amplified templates was 
unsuccsseful. In most cases the autoradiographs showed a high background with almost no
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sequencing ladder at all. To ensure that the problem did not lie in the radiolabelling of the 
sequencing primers, the primers were tested for the degree of isotope incorporation before use. 
This was done using Whatman DE-81 filters as described in the methodology. These filters being 
positively charged, strongly adsorb and retain nucleic acids, including oligonucleotides. 
Unincorporated nucleotides bind less strongly to the filters and are removed by washing with 
sodium phosphate. In most cases the proportion of radioactivity incorporated into the primers 
was well above 70%. To be effective, the sequencing primers should incorporate at least 20% of 
the radiolabel.
To circumvent the problems associated with sequencing of dsPCR derived templates, attempts 
were made to produce single-stranded templates using strand separation gel electrophoresis. 
Following a standard PCR, the double-stranded products were precipitated in ethanol, washed 
twice in 70% ethanol and the pellet dissolved in a strand separation buffer containing 30% 
DMSO, 1 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol FF. The mixture was 
then heat denatured and fractionated in a 5% non-denaturing polyacrylamide gel as previously 
described. The gel was stained with ethidium bromide and the DNA visualised under U.V. light. 
Results of these experiments as shown in figure 9a and 9b, indicate the presence of several bands 
though three of them appeared to be more prominent then the others. The electrophoretic 
mobility of ssDNA fragments in non-denaturing polyacrylamide gel is unpredictable because to 
some extent this depends on secondary structure. In figures 9a and 9b, it was therefore 
impossible to tell which band belonged to which strand. Moreover, the presence of multiple 
bands presumably due to spurious products which are otherwise undetected in agarose gels 
further complicated the interpretation. It was, however, assumed that the fast main band 
represented the non-denatured dsDNA and the two slower bands the two separated bands. The 
method was also found to be cumbersome and labour-intensive.
These early attempts at direct sequencing of PCR amplified products were possibly 
unsuccessful because of a combination of several factors. These factors where in two main areas 
namely, inefficient purification of the PCR products and poor primer-template annealing and
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extension during the sequencing reactions. The inefficient purification was associated with poor 
DNA recovery and hence inadequate templates for sequencing. In addition, there was inefficient 
primer removal and this must have contributed to the poor results. Although not proven, it is also 
very likely that this inefficient purification from using spun columns might have been associated 
with inadequate removal of salts and dNTPs which may have also contributed to the poor results. 
Sequencing primer-template annealing was performed at different temperatures and for different 
durations some of which were sub-optimal. In some experiments the annealing was carried at 
0°C and the duration not timed. The primentemplate ratio was also sub-optimal and ranged 
between 1:1 to 10:1. These variation reflect the diversity of protocols in use for sequencing of 
dsPCR products.
From these experiments, it was concluded that the most significant problem was in the 
purification method. To improve this, other PCR product purification methods were used and 
compared. In addition, in order to improve the resolution of the sequencing ladders, 35S was used 
instead of 32P.
5.2. Direct sequencing of dsPCR products using incorporation labelling.
Following the failure to sequence dsPCR products by the above methods the approach was 
revised. Double-stranded products produced by standard PCR were concentrated and purified 
with NACS columns using two approaches. In one set of experiments, the products were first 
fractionated in 1.5% low melting NuSieve agarose gel and the appropriate band excised. The gel 
slice was then melted and the cDNA eluted and purified with the NACS columns. Alternatively, 
following PCR, the products were directly purified in the NACS columns. NACS is an ion 
exchange resin that binds nucleic acids in low salt (0.1-0.5 M NaCl) and releases them in high 
salt solutions (0.7-2.0 M NaCl). The principle of NACS column purification is based on the fact 
that generally the resin binds larger polynucleotides more tightly than smaller ones. It also binds 
single-stranded nucleic acids more tightly than double-stranded molecules.
In sequencing reactions, prior to the primer-template annealing, templates were denatured by 
either alkali or heat treatment as described before. Of the two methods, heat denaturation was 
found to be more effective than alkali treatment. This is in contrast to the experience of Chen and 
Seeburg (1985), who on sequencing double-stranded plasmid templates found the opposite to be 
true. It is of interest, however, to point out that virtually all successful reports on sequencing of 
dsPCR amplified templates have been based on the heat denaturation method (Wong et al., 1978; 
Wrischnik et al., 1987; Newton et al., 1988; Higuchi et al., 1988; Kretz et al., 1989; Winship, 
1989; Bachmann et al., 1990; Casanova et al, 1990). This may be due to the fact that, dsPCR 
being short and linear tend to reanneal much faster then the supercoiled plasmid templates. The 
optimal primentemplate ratio was determined by altering the amount of the template used. This 
was thought to be necessary because of some of the previous reports that have indicated that one 
of the main problems of direct sequencing of PCR products was due to insufficient template 
DNA (Saha, 1989). To overcome this problem Saha (1989) recommended to either perform 
PCRs in 500 ul instead of the usual 100 ul reactions or to pool several PCRs prior to sequencing. 
In the current study different amounts of dsDNA templates ranging from 50% of a PCR to two 
pooled PCRs were sequenced with 1 p mol of the sequencing primer as shown in figure 10. In
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the experiment depicted in figure 10, bacteriophage lambda DNA was amplified and sequenced 
with one of the primers used in the amplification. Figure 10b shows that the sequencing ladder 
generated from templates that were gel fractionated prior to NACS purification had a cleaner 
background than those that were directly purified by the NACS columns. It also shows higher 
intensity of the sequencing bands when two PCRs were pooled than when only one PCR was 
used in the sequencing reactions. Paradoxically, it was the templates that were directly purified 
by the NACS columns without any prior gel separation that gave the best results in terms of the 
number of readable bases. Using samples which their purification included gel separation, the 
sequencing bands were faint and in many areas the same bands appeared in all four lanes. The 
latter phenomenon often referred to as ‘pile-ups’, ‘full stops’ or ‘walls’ usually occurs when a 
sequencing enzyme especially Sequenase T7 DNA polymerase, encounters a complex secondary 
structure in the DNA template being sequenced. Such artefacts may also occur with bad template 
preparations especially if there is an excess of salt or nicking of template DNA during the 
purification. The complex process of gel separation, melting and passing through the NACS 
columns may explain this. In addition, it has been discovered that agarose contains substances 
that inhibit Taq DNA polymerase and it has therefore been suggested that agarose separation 
should not be used for those samples which are going to be sequenced with this enzyme 
(Gyllensten, 1989). This has however, been shown not to be the case with Sequenase T7 DNA 
polymerase by Kert et al., (1989), who were able to directly sequence PCR products from low- 
melting agarose, thus circumventing the need for DNA elution and further purification. The faint 
sequencing bands noted in the samples that were first fractionated in agarose gels compared to 
those that were directly purified through the NACS column may be due to inefficient elution of 
the DNA templates from agarose using this method. In a similar experiment depicted in figure 
10c, a readable sequencing ladder was obtained from the sequencing of as little as 50% of one 
PCR, indicating that in a single amplification reaction, there is sufficient DNA for sequencing as 
long as it is processed efficiently in the course of template purification.
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The quality of the sequencing ladders obtained from dsDNA was however not always 
satisfactory. The quality of such templates in terms of the number of bases which can be 
accurately read depends on the purity of the DNA templates (Murphy and Ward, 1989). Artefacts 
are seen more often in the sequencing of double- rather than single-stranded templates. The 
majority of the artefacts are likely to be caused by the greater tendency of the denatured dsDNA 
templates to form inter-chain cross links through reannealing. Pile-ups, often observed at several 
points in the sequencing ladder appear to be produced more often in the sequencing of double­
stranded templates. These can often be eliminated by performing the chain extension and 
termination reactions at a higher temperature (42°C up to 50°C) or by sequencing the opposite 
strand (Hatori and Sakaki, 1986; Murphy and Ward, 1989). When performing the chain 
extension and termination reactions at such high temperatures it may be necessary to add more 
sequencing enzyme in a chase-mix. Alternatively these pile-ups may be eliminated by using 
dITP or 7-deaza-dGTP instead of dGTP in the sequencing reactions (Murphy and Ward, 1989) or 
by sequencing with Taq DNA polymerase (Innis et al., 1988; Gyllensten, 1989; Brow, 1990). If 
this problem persists, it may necessitate the use of ssDNA-binding protein in the sequencing 
reactions. Single-stranded DNA-binding protein acts by preventing the formation of secondary 
structures. The disadvantage of using this, is that it requires removal by digestion with proteinase 
K prior to electrophoresis of the samples as it causes retardation of nucleotide migration 
(Murphy and Ward, 1989). Template reannealing is also responsible for the high background 
seen in the sequencing of double-stranded templates.
In the experiments referred to in figure 10, in addition to the problems associated with the 
sequencing of double-stranded templates, inconveniences were noted with the use of NACS 
columns. As purification with NACS columns is based on gravitational force, the drip columns 
tend to be slow and time consuming. Practical problems such as entrapped air bubbles within the 
columns interfering with elution of the cDNA, was a very common occurance. This hampered 
the simultaneous handling of many samples. To improve on this, attempts were made to produce
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single-stranded PCR templates through PCR and to find simpler and more convenient ways of 
purifying these templates.
5.3. Direct sequencing of ssPCR amplified templates from genomic DNA.
Single-stranded templates were produced by asymmetric PCR from various sources including a 
fragment of the cystic fibrosis gene, spanning across the G1>784->A (G551D) mutation. In the 
case of the cystic fibrosis gene, this segment was amplified both from a known cystic fibrosis 
carrier and a normal control. In these experiments, the amplification primers were used at a ratio 
of 1:100 to amplify approximately 0.5 ug of genomic DNA. In asymmetric PCR, by using 
unequal amounts of amplification primers, most of the product generated during the first 20-25 
cycles is double-stranded and accumulates in the usual exponential way. As the limiting primer 
becomes exhausted, the later cycles generate an excess of ssDNA complementary to the limiting 
primer. However, in contrast to the exponential growth of the dsDNA, ssDNA accumulates 
linearly (Gyllensten and Erlich, 1988; Kreitman and Landwber, 1988; Saiki et al., 1988c). 
Because of the fact that ssDNA products appear only in the later cycles of the PCR and that they 
increase by arithmetic progression, efficiency of asymmetric PCR is low when compared to the 
standard PCR (Gyllensten, 1989; McCabe, 1990). To compensate for this sub-optimal 
amplification it has been suggested that the number of PCR cycles be increased (Gyllensten and 
Erlich, 1988). In these experiments the number of PCR cycles was raised to 40 instead of 30. 
Alternatively, the low efficiency of the asymmetric PCR can be overcome by adding more Taq 
DNA polymerase in the late cycles of the PCR or by using more of the enzyme right from the 
outset
To enable sequencing of both strands two sets of PCRs were done with reciprocal ratios of the 
limiting primers. The results of these amplifications are shown in figure 11a. One of the features 
associated with asymmetric PCR and shown in figure 11a, is the production of spurious products. 
Amplification of these spurious products can be minimised by using the minimum necessary 
amount of target DNA and dNTPs. A balance should nevertheless be considered between the
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DNA yield and the presence of the spurious products. In most cases, however, the presence of 
these spurious products do not seem to interfere with the sequencing of the templates. This can 
be explained by the fact that these products have discrete 3’ ends and are heterogeneous only at 
their 5’ ends; the ends that are oriented away from sequencing primers (McCabe, 1990). 
Following the asymmetric PCR, the templates were purified by selective precipitation in 2 M 
ammonium acetate (pH 5.2) and 2 vol of propan-2-ol at room temperature as described before. 
Sequencing was performed by Sangers’ dideoxy-method, using Taq DNA polymerase and 
limiting primers. From each PCR, only 50% of the purified products were used in the sequencing 
reactions contrary to other suggestions in which up to five PCRs were pooled (Saha, 1989). The 
primer-template annealing was performed by heating the primer-template annealing mixture to 
65°C and allowing it to slowly cool to below 30°C. The samples were stagger-loaded, running 
one batch for 2 h the other for 3 h. Figure l ib  demonstrates the G1 784->A mutation in the sample 
electrophoresed for 3 h from the cystic fibrosis carrier. At this position the cystic fibrosis carrier 
has both bases G and A denoting heterozygosity while the normal control has only the expected 
base G. This single base substitution changes the codon GGT for glycine to GAT for aspartic 
acid. This change which replaces a neutral amino acid with a charged one, is the second 
commonest mutation in cystic fibrosis. It accounts for about 5% of of all mutations in the cystic 
fibrosis chromosomes in Caucasians (Cutting, et al., 1990).
This experiment illustrates one of the major advantages of direct sequencing of PCR amplified 
products in that it enables the demonstration of a heterozygote position in those cases where two 
alleles differ by a point mutation. Both alleles are are seen in the the same position in the 
sequencing ladder as in this case the bases G and A. This is because both alleles are amplified in 
the PCR and hence represented in the amplification reactions. In contrast, in the case of cloned 
products, several templates would have needed to be sequenced before the heterozygosity was 
determined. In such cases indeed both alleles need to be seen before heterozygosity can be 
proved. In addition several templates need to be sequenced or else the mutant allele would be 
missed if by chance all the clones picked for sequencing consist of the wild-type sequences.
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The sequencing ladders generated from ssPCR products from the genomic DNA of cystic 
fibrosis hetreozygotes were much clearer and more easily read in comparison to the double­
stranded templates shown in the preceding experiments. In these particular sequencing ladders, 
no pile-ups or high backgrounds were observed. Part of the explanation for this may have been 
due to the use of Tag DNA polymerase for sequencing of the templates. The high processivity 
and heat stability of this enzyme enables it to easily sequence through areas were formation of 
secondary structures are likely to cause problems (Innis et al., 1988).
The templates were purified simply by selective precipitation in propan-2-ol in the presence of 
ammonium acetate. Ammonium acetate works by inhibiting the co-precipitation of dNTPs. Two 
sequential precipitations of DNA in the presence of 2 M ammonium acetate for instance, results 
in the removal of over 99% of dNTPs from DNA templates (Okayama and Berg, 1982). The 
precipitation was performed at room temperature and the DNA pellet collected after a 10 min 
centrifugation in a bench-top centrifuge, making this purification method simple, convenient and 
inexpensive.
In this experiment, it was therefore possible to successfully produce and sequence ssPCR 
amplified templates from genomic DNA. The templates generated very satisfactory sequencing 
ladders free of ambiguities and it was possible to demonstrate a point mutation in a subject 
heterozygous for the mutation G551D in the cystic fibrosis gene. From these results it was 
therefore decided to adapt and apply this technique to the detection and characterisation of the 
mutations responsible for acute intermittent porphyria.
5.4. PCR amplification and direct sequencing of PBG-D cDNA.
PCR amplification and sequencing of the G1 784->A mutation in the cystic fibrosis gene 
described above was performed on genomic DNA. This method was modified to amplify and 
sequence PBG-D cDNA from its mRNA. Two approaches were used. In the first approach, 
referred to here as ‘one-step’ direct sequencing, single-stranded products were amplified directly 
from R-T PCR. This was modified in a similar way to asymmetric PCR in that unequal molar
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quantities of primers were used and hence referred to in the current study as ‘asymmetric R-T 
PCR.’ In the second approach which is referred to here as a ‘two-step’ direct sequencing, regular 
R-T PCR was performed on RNA samples and the cDNA eluted before it was reamplified by 
asymmetric PCR to produce single-stranded templates.
5.4.1. ‘One-step’ direct sequencing of PBG-D cDNA.
PBGD cDNA was produced by a process referred to as RT-PCR. In this procedure, cDNA is 
initially synthesised either from total cellular RNA or from mRNA by a reverse-transcriptase and 
then PCR amplified with Taq DNA polymerase. Both reactions are done in the same reaction 
mixture, greatly simplifying the procedure (Sherman et al., 1989; Sambrook et al., 1989a). In 
performing R-T PCR, three approaches are available based on the method used for the first- 
strand cDNA synthesis. First-strand cDNA synthesis may be accomplished by extension with 
random hexamers, oligo(dT)12_18 or an amplification primer complementary to the respective 
mRNA (upstream primer). In the current study, the last two approaches were employed and 
compared.
Asymmetric R-T PCR was performed to directly produce single-stranded cDNA from RNA. To 
achieve this two approaches were employed, hi the first approach the first-strand cDNA was 
synthesised by using an upstream primer, whereas in the second oligo(dT)12_18 was used instead. 
Both methods worked equally well but the latter was preferred because of its simplicity and 
adaptability to produce either of the cDNA strands. By using an upstream primer for first-strand 
cDNA synthesis the only option of performing an asymmetric RT-PCR is with the downstream 
primer limiting. This therefore, restricts one to the amplification of the sense strand only. On the 
other hand, by priming the first-strand cDNA synthesis with oligo(dT)12_18 in asymmetric R-T 
PCR, one can interchange limiting primers to enable amplification of either strand.
Optimisation of both the standard and asymmetric R-T PCR was performed on RNA samples 
from HeLa, human placenta and chorion cells. This was done, partly to evaluate the robustness 
of the technique and partly because these RNA samples were already available. In addition RNA
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was also extracted from normal volunteers. R-T PCR amplification was performed with primers 
F2 and R2 kindly supplied by professor Grandchamp. The R-T PCR was performed by first 
heating the RNA samples at 65°C for 10 min and placing on ice before the addition of other 
components. This enhances the cDNA priming step by breaking up aggregates and some 
secondary structures in the RNA molecules (Kawasaki, 1990). After completion of the reverse- 
transcriptase step, the samples were heated at 95°C for 5 min before proceeding with the PCR 
amplification. The 95°C heat treatment inactivates the reverse-transcriptase and denatures the 
RNA-DNA hybrids; a process that improves both the efficiency and specificity of the PCR 
(Kawasaki and Wang, 1989, Sambrook et, al 1989a). The PCR was performed according to 
Grandchamp et al., (1989c), whereby denaturation was performed at 95°C for 1 min followed by 
annealing at 55°C for 1 min and extension at 72°C for 2.5 min. The final extension was 
performed at 72°C for 7 min to ensure full strand polymerisation in the PCR products. This led to 
the amplification of a 500 bp fragment instead of the expected 1,108 bp product as shown in 
figure 12a bottom row. The amplification of this 500 bp PCR product occurred in all samples no 
matter the source or method of RNA extraction used. Similar results were also obtained from 
asymmetric R-T PCR amplifications performed with different primer ratios for the optimisation 
of single strand production as shown in figure 12a top row. hi these optimisation experiments the 
optimal primer ratio was found to be 100:1 as seen in lanes 2 and 8 of figure 12a top row. This 
was determined by fractionating the PCR products at 15 V/cm in 1.4% agarose in TBE. Under 
these condition the single-stranded product runs slower than the double-stranded product. Figure 
12a, lanes 2 and 8 in the top, shows two bands with hardly any background from spurious 
products.
Both the single- and double-stranded PCR amplified templates were sequenced. The 
purification was done either by centrifuge-driven dialysis using Amicon 30™ 
microconcentrators or by selective precipitation in propan-2-ol. In centrifuge-driven dialysis, 
purification and concentration is achieved by ultrafiltration of the samples through an anisotropic 
membrane with a specific pore size cut-off. This is effected by adding diluted PCR products into
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the reservoir chamber of the microconcetrators as described previously and shown in figure 7. 
Centrifugal force is then used to drive the solvent and low molecular weight solutes through the 
membrane into the filtrate cup leaving behind macromolecules larger than the membrane pore 
size, which in the case of Centricon 30 represents a molecular weight of 30,000. Smaller 
molecules like dNTPs, amplification primers and salts used in PCR can therefore be readily 
removed from the template DNA to be sequenced.
Sequencing reactions were performed with Sequenase T7 DNA polymerase with chain- 
termination and extension reactions being carried out either at 37°C, 42° C or 50°C. In the case of 
double-stranded products, primer-template annealing was performed by heating the samples in 
file presence of the primers and immediately snap freezing as described in the methods.
Sequencing was done with either one of the sequencing primers or with nested primers using 
different amounts ranging from 1 pmol to 10 pmol. The amount of the template DNA was also 
varied. This was done to determine the optimal set of conditions required in the sequencing 
reactions. Results of two of these experiments are illustrated in figure 12b.
Sequencing ladders generated from these experiments were faint and in some cases there were 
high backgrounds. Pile-ups were also observed at several areas on the sequencing ladders. Most 
of these problems were similar to those that were encountered and discussed earlier while 
sequencing other double-stranded templates like the bacteriophage lambda DNA and plasmid 
pBR322. Figure 12b demonstrates that pile-ups were no2. Figure 12b demonstrates that pile-ups were nc 
chain-extension and termination reactions were carried out at 50°C while sequencing with 
Sequenase T7 DNA polymerase.
To circumvent these problems, single-stranded products in figure 12a, lanes 2 and 8 top row, 
were purified by centrifuge-driven dialysis and sequenced. The sequencing was performed with 
Sequenase T7 DNA polymerase by carrying out the chain-extension and termination reactions at 
37°C. To optimise for the primer-template annealing and extension reactions during sequencing, 
different amounts of DNA templates were used while keeping the amount of the sequencing 
primers constant at 1 p mol. In the experiment depicted in figure 13, sequencing was performed
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using 30,40, 50 and 75% of one PCR reaction. This is in contrast to the suggestion of Saha 
(1989) of pooling together up to five PCRs. This suggestion, as previously mentioned was made 
to ensure that there is sufficient DNA template for sequencing. In figure 13, set 3, it is in fact 
demonstrated that the best results were obtained when 50% of a PCR was sequenced with 1 pmol 
of the sequencing primer. It also shows that the sequencing ladder generated from ssPCR 
products is much superior to that generated from dsPCR products (figure 12). Sequences 
obtained from both the dsPCR and ssPCR products were, however, the same and did not match 
the already published sequences of either the erythropoietic or the non-erythropoietic PBG-D 
cDNAs (Raich et al., 1986; Grandchamp et al., 1987).
From these experiments it emerged that the optimal amount of PCR products to be used in 
sequencing reactions with 1 p mol of the sequencing primer was 50% of each PCR reaction. The 
above experiment was therefore repeated using these amounts of template and sequencing primer 
except that sequencing was performed with a nested primer R3 instead of the limiting primer. 
This was done because reamplification or sequencing with nested primers greatly improves 
specificity (Wrischik et al.,1987; Engelke et al., 1988). Sequencing with the nested primer R3 
generated the same sequences as those described above, confirmirming that the 500 bp PCR 
product being amplified was not part of the PBG-D cDNA. This therefore, implied that either the 
R-T PCR was amplifying a cDNA product completely different from PBG-D cDNA or was 
amplifying genomic sequences and that the sequences obtained were part of the intronic 
sequences of the PBG-D gene. The later was unlikely because the amplification primers were 
known to correspond to different exons spanning across several introns. Nevertheless, to test 
these hypotheses both strands of cDNA were produced to enable sequencing of as much of the 
product as possible. This was achieved by using oligo (dT)12.18 in the reverse transcription and 
performing the PCR amplification with unequal molar amounts of primers as described in the 
methodology. In these experiments the RNA was first treated with RNAase free-DNAase prior to 
being used in RT-PCR amplifications. This was done to ensure that the amplification was not 
arising from contaminating genomic DNA. Despite this modification the same 500 bp product
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was obtained. Furthermore, direct sequencing of the RNA samples without prior reverse- 
transcription was not successful, again proving that the amplification of the 500 bp product was 
not arising from contamination of the RNA samples with genomic DNA. Using EMBL and 
GenBank data bank computer programmes, sequences obtained from these experiments were 
compared to previously reported sequences to determine the degree of homology. The closest 
homology, albeit very low, was with the starfish Poacta ochraceus cytoplasmic actin gene, 
confirming that the generated sequences were most probably not associated with the PBG-D 
gene. The conclusion from these experiments was that the primers F2 and R2 were somehow 
amplifying a mRNA other than the PBG-D mRNA. This may have risen through mispriming or 
misextension of the primers. Similar problems supposedly to be due to non-specific annealing of 
amplification primers to templates have been reported before (Haqqi et al., 1988; Fedlman et al., 
1988; Anwar et al., 1990). Despite multiple attempts under different conditions and using two 
different set of primers, Haqqi et al. (1988), were unable to obtain specific amplification for a 
region of the coding sequence of the mouse V-f3-6 receptor gene. This problem was overcome by 
performing a two-step PCR amplification in which following the first amplification the products 
were diluted 100,000-fold and reamplified with a second set of primers. A large dilution was 
found to be necessary as a 1,000-fold dilution still resulted in amplification of non-specific 
products. In other experiments, while amplifying the KM 19 locus in cystic fibrosis gene,
Feldman et al (1988) and Anwar et al., (1990) separately detected co-amplification of an 
extraneous product. On sequencing, no homology was found between this extraneous product 
and the KM19 product. Moreover, a search of the EMBL, GenBank and NBRF databanks did not 
reveal any significant homologies (Anwar et al., 1990). The amplification of the extraneous 
product was thought to arise from non-specific hybridisation of the amplifying primers to LI 
repeats elements in the nonfunctional long terminal repeat (LTR) sequence. This problem was 
solved by either introducing a set of new amplification primers or by raising the annealing 
temperature from 55°C to 60°C, thus performing all steps in the PCR without allowing the
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temperature to fall below 60°C. In the current study, to solve the problem of amplification of the 
500 bp extraneous product, optimisation for different PCR parameters were performed.
Specificity in PCR depends on several factors including amplification primers, cycling thermal 
profile and concentrations of magnesium ion, dNTPs, template and enzyme used. Failure of 
optimisation can lead to the amplification of non-specific products which at times may even be 
more predominant than the desired product. One obvious discrepancy between the current study 
and the work done by Grandchamp et al. (1989c), was the type of heating block used. In their 
work Grandchamp et al. (1989d) used DNA Thermal Cycler (Perkin-Elmer-Cetus 
Instruments™) while in this study a Techne PHC-1 Thermal Cycler™ was used. This difference 
in the type of the heating block used may have affected the actual ramp temperatures. The ramp 
time, which is the time taken to change from one temperature to another, depends on the type of 
equipment used (Saiki, 1989). This is significant because one of the important factors influencing 
PCR specificity is the annealing step. Although, a temperature of 55°C is a good starting point 
for annealing of most 20-base primers with about 50% GC content, in some cases higher 
temperature may be necessary to improve primer specificity. In addition, PCR specificity may 
also be improved by minimising the incubation time during the annealing and the extension step 
because this reduces the chances of mispriming and misextension (Saiki, 1989). After trying 
different thermal profiles, ultimately the right sized product was obtained when the initial 
denaturation was performed at 95°C for 3 min and subsequent denaturations carried out at the 
same temperature for 1 min, followed by annealing at 60°C for 1 min and extension at 72°C for
1.5 min. The final extension was carried out as before at 72°C for 7 min. Thus, modifications on 
the original protocol included the introduction of a 3 min initial denaturation step, raising of the 
annealing temperature from 55°C to 60°C and the reduction of the extension step from 2.5 min to
1.5 min. In addition to this, new primers FI and R1 situated externally to the original primers 
were constructed. Alternatively, the correct sized products could be amplified by using one of the 
original primers, F2 or R2 with an internal primer on the opposite end. Thus for example by
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performing one set of PCR with F2 and R3 and another with F3 and R2, the right sized products 
which overlap each other and span across the entire PBG-D cDNA could be amplified.
In PCR, primers are the single most important determinants of the outcome of amplification. In 
most cases amplification primers work, but for a variety of reasons some of which are not yet 
fully understood, some primers fail to amplify their intended target. This failure in amplification 
of the intended product can often be solved simply by moving the primers a few bases either 
upstream or downstream from the original position (Saiki, 1989). Optimisation experiments 
illustrated in figure 14a to 14d illustrate these points. In figure 14a the annealing step was 
performed at 60°C instead of 55°C as recommended in the original protocol. With these 
parameters using primers F2 and R2 the predominant product was approximately 500 bp long 
and overshadowed the desired 1,108 bp long product as shown in lanes 2-6. On the other hand, 
by changing one of the primers the expected product became more predominant than that 
produced by mispriming. This is shown in lanes 7-10, where the same PCR parameters as those 
used in lanes 2-6 were applied except that amplifications were performed with primers F2 and R3 
instead of F2 and R2. Moreover, by performing the annealing reaction at 55°C with primers F2 
and R2 the 500 bp fragment was predominantly amplified both in the asymmetric and the 
standard PCRs as shown in figure 14b, lanes 2-5 were lanes 1 and 2 are products from 
asymmetric PCR and lanes 4 and 5 from a standard PCR. Thus specificity was to a large extent 
improved by merely changing the amplification primers. This modification on the protocol, 
however, did not completely prevent amplification of the 500 bp product. This problem was 
solved by performing PCR with the new set of primers FI and Rl, a few bases outside the 
original positions and modifying the thermal profile as mentioned earlier. This is depicted in 
figure 14b in lanes 6 and 7, where by performing the annealing reaction at 60°C, the desired 
products were predominantly amplified. Thus by both using these new primers and altering the 
PCR conditions it was possible to amplify the desired product. On the other hand, when these 
new primers were used and the annealing step performed at 55°C both the 500 bp and the desired 
products were amplified as shown in figure 14c.
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In some cases, spurious products resulting from non-specific priming become persistent even 
after the most stringent optimisation. In such cases the use of specificity enhancers like TMAC 
(Hung et al., 1990) or formamide (Sarkar et al., 1990) may be helpful. These agents were not 
used in the current study and indeed their use may have not been desirable as they could have 
encouraged the amplification of the 500 bp product. This is due to the fact that these specific 
enhancers work by discouraging non-specific priming, but under these PCR conditions there is a 
preference for the production of the 500 bp product. Alternatively, this intractable problem of 
spurious products can be overcome by separating the products in a gel and excising the desired 
band. This is followed by a second round of amplification preferably with internal primers. The 
second round of amplification can be carried out directly or after elution of the DNA from the 
first amplification (Gyllensten, 1989). This approach was found to be convenient and was used in 
this study even after the desirable products were obtained following optimisation as shown in 
figure 14b lanes 6 and 7 and in figure 15a. This approach was preferred for two reasons. Firstly, 
after the first PCR amplification, the eluted cDNA could be stored in this form for a long time 
without resorting to repeated thawing and freezing of the less stable RNA samples. Secondly, the 
second round of amplification with internal primers increased the specificity and quantity of the 
cDNA templates.
5.4.2. ‘Two-step’ sequencing of PBG-D cDNA.
Although direct sequencing of asymmetric R-T PCR amplified PBG-D cDNA templates was 
successful as shown in figure 13, the sequencing ladders generated were faint in comparison to 
those that were obtained from direct sequencing of genomic DNA from the cystic fibrosis gene. 
This can be explained by having too little template cDNA from the porphobilinogen gene. This 
in turn, may be due to either sub-optimal reverse-transcription or insufficient PBG-D mRNA. To 
circumvent this, a first round of R-T PCR was performed with primers FI and R l in a standard 
manner to produce double-stranded products. The desired band was then excised and the cDNA 
eluted and reamplified with internal primers F2 and R3 in an asymmetric PCR. This is shown in
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figures 15a and 15b where PCR amplification products of primers FI and Rl in figure 15a were 
reamplified with primers F2 and R3 at a ratio of 1:100 (Figure 15b). The adequacy of the single­
stranded products was monitored by running in 1.4% agarose gels as described earlier. Thus in 
this example it was possible to produce both cDNA strands with equal efficiency. The templates 
were purified by either selective precipitation in propan-2-ol or by centrifuge-driven dialysis 
methods and sequenced with the limiting primer F2 or an internal primer F3 using Sequenase T7 
DNA polymerase. The results of these experiments shown in figure 15 c, again demonstrate that 
purification of PCR templates by selective precipitation in propan-2-ol was as equally effective 
as the centrifuge-driven dialysis method using Amicon™ concentrators. It also shows that 
sequencing ladders generated with internal primers were superior to those sequenced with 
limiting primers. The best results in these experiments are seen in sequencing set 4 in which the 
PCR amplified templates were purified by the selective precipitation in propan-2-ol and 
sequenced with the internal primer F3. In addition all sequences generated from these 
experiments corresponded to the normal sequences of the PBG-D cDNA.
These experiments were repeated by amplifying PBG-D cDNA from human placenta, HeLa 
cells and from lymphocytes of a normal subject. Following the two-step PCR amplification, 
templates were purified by the selective propan-2-ol method and sequencing performed with the 
limiting primer F3 using Taq DNA polymerase. The results of this experiment, illustrated in 
figure 16 (sequencing sets 1-3), demonstrate very clear sequencing ladders comparable to that 
produced with the cloned M13mpl8 control DNA in set 4. These sequencing ladders, devoid of 
both high backgrounds and band artefacts, were easily readable for up to 200 bases. Although 
these sequencing ladders were somewhat superior to those generated with Sequenase T7 DNA 
polymerase, the difference did not appear to be very significant. From these experiments it 
became clear that the strategy to follow in the sequencing of the PBG-D gene was first to amplify 
the PBG-D cDNA by a standard R-T PCR and elute the amplified cDNA from an agarose gel. 
Such eluted cDNA could be stored at -20°C for several months. The cDNA should then be 
reamplified asymmetrically and the products purified by either centrifuge-driven dialysis or
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selective precipitation in propan-2-ol in the presence of 2 molar ammonium acetate. Sequencing 
can then be performed with either internal primers or limiting primers using Sequenase T7 DNA 
polymerase or Taq DNA polymerase. In this study, purification by selective precipitation in 
propan-2-ol was preferred to centrifuge-driven dialysis because it is simple, inexpensive and 
does not require any special equipment. Besides Amicon™ microconcentrators used in this 
study, there are a myriad of other commercially available systems for purification of PCR 
templates prior to sequencing. Success with selective precipitation using propan-2-ol, however, 
circumvented the need for these costly purification methods. Moreover, as there was no 
remarkable difference between Sequenase T7 DNA polymerase and Taq DNA polymerase as far 
as clarity and accuracy of the sequencing ladders were concerned, the former was used in all 
routine sequencing. Taq DNA polymerase was reserved only for those cases where pile-ups 
could not be resolved by Sequenase T7 DNA polymerase even when the chain-extension and 
termination reactions were carried out at 50°C. Both internal and limiting primers were used for 
sequencing, depending on which area was to be sequenced.
In all cases successful R-T PCR was performed without resorting to the use of RNAase 
inhibitors like RNasin or placental RNAase inhibitor. Although, these are generally included in 
all protocols that involve PCR amplification of RNA, no systematic evaluation of their 
importance has been made. In the current study, it has therefore been shown that these RNAase 
inhibitors can be safely left out of the R-T PCR protocols so long as other measures for reducing 
exposure to RNAase are enforced, hi addition, the R-T PCR does not require the selection of 
Poly (A)+ mRNA from total cellular RNA.
Following the successful development and application of direct sequencing in the 
characterisation of mutations of the PBG-D gene, modifications were introduced to simplify the 
protocol. This, for instance, included attempts at introducing a non-invasive method such as the 
use of buccal washings as the source of RNA instead of lymphoblastoid cell lines. As cell 
cultures and RNAs extraction introduce additional steps and delay in the analysis of samples, a 
method of processing crude cell lysates of uncultured lymphocytes was also employed.
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Patients with AIP receive numerous venopunctures, either for investigations or medication. This 
not only is a cause of discomfort but can pose difficulties for the clinician. A non-invasive 
diagnostic test will therefore greatly alleviate this problem. In addition such a procedure would 
encourage corporation from asymptomatic gene carriers or unaffected family members who 
otherwise may be reluctant to volunteer blood specimen. It also eliminates the need of medical 
supervision in sample collection and the chance, albeit remote, of transmitting such blood borne 
infections like hepatitis and HIV (Lench et al., 1988). In the current study buccal epithelial cells 
were collected from volunteers by mouth washings using normal saline, and R-T PCR done 
directly on cell lysate without any elaborate RNA extraction. This approach was unsuccessful 
despite many attempts. Although, there have been reports of successful PCR amplification of 
genomic DNA from buccal cells, similar RNA amplification may be logistically difficult due to 
the presence in the saliva of non-specific inhibitors and ribonucleases. In addition, in mouth 
washings there may be insufficient PBG-D mRNA molecules for reverse transcription and 
therefore this may be another limiting factor in this approach.
Another attempt at simplification of the protocol for the characterisation of PBG-D mutations, 
was done byjy f  circumventing the need for cell cultures and elaborate RNA extraction. This was 
accomplished by performing the R-T directly on blood lymphocytes. Following a venopuncture, 
the lymphocytes were separated and lysed to release total cellular RNA in the presence of DEPC 
and R-T PCR performed directly on the cell lysate without any further purification of the nucleic 
acids (Sherman et al., 1989). Thus, cell lysis, reverse transcription and PCR amplification of the 
PBG-D cDNA were all performed in the same tube greatly simplifying the procedure. 
Consequently in a matter of less than eight hours, the cDNA was amplified, eluted and a second 
round of amplification done with unequal molar amounts of internal primers to produce single­
stranded cDNA templates suitable for sequencing. Therefore, starting from the receiving of 
blood samples to the reading of the results it may take less than two normal working days. 
Additionally, a further attempt at simplifying this procedure by doing a direct asymmetric R-T 
PCR was made. In this method single-stranded cDNA was prepared directly without a second
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round of amplification thus carrying out the whole procedure from start to reading of the results 
in less than 24 h. Results of the direct asymmetric R-T PCR depicted in figure 17b show 
successful amplification, though direct sequencing of these products resulted in a very faint 
sequencing ladder as shown in the sequence set 4 of figure 17c. The faint sequencing ladder may 
be due to insufficient amount of single-stranded cDNA in the templates (Gyllensten and Erlich,
1988). As it has been mentioned before, the estimation of ssDNA by ethidium bromide staining 
may not be consistent. It may also be recalled that direct asymmetric R-T PCR performed 
previously on different RNA samples similarly gave very faint sequencing ladders and prior to 
the present optimisation, gave rise to sequences which were not from the PBG-D cDNA. Similar 
results associated with faint sequencing ladders has been observed by other workers (Gyllensten 
and Erlich, 1991). It therefore, seems that, in optimisation, there is an improvement in the 
specificity of the PCR amplification at the expense of its sensitivity. Sub-optimal cDNA 
synthesis may also be a factor since traces of DEPC are known to inhibit reverse-transcriptase 
and to modify purine residues in RNA by carboxymethylation. DEPC must therefore be removed 
prior to the R-T PCR, and in this study this was achieved by boiling the samples during the cell 
lysis step. Theoretically, it is most likely that this approach may be successful with another 
template, other then PBG-D cDNA, which produces a more homogeneous PCR amplified 
product.
Sequencing ladders generated from the second round of amplification were, however, more 
easily read and comparable to those produced from cultured cells after an elaborate RNA 
extraction procedure using guanidinium thiocynate and equilibrium centrifugation with caesium 
chloride. By doing the PCR in two steps and eluting the cDNA in the first step, the technique 
also provides material that can be stored on a long term basis, allowing further experiments or 
confirmation of the results. In addition, as discussed before and unlike direct asymmetric PCR, 
the second round of amplification also allows the generation of both cDNA strands, depending 
on which primer is chosen to be limiting.
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5.4.3. Problems associated with direct sequencing of PCR amplified templates.
Several problems worth mentioning were, however, encountered with this method of direct 
sequencing of PCR amplified templates. Some of these problems were universal and may be 
observed in any sequencing project while others are perculiar only to the direct sequencing of 
PCR amplified templates. Thus, problems like compressions, band artefacts, variation in band 
intensity, smiling and frowning of bands are not for instance peculiar to this method and will not 
be discussed in detail except when relevant to the study. Certain problems were, however, 
particularly associated with direct sequencing of PCR amplified products and these included, 
inability to sequence certain strands, band artefacts, faint sequencing ladders and high 
background. Most of these problems were easily solved by optimising for PCR or sequencing 
reaction conditions and moreover none of them seriously interfered with the interpretation of the 
results. Other problems were resolved by improving template purification methods and gel 
electrophoretic conditions.
In a few occasions it was very difficult to sequence a specific strand in some templates. In its 
extreme form, this problem presented itself as failure in the PCR amplification of that particular 
strand. For reasons not as yet fully understood, on some occasions asymmetric primer ratios were 
able to amplify one strand and yet fail with the opposite strand. More commonly and subtly, the 
reciprocal asymmetric primer ratios may give rise to different amounts of ssDNA (Gyllensten,
1989). This problem was easily solved by simply changing the amplification primers. This is 
shown in figure 18a and 18b. In 18a, PBG-D cDNA from one patient was amplified in an 
asymmetric PCR with primers F2 and R3, in which R3 and F2 were limiting in lanes 2-5 and 6-9 
respectively. It can be observed that there is a suboptimal amplification in the PCR where primer 
R3 was limiting. Thus in this experiment there was a more efficient amplification of ssDNA 
when the forward primer was limiting leading to the production of the antisense strand. Samples 
from this patient were amplified in another asymmetric PCR, this time with primers F2 and R2 
and shown in figure 18b lanes 6-9, in which the limiting primers were F2 in the top and R2 in the 
bottom row. This time it was possible to demonstrate adequate amplification of ssDNA in the
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PCR when the reverse primer (R2) was limiting, therefore amplifying the sense strand. Thus by 
changing the amplification primers it was possible to overcome difficulties associated with poor 
amplification of a particular strand. Theoretically, this problem can also be solved by using a 
different ratio of the primers in the asymmetric PCR. Therefore, in practice it was found to be a 
good policy to always monitor the amount of ssDNA, by size-fractionation of the PCR products 
in 1.4% agarose gels as shown in figure 18a and 18b. As mentioned earlier, under these 
conditions the single-stranded cDNA moved more slowly and just behind the double-stranded 
fragment. It must, however, be mentioned that ssDNA cannot be consistently quantified from 
staining with ethidium bromide, because its tendency to form secondary structures and 
intercalate the dye may vary between templates (Gyllensten, 1989). Nevertheless, this should not 
be a major problem when sequencing the same DNA or cDNA fragments. The importance of 
monitoring for ssPCR templates prior to sequencing is further shown in figure 18c, where in the 
sequence set 1, PCR amplified templates in lane 6 bottom row were successfully sequenced with 
the limiting primer R2, whereas sequencing of the products in lane 6 top row completely failed 
as shown in sequence set 2. This is due to the fact that although seemingly positive, the PCR 
templates in lane 6 top row consists mainly of dsDNA. Like templates in sequencing set 1, 
products from lane 6 bottom row were also sequenced with the limiting primer F2. Finally, the 
importance of checking PCR templates is also shown in figure 18b, where in lanes 2-5 top row 
there is a complete failure in the PCR amplification when primer F2 is limiting and very 
suboptimal amplification in lanes 2-5 when R2 is the limiting primer.
The sequencing ladder in set 1 of figure 18c, demonstrates two other problems. First there is a 
fairly high background and secondly there are some sections in the sequence where two or three 
bands are appearing in the same position. In this case it is possible that both problems are arising 
from the same cause. High background and band artefacts of this sort may arise from the 
reannealing of dsDNA present in the templates or from bad template preparation. Bad template 
preparation may lead to nicking or contamination with salts. Both template nicking and salt 
contamination may cause bands to appear at the same position in two or three lanes and in
- 1 3 9 -
addition, the former may give rise to a high background as well. Salt contamination can be easily 
detected from the appearance of the cDNA pellet because of the presence of salt crystals. 
Sometimes the only clue to this, is the appearance of a larger cDNA pellet than usual. When salt 
contamination is suspected, it is advisable to wash the cDNA pellet twice in 70% ethanol, 
otherwise in most cases a single wash after purification by precipitation in ammonium acetate 
and propan-2-ol is sufficient. These band artefacts may also arise from inadequate mixing of the 
reagents in the sequencing reactions or may be due to genuine compressions. The last two causes 
of such band artefacts are not peculiar to the sequencing of PCR amplified templates and may be 
observed in any sequencing experiment.
The other common problem was the presence of bands appearing at the same position in all four 
lanes. This problem, slightly different from the above problem, presented with artefacts of two 
types as shown in figures 19 and 20. The first type (a) is a gel artefact and is commonly seen in 
the sequencing of PCR amplified products ( Brow, 1990). Bands of this sort vary from gel to gel 
and their relative positions of migration, change with the gel running temperature. These bands 
are not dependent on the sequence of the templates as demonstrated by their appearance across 
the entire gel width as shown in figures 19 and 20. This was not found to be a serious problem in 
the present study since such band artefacts tended to occur at the extreme 5’ end of the 
sequences, that is at the top-most end of the gels where sequences were difficult to read in any 
case. Nevertheless, when necessary this problem can be easily solved by running the same 
samples in another gel at a different running temperature and duration as shown in figure 20. By 
altering these gel running conditions the band either becomes more diffuse, or migrates at a 
different rate thus enabling the reading of the sequence segment that had been previously 
obscured by the band.
The second type (b) of artefact bands are sequence dependent and seem to be due to pauses and 
mild compressions. Sequenase T7 DNA polymerase quite often pauses when it encounters 
exceptional secondary structure. In its severe form, this can lead to pile-ups. Genuine 
compressions are observed in G-C rich segments because this leads to the formation of G-C
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hairpins which in turn form localised secondary structures in the DNA template, which persist 
during electrophoresis. These secondary structures cause oligonucleotides to behave as though 
they are shorter than is actually the case, thus causing them to migrate faster. This causes 
sequencing bands to run close together and sometimes to be even superimposed, usually with an 
increased inter-band space in the region immediately above this position. In many cases this was 
solved by performing the chain extension-termination reactions at 50°C as mentioned earlier. 
Alternatively the problem was resolved by using Taq DNA polymerase for sequencing, thus 
enabling extension-termination reactions to take place at 70°C. For this reason, the most 
consistent sequencing results with PCR-generated templates have been obtained using Taq DNA 
polymerase (Innis et al., 1988). In refractory cases dITP was substituted for dGTP in the chain 
extension-termination reactions. This analogue forms I-C base pairs which, having two hydrogen 
bonds instead of the three found in G-C pairing, are weaker than the latter and therefore their 
secondary structures are less stable. It must be mentioned that although this problem is common 
in the direct sequencing of PCR amplified products, it not peculiar to this method. Any complex 
secondary structure can give rise to this, hi addition, practical problems like bad template 
preparation, failure to properly mix reagents and performing the labelling reaction at 
temperatures higher than 20°C or prolonging the reaction beyond 5 min may all lead to this. In 
the case of the direct sequencing of PCR amplified products, this problem may be intractable due 
to reannealing of the short linear templates especially when sequencing dsPCR templates but can 
also be seen in the asymetrically amplified products as they are bound to contain certain amounts 
of dsDNA. Unless absolutely necessary to sequence a particular strand as in the confirmation of a 
mutation, this problem can also be solved by simply sequencing the opposite strand.
Another problem observed occasionally was faint sequencing ladders. The commonest cause 
for this is simply an inadequate amount of template cDNA available for sequencing. This can 
arise from suboptimal PCR amplification or from loss of DNA template in the course of 
purification. The presence of double-stranded cDNA and its competitive participation in the 
sequencing reaction may also contribute to this. Similarly the presence of salt contamination in
- 1 4 1 -
the course of DNA preparation may cause a dramatic inhibition of the sequencing enzyme 
leading to faint bands (Ward and Howe, 1989). To ensure the presence of adequate cDNA in the 
templates the PCR was performed as a two-step reaction as described earlier. This, besides 
guaranteeing the adequacy of the template cDNA, also provides specificity in the sequencing 
ladders. Faint sequencing ladders may also be caused by low sequencing primer concentrations 
which may arise through degradation due to repeated freezing and thawing. This can easily be 
prevented by storing the sequencing primers in small aliquots and keeping stock solutions at 
-20°C or below.
Sequence dependent variations in band intensity occur during dideoxy-mediated sequencing of
templates from any source and are not necessarily confined to direct sequencing of PCR
amplified products. In this type of sequencing, single C bands are usually weaker then single
bands from other nucleotides and in a homopolymeric run the first (bottom band) C tends to
appear much weaker then the rest. On the other hand in a homopolymeric run of A bands, the
first A (bottom band) generally appears the strongest. Finally, G bands appear weak when they
are preceded by a T. Besides these universal variations in band intensity, in the direct sequencing
of PCR amplified templates from heterozygote individuals, the two bands at the mutation site
may not appear to have the same intensity. This is because in a heterozygote at a particular locus 
transcript,
one ^  may be more frequent in the product then the other (Cotton, 1989). This type of band 
intensity variation may at times cause difficulties in intrepretation of the results especially when 
the sequencing ladder has other artefacts or a high background. The problem can be easily solved 
by repeating the sequencing and using the opposite strand.
5.5. Characterisation of mutations in patients with AIP.
Included in this study were 30 individuals from 29 families with acute intermittent porphyria 
and 10 normal controls. Diagnosis of AIP was based on increased excretion of delta- 
aminolevulinic acid and porphobilinogen in urine and decreased activity of erythrocyte PBG-D 
coupled with a clinical history of one or more acute attack (Moore et al., 1987).
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RNA was extracted mainly from lymphoblastoid cell lines in all patients and controls. The 
extraction was performed by the guanidinium thiocyanate and caesium chloride equilibrium 
centrifugation method (Glisin, et al., 1974, Ullrich et al., 1977). Guanidinium thiocynate, a 
chaotropic salt is included in the primary extraction buffer to protect the RNA from degradation 
by RNAases (Chirgwin et al., 1979). This is necessary because the isolation of intact RNA is 
made difficult by the release of ribonucleases during cell lysis. Guanidinium thiocynate, a very 
potent denaturing agent, readily dissolves proteins, thus disintegrating cellular structures causing 
nucleoproteins to dissociate from nucleic acids as the protein secondary structure is lost 
(Sambrook et al., 1889c). RNAase are inhibited by the presence of 4 M guanidinium as well as 
reducing agents like (3-mercaptoethanol (Sela et al., 1957). This combination of reagents was 
used in the extraction of RNA in this study. Following extraction in guanidinium thiocynate 
buffer the RNA was purified and collected by equilibrium centrifugation through a caesium 
chloride cushion. Under the conditions described and used in this study, RNA collects at the 
bottom of the tube while DNA remains floating as a ring near the top of the caesium cushion 
with proteins above it. hi all cases no visible RNA pellet was seen but the quantity was more 
than sufficient for several experiments. The centrifugation was done in a swinging-bucket rotor 
with the centrifuge brake off. A swinging-bucket is preferred to a fixed-angle rotor because it 
allows the RNA to be deposited at the bottom of the tubes rather then along the walls where it 
may come into contact with the cell lysate and RNAases. The brake was turned off to prevent 
disturbance of the minute RNA pellets, hi addition, throughout the extraction processes and 
during subsequent handling of RNA, precautions were constantly taken to prevent contamination 
of the samples with nucleases. Thus disposable sterile plasticware and DEPC treated plastic and 
glassware were always used as mentioned earlier. Whenever possible solutions were also treated 
with DEPC or made up in DEPC-treated water. Furthermore, gloves were worn at all times to 
protect the RNA samples from skin nucleases.
This extraction method was found to be satisfactory and convenient, the rotor dealing with six 
samples simultaneously. Usually the extraction was performed at the end of the day allowing the
centrifugation to be carried out overnight and the RNA harvested first thing in the morning. The 
RNA recovery was totally adequate and concentrations ranged from 128-1400 ug/ml with a mean 
of 650 ug/ml. In fact, in all cases that had an RNA concentration below 650 ug/ml, sample 
spillage in the course of their handling was the cause. This occurred during the shearing of 
sample nuclear DNA which was carried out by passing the samples several times up and down a 
23-gauge needle. The RNA extracted by this method was also of very good quality and free of 
protein contamination as determined by the mean OD260/OD280 value of 1.98. Pure RNA 
preparations, have an OD260/OD280 value of 2.0. The RNA integrity was checked by 
electrophoresis in agarose gels containing formaldehyde. Prior to running of the samples, the 
RNA was denatured by heating at 55°C for 10 min in the presence of formamide and 
formaldehyde. This is necessary in order to disrupt aggregates and hydrogen-bonded structures. 
At the end of the electrophoresis, the gels were washed to remove formaldehyde for better 
resolution of the rRNA bands. Under these denaturing conditions as is shown in figure 21, there 
is twice as much of the 28S rRNA (top band) as 18S rRNA (bottom band) in all samples. 
Typically undegraded RNA exhibits a 2:1 ratio of 28S:18S. The smear seen in all lanes indicate 
presence of mRNA and possibly rRNA degradation products.
The RNA was divided into two aliquots. To one aliquot, 0.1 volume of 2 M potassium acetate 
and 2.5 volumes of ethanol were added and the mixture stored at —80°C until required. To 
recover the RNA the mixture was simply centrifuged at 5000^ for 10 min. The use of chloride 
containing salts such as lithium chloride were avoided in these preparations because of their 
inhibitory effect on the reverse-transcriptase enzyme. The other aliquot was stored at -20°C and 
used for R-T PCR amplification. The amplified PBG-D cDNA was also stored at -20°C until 
required in the second round of amplification in asymmetric PCR for the production of suitable 
single-stranded templates. Conveniently, several single-stranded templates were amplified and 
purified by selective precipitation in propan-2-ol and ammonium acetate. The cDNA pellets were 
resuspended in either 10 ul or 14 ul of water and stored at -20°C until required in sequencing 
reactions. In each sequencing reaction, a half of these aliquots was used, taking 10 ul aliquots for
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Sequenase T7 DNA polymerase and 14 ul aliquots for the Taq DNA polymerase mediated 
sequencing reactions.
To characterise all types of mutations in the coding sequence of the PBG-D gene, the entire 
cDNA had to be sequenced. This required sequencing with at least four different sequencing 
primers complementary to the cDNA and mRNA of the PBG-D gene. The use of these primers 
made it possible to sequence the entire PBG-D cDNA in one experiment. To achieve this, several 
techniques which highlight different parts of the template sequence were utilised. For instance, 
the sequencing of regions close to sequencing primers were facilitated by the use of manganese 
buffer. On the other hand to enable sequencing of regions more distant to the sequencing 
primers, the concentrations of dNTPs used in the labelling mixture was increased. Furthermore, 
staggered loading was used, making it possible to run the sequencing reactions for different 
lengths of time. This enabled the reading of sequences from different segments of the gene all at 
once. This is demonstrated in figure 22, where sets 3, 4, 5 and 8 were from the same patient 
highlighting different regions of the PBG-D cDNA.
One of the major problems in sequencing regions close to the primers is the presence of very 
faint bands. This problem is particularly seen when there is only a small amount of template 
DNA. To circumvent this problem, two approaches were employed. In the first approach 
manganese buffer (0.15 M Sodium isocitrate, 0.1 Manganese chloride) was addeed in the 
sequencing reaction in addition to the usual magnesium based reaction buffer. In the second 
approach, the amount of nucleotides used in the labelling reactions was reduced to favour chain 
termination closer to the sequencing primers. The addition of manganese buffer works by 
potentiating chain termination properties of the dideoxynucleotides. When using T7 DNA 
polymerase and substituting Mn++ for Mg++, discrimination against dideoxynucleotides 
incorporation by this enzyme is reduced four fold, thus allowing dideoxynucleotides to be 
incorporated virtually at the same rate as deoxynucleotides. Isocitrate is included in the buffer to 
expand the effective catalytic range of the Mn++(Tabor and Richardson, 1989). Thus the addition 
of manganese buffer to sequencing reactions reduces the average length of DNA synthesised in
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the termination step, intensifying bands close to the sequencing primer. With manganese buffer, 
sequences from less than 20 bases from the sequencing primers to approximately 200 bases can 
be clearly read even with reduced amount of template DNA. Alternatively, the region close to the 
sequencing primer was highlighted by diluting the labelling mix and restricting the labelling 
reaction duration to under 5 min as described in the methods. Use of reduced concentrations of 
nucleotides favours chain termination closer to the starting point. For this method to work 
effectively, it requires an adequate amount of template DNA, usually not less than 1 ug or else, 
the sequencing ladders generated will be very faint. This problem was overcome by 
concentrating the 10 ul aliquots of asymmetrically amplified templates mentioned before to 5 ul, 
thus effectively using an entire PCR mixture for each sequencing reaction. Of the two methods, 
the addition of manganese buffer was found to be more convenient and effective and therefore 
routinely used in this study.
Reading of long sequences or distant regions from the primers was facilitated by using more 
nucleotides and label in the labelling mixture as described earlier. Under normal circumstances, 
even when using high-resolution electrophoresis and cloned single-stranded templates, 
sequence-specific bands generated by the standard sequencing protocol begin to fade at about 
600-800 bases from the primer. The exact point where sequence information fades out depends 
on many factors including the concentrations of template DNA, sequencing primers and label. In 
the direct sequencing of PCR generated templates this point where sequences begin to fade is 
observed earlier than with cloned templates, hi most cases this problem was solved by changing 
sequencing primers, using a primer that was nearer to the region of interest. In some cases, 
however, a region of particular interest especially at the extreme ends of the PBG-D cDNA 
fragments, could not be reached by the available primers. This was seen in a few instances where 
a base change needed to be substantiated by resequencing of a specific region or confirmed by 
sequencing of the opposite strand. It is in these instances that this method of sequencing regions 
distant from the primers became very useful. This method, however, generated faint sequences 
close to the primers. To counter this, the manganese buffer method for sequencing regions close
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to the primers was used alongside it, and the sequences generated from both were run in the same 
gel in a staggered fashion. The samples that were prepared to read distant regions were loaded 
first and electrophoresed for up to 4 h before the other samples were applied on the gel.
Following the second loading, both samples were run together for a further 2 h. In most cases the 
electrophoresis was carried out using normal sequencing gels as mentioned in the methods.
Under normal experimental conditions, using 50 cm sequencing gels as was done in this study, a
2.5 h nm is expected to generate a sequencing ladder of 250 bases. In order to read more 
sequences, longer durations of electrophoresis can be used but at the expense of losing the early 
part of the sequencing ladder through running off the gel. To circumvent this, wedge gels or 
buffer gradient gels can be used. In wedge gels, the thickness of the gel is increased linearly 
down its length from top to bottom, causing the voltage drop to decrease in accordance with 
Ohm’s law. This is due to the fact that electrical resistance of polyacrylamide gels in TBE, 
decreases with increasing cross-sectional area. In such gels, the small DNA molecules slow 
down towards the bottom of the gel thereby reducing the space between bands, whereas the 
larger chains are fractionated through a greater length of the thin area of the gel. Thus this 
technique reduces the tendency of the small DNA chains to be run off the gel enabling long 
sequencing ladders to be generated. The main drawbacks of this technique is that the bottom 
bands tend to be ill defined and that the gels take slightly longer to be well fixed and dry. 
Alternatively, the field strength gradient can be created by using buffer gradient gels (Sambrook 
et al., 1989a). In buffer gradient gels, the gels are poured in such a manner that there is an 
increasing concentration of buffer towards the the base of the gel (Biggin et al., 1983; Hong, 
1997). Buffer gradient gels are easy to run and generate sequencing bands of good even 
resolution, but are difficult to pour. Taking all these factors into consideration, it was found that 
wedge gels were more convenient to use than buffer gradient gels. Therefore, in this study, 
particularly when specific distant regions needed to be sequenced, the electrophoresis was 
performed in wedge gels at a low gel running temperature of 40°C.
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Using these methods, cDNA from patients with AIP were sequenced to delineate the molecular 
pathology in this disorder. For comparison the AIP samples were always run with normal 
controls. This served two purposes; firstly, for comparison of the sequences to ensure that any 
changes observed were genuine and not due to artefacts and secondly, to compare the incidence 
of these changes in affected and normal individuals.
Seven point mutations were detected in nine patients with AIP and none in the controls. Four of 
these mutations are associated with amino acid substitutions and it is proposed that these are 
responsible for the causation of AIP, whereas in the remaining three, there are no amino acid 
changes and are therefore regarded as neutral polymorphisms. With the exception of the R167Q 
which has been previously described by Delfau et al (1990) all the remaining mutations are 
novel.
Q34K (C100->A) caused by a C to A transversion in exon 4, changes codon CAG for glutamine 
to AAG for lysine at nucleotide 100 or amino acid residue position 34. At this position, 
glutamine is a highly conserved amino acid, present in the PBG-D from all species for which 
sequence data are available including Escherichia coli, rat, mouse, bacillus, euglina gracilis and 
human as shown in appendix C (Raich et al., 1986; Thomas and Jordan, 1886; Grandchamp et 
al., 1987; Chretien et al., 1988; Stubnicer et al., 1988; Beaumont et al., 1989; Sharif et al., 1989). 
In addition, according to prediction by the PEPTIDESTRUCTURE and PLOTSTRUCTURE 
programmes from the Genetics Computer Group (Chou and Fasman, 1978) this change is most 
likely to lead to the disruption of (3-strand. Moreover, the mutation affects an amino acid which 
is located at the base of an active site cleft and is involved in hydrogen bonding to conserved 
amino acids, serine and arginine located at residue positions 96 and 191 respectively. The change 
is, therefore, likely to result in disruption of hydrogen bonding network, and in particular of the 
residues, arginine at position 32 and isoleucine at position 33, in its close 
proximity. This mutation, however, does not cause any alteration in the recognition sites of 
restriction enzymes. The mutation was seen in two related patients, a mother and her daughter 
one of whom had also the silent mutation G606->T (V202V). The fact that this mutation is
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predicted to cause disruption of the |3-strand and that it affects a highly conserved amino acid at 
an active site, strongly support the view that this change is most likely to be the putative cause of 
AIP in this family. This claim is made stronger by the fact that after sequencing of the entire 
PBG-D cDNA no other changes were seen in one member of this family, while in the other there 
was a silent mutation in which the codon GUG (GTG) for valine was altered to GUU (GTT) 
coding for the same amino acid.
R167Q (G500->A) mutation, altering codon CGG for arginine to CAG for glutamine at 
nucleotide 500 and amino acid residue position 167 was seen in one individual. This change 
affects a conserved amino acid which forms a direct salt bridge to the acetyl side group of ring 2 
of the cofactor. The position occupied by this ring may become the binding site for the incoming 
substrate porphobilinogen. Mutation at this site result in loss of stabilising interaction to 
carboxylate group of the cofactor and possibly of the substrate. In addition, this mutation has 
been described before and is known to be associated with abnormal PBG-D activity (Delfau, et 
al., 1990). In a similar study, Delfau and co-workers (1990) starting with mRNA from AIP 
patients, amplified and cloned in a procaryotic expression vector the PBG-D cDNA containing 
the entire coding region of the gene and were able to demonstrate a G to A transition at position 
500 from the translation initiation codon in several clones that had failed to express human 
PBG-D activity. This was originally noted in two unrelated patients but on further investigation 
using the ASO hybridisation technique, two additional unrelated patients with this mutation were 
discovered. Delfau et al. (1990), also showed that the mutated protein produced by this change 
was immunoreactive, indicating that the mutation was CRIM positive. In addition, through 
Western blot analysis it was demonstrated that the migration pattern of the mutated protein in 
SDS polyacrylamide gels was similar to that of the normal enzyme. This mutated protein was, 
however, shown to have reduced PBG-D activity with a specific activity of approximately 0.7% 
of the normal enzyme when measured at pH 8. In addition, the optimal pH for the mutated PBG- 
D was found to be dramatically reduced in comparison to the normal. This mutation has also 
been described previously in a retrospective diagnosis of a probable compound heterozygote
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carrier of this defect (Beukeveld et al., 1990; Picat et al., 1990). This was reported 
retrospectively in a girl who died at the age of seven, from a severe and unusual presentation of 
at AIP (Beukeveld et al., 1990). The girl had presented with porencephaly associated with mental 
retardation and persistent excessive amounts of delta-aminolevulinic acid, porphobilinogen and 
uroporphyrin in her urine. It was inferred that she must have inherited both abnormal alleles with 
the G50o">A mutation coming from her father and the G518->A from her mother (Picat et al.,
1990). Although, in the CRIM negative group, the same mutation has never been described in 
more than one family, this does not apply to the CRIM positive group (Nordmann et al.,1990). It 
is possibe that the G500->A may turn out to be one of the commonest mutation responsible for 
acute intermittent porphyria, though further studies are required before this conclusion can be 
made with certainty (Delfau et al., 1990). Nevertheless, this is the first time in AIP that the same 
mutation has been described independently from two different centres. Li this mutation, it is 
interesting to note that the G to A substitution is occurring within a CpG dinucleotide. These 
kinds of mutations are thought to arise from the oxidative deamination of methylated cytosines 
and have previously been detected with a high frequency in several genetic diseases (\bussoufian 
et al., 1988; Grandchamp et al., 1989b; Lee and Nassbaum, 1989; Delfau et al., 1990). This 
mutation like the G100->A mutation is involving a highly conserved amino acid as shown in 
appendix C. Also like the G100->A mutation, it is not associated with alteration of a recognition 
site of any restriction enzyme.
The L177R (T530->G), mutation caused by a T to G transversion at nucleotide 530, was seen in 
two unrelated patients with AIP. This changes codon CUG (CTG) to CGG thus substitution 
arginine for leucine at amino acid residue 177. Like the other two previously described mutations 
in this study, this transversion also affects a highly conserved amino acid. The involved amino 
acid leucine, forms part of the hydrophilic core of the PBG-D. Therefore, replacement of this 
residue by arginine introduces a charged group resulting in destabilisation of the core. In 
addition, this mutation abolishes a recognition site for the Alul/CvUl restriction enzymes 
allowing these to be used for screening purposes. Alul is a frequent cutter of PBG-D cDNA,
dividing the cDNA into seven fragments in the normal and six in this mutation. For easier 
interpretation it may, however, be convenient to amplify a 549 bp fragment using primers F4 and 
R4. In the normal allele, Alul digests this fragment into four segments of 190, 91,43 and 225 bp. 
In this mutation, the abolishing of the recognition site between the 91 and 43 bp segments leads 
to the production of three segments of 190,134 and 225 bp. The screening can be performed 
simply by amplifying the cDNA using the R-T PCR technique and fractionating the products in 
agarose gels as previously described. Following ethidium bromide staining, the PCR products 
can then be directly visualised under U.V. light. Using such a method, it is possible to quickly 
scan individual members in affected families. Because the change is intragenic and caused by the 
mutation, the diagnosis is made directly. This information is useful in the counselling of the 
affected family members. Depending on the frequency of the mutation this method can also be 
useful in screening for the mutation in unrelated individuals (Delfau et al., 1990; Lee, 1991a).
Mutation H256N (C766->A), a transversion of C to A at nucleotide 766 leading to the 
substitution of histidine to asparagine at amino acid residue 256 was detected in one patient. The 
mutation changes codon CAC to AAC which in addition to the above mentioned amino acid 
substitution, also abolishes a recognition site fovBanl, situated one base upstream from the 
mutation site. The mutation is situated towards the end of a helix and does not affect a conserved 
amino acid. The substitution of the positively charged histidine by asparagine does, however, 
affect a conserved charge. In E. Coli protein, the corresponding residue argenine at this position, 
forms a salt bridge to glutamine. It is possible that in the human, the corresponding hydrogen 
bond is formed by histidine at this position with asparagine at residue 322. Therefore, 
substitution of histidine by asparagine results in pairing of the two asparagines, which may be 
less efficient at forming hydrogen bonds. Since a search through the entire PBG-D did not reveal 
any other mutation, it is most likely that this change is responsible for the disorder in this patient 
The abolishing of the recognition site for the enzyme Ban! offers an alternative method of 
tracking this mutation. In the normal, this enzyme cuts the entire PBG-D cDNA and the 
immediate intervening sequences twice giving three segments of 87, 694 and 369 bp. This
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mutation abolishes the restriction site between the 694 and the 369 bp segments leading to the 
production of two segments consisting of 87 and 1,063 bp. Similar mutation (L245R or T734-G) 
also involving a non-conserved amino acid in exon 12 has been reported (Delfau et al., 1991). 
This mutation caused by a T to G transversion at position 734, is close to the H265N mutation 
and like it, does not involve a conserved amino acid.
The remaining three mutations, L42L, S45S and V202V were not associated with any change in 
amino acid residues and are therefore regarded as silent mutations. In some cases, these so called 
silent mutations may still be responsible for pathology. This especially occurs in highly 
expressed genes where despite degeneracy of the code, a particular codon or a set of codons may 
be preferred for certain amino acid than others. In such cases, changing of a codon or a set of 
codons to another, even if still codes for the same amino acid, may lead to inefficient 
incorporation of that particular amino acid residue. These mutations in the PBG-D gene did not 
appear to be of this type, since in all cases the frequency of the original and the changed codons 
in the PBG-D cDNA appeared to be the same.
V202V was the most frequent mutation and was seen in four unrelated individuals, three of 
whom had other mutations including L117R, R167Q and Q34K. This mutation alters codon 
GUG (GTG) to GUU (GTT), but as both code for the same amino acid valine, there is no change 
in the protein structure. The mutation is not associated with any alteration in the recognition sites 
of restriction enzymes. Similarly, the L42L mutation due to the change of codon UUG (TTG) to 
CUG (CTG) seen in one patient in this study, does not lead to any change in the amino acid 
residues or recognition sites for restriction enzymes. Therefore, this mutation which is most 
probably a neutral polymorphism, is very unlikely to be the cause of AIP. In addition, since the 
mutation does not alter a recognition site for any restriction enzyme, it is not useful in the 
diagnosis or linkage studies for tracking of this condition in the affected family.
The remaining mutation S45S, which was also seen in one patient, is not associated with any 
amino acid change. The mutation alters codon UCG (TCG) to UCA (TCA) both coding for 
serine. The change, however, abolishes the recognition site for the enzyme Rsal. This enzyme
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digests the normal PBG-D cDNA and its immediate intervening sequences into two fragments of 
136 and 1114 bp. As in the mutant allele this recognition site is abolished, the amplified cDNA 
will fail to cut. This may prove to be useful in linkage studies within affected families. To date, 
only five RFLPs have been recognised in the human PBG-D locus. These are due to Mspl, Pstl, 
ApalA and a polymorphism recognised by Bst NI and ScrFl (Llewellyn et al., 1987; Lee and 
Anvret, 1987; Lee et al., 1988; Lee 1991b; Picat et al., 1991). Interestingly, four of these RFLPs 
have been mapped within a region of 1.5 kb in the first intron of the PBG-D gene which spans 
approximately 3 kb (Lee, 1991a). The fifth RFLP has been located in exon 1 at position -64 
relative to the initiation translational codon (Picat et al., 1991).
DNA polymorphism may arise either from point mutations, tandem repeats of short DNA 
sequences, or chromosome rearrangements caused by deletions and insertions (Kidd et al., 1989). 
In the human genome, sequence differences between any two alleles, on average, occur at the 
rate of 1 in 500 nucleotides (Jeffreys, 1979; Antonorakis et al., 1982). However, only about 5% 
of such sequence differences in the human DNA are detectable by conventional Southern blot 
analysis after restriction enzyme digestion (Antonoarakis, 1989). These polymorphisms can, 
however, be detected by direct visualisation of the amplified products after digestion with the 
relevant restriction enzymes. Demonstration of polymorphism by using PCR in linkage studies 
requires considerably less time and effort. Within a day, target sequences can be amplified using 
primers flanking the polymorphic site, digested with the relevant restriction enzymes,
fractionated and visualised on gels (Kogan et al 1987). Haplotyping analysis using RFLPs in the
b i
diagnosis of acute intermittent porphyria has been done before and found to especially useful in
A
the diagnosis of those subjects whose enzyme activity lies within the overlap zone (Lee et 
al.,1988; Lee et al., 1991a). The use of these intragenic RFLPs in the tracking of PBG-D gene 
within affected families thus allows asymptomatic carriers and normal individuals to be 
identified with greater certainty than can be achieved by the conventional biochemical methods 
(Llewellyn et al., 1987; Lee et al., 1988; Grandchamp and Nordman 1988; Lee et al., 1991). 
However, this approach is limited to the families of patients who have both potentially
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informative genotypes and sufficient unequivocally affected, living relatives to enable linkage 
studies to be used (Scobie et al., 1990b). In a study involving 47 unrelated AIP patients of mainly 
European stock, Scobie et al. (1990b) found a marked linkage disequilibrium between the 
polymorphic sites for Ms/?I, Pstl and BstNl/ScrFl. They were able to identify only four out of the 
eight theoretically possible haplotypes from these polymorphic sites. Furthermore, the frequency 
of one of the haplotypes was less than 2% making the three RFLPs less informative then they 
would have been when inherited independently. The usefulness of the polymorphic site for Rsal 
caused by the transition of G to A at position 135 detected in this study is yet to be determined. 
Theoretically these RFLPs or direct detection of the above described mutations which alter 
restriction sites can both be used for prenatal diagnosis of AIP. In practice, however, this will 
probably be considered only in those rare occurrences where both parents are affected. AIP being 
an autosomal disorder, it is possible that homozygosity is non-viable or may lead to a severe and 
crippling form of the disease (Beukeveld et al., 1990; Picat et al., 1990).
Among the main problems in the management of AIP, is the variability in the clinical 
presentation and heterogeneity both at protein and DNA level. As the majority of gene carriers of 
AIP are not symptomatic, follow up of affected families may not be easy. This problem is 
compounded by the heterogeneity of the molecular pathology responsible for this condition. To 
date, 13 confirmed mutations responsible for both CRIM-positive and and -negative AIP have 
been reported in the literature. Most of these mutations have so far been unique to the index 
family in which they were first reported. This particularly applies to the common CRIM negative 
phenotype, where so far the same mutation has never been found in more than one family 
(Nordmann et al., 1990). With the exception of one mutation caused by a deletion of T, the rest 
of the reported mutations are due to single base substitution. These mutation summarised in table 
2, have different effects on PBG-D cDNA and/or protein. These include splicing defects leading 
to skipping of exons, premature introduction of stop codons with the subsequent production of 
truncated proteins, missense and nonsense mutations resulting in the synthesis of abnormal
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proteins and frameshift with production of truncated products. Also included in the table, are 
mutations detected in this study.
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Table 3: Reported mutations of the PBG-D gene in AIP.
Putative pathological mutations:
Mutation Exon Amino acid change Reference
G33->T 1 None (splicing 
defect)
Glu to Lys 
(splicing defect).
(Grandchamp et al., 1989a).
2. G34->A -1 (Grandchamp et al., 1989b).
3- Cioo->A 4 Gin to Lys (Mgone et al., 1991).
4- C346->T 8 Arg to Trp (Lee et al., 1990).
5. G446->A 9 Arg to Gin (Delfau et al., 1991).
6. C463->T* 9 Gin to stop (Scobbie et al., 1990).
7* G500->A 10 Arg to Gin (Delfau et al., 1990).
8- ^517_>rr 10 Arg to Trp (Lee et al., unpublished).
9- G5!g->A 10 Arg to Gin (Delfau et al., 1990).
10* T53q->G 10 Leu to Arg (Mgone et al., 1991).
11. G593->A 10 Trp to stop (Lee and Anvret, 1991).
12. g 612->t 10 del of 9 bases (Delfau et al., 1991).
13- T734->G 12 Leu to Arg (Delfau et al., 1991).
14. T766_>A 12 His to Asn (Mgone et al., 1991).
15. G771->A 12 skipping of 
exon 12 (Grandchamp et al., 1989c).
16. del T900 14 frame shift of 
stop codon (Delfau et al., 1991).
Neutral polymorphisms:
17. C_64->T 1 - (Picat et al., 1991).
18. G117->A 4 Leu to Leu (Mgone et al., 1991).
19. G135->A 4 Ser to Ser (Mgone et al., 1991).
20. G^g-^T 10 Val to Val (Mgone et al., 1991).
21. T633->G - - (Grandchamp et al., 1987).
22. C731->T - - (Grandchamp et al., 1987).
-1 refers to the first intron.
*The numbering referred to here, is from the translational initiation site, whereas in the Jhd"cited 
reference, this mutation is actually reported as C412->T.
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The first two mentioned mutations in table 2 above, involve the first exon-intron junction 
changing the consensus splice junction sequences. In these two splicing defects, since the 
aberration affects only the the coding sequences of the non-erythroid isoform of PBG-D, the 
enzyme defect is found to be restricted to non-erythropoietic cells. The first mutation caused by a 
G to T transversion in the last position of the first exon, was observed in a Finnish kindred. 
Although this change does not modify the amino acid alanine specified in the last codon, since 
the change of codon GCG to GCU (GCT) still encodes for the same amino acid, it does, 
however, interfere with the normal splicing by changing the normal splice consensus sequence 
5’CGGTGAGAGT 3’ to 5’CTGTGAGT 3’ (Grandchamp et al 1989a). The second mutation 
occurring only one nucleotide 3’ to the first, was described in a Dutch family. The mutation is 
caused by a G to A transition in the first position of the first intron, causing substitution of the 
amino acid glutamic acid to lysine and at the same time changing the consensus splice 
sequences, 5’CGGTGAGT 3’ to CGATGAGT 3’. This like the first mutation leads to the 
defective splicing of the primary transcripts initiated at the upstream promoter of the gene 
without affecting the expression of the PBG-D gene in the erythroid cells which utilise the 
downstream promoter found 2.8 kb 3’ to these. Thus affected individuals with any of these two 
mutations will have normal erythrocyte PBG-D activity. Both mutations were characterised by 
cloning of the mutant alleles and the subsequent detection in other individuals performed by 
ASO hybridisation after PCR amplification. These mutations result in CRIM-negative 
phenotype.
The fourth shown mutation in table 2, was originally observed in one Swedish ATP patient with 
hepatoma (Lee et al., 1990). This mutation is confined the index family and a further search for 
the mutation in 28 other affected Swedish families proved fruitless. In this mutation the 
transversion of base C to T at nucleotide position 346 changes the codon CGG for arginine to 
UGG (TGG) for tryptophan at the residue position 116 (R116W). Although this mutation is not 
likely to result in any predictable major secondary structural change, it does, however, affect a 
highly conserved amino acid as shown in appendix C. This mutation is very similar to the ones
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reported in the current study and like the first and second described mutations, was characterised 
by sequencing of cloned PCR amplified templates and results in CRIM-negative phenotype. 
Further screening for the mutation in the affected family members and other individuals was 
performed by ASO hybridisation after PCR amplification.
The fifth mutation, a G to A transition at nucleotide position 446 in exon 9 changes codon CGA 
for argenine to CAA for glutamine at amino acid residue position 149 (R149Q). This affects a 
highly conserved amino acid and moreover is likely to disrupt the helix in the secondary 
structure of the protein. The mutation which results in CRIM-negative phenotype, has been so far 
described in one individual after sequencing of cloned PCR amplified products (Delfau et al., 
1991). The sixth mutation in table 2, referred to in the original publication as C421 ->T is actually 
C463->T, counting the nucleotide position from the translation initiation site. The transition of C 
to T at this position converts codon CAG for glutamine to the stop codon UAG (TAG). This 
mutation does not affect a conserved amino acid, but the premature introduction of a stop codon 
prevents the translation of about 60% of the coding sequence leading to the production of a 
catalytically inactive truncated protein lacking the cysteine residue necessary for of the 
attachment of the pyrromethane cofactor. The mutation which results in CRIM-negative 
phenotype was observed in only one patient in spite of investigating 43 unrelated individuals. It 
was demonstrated by sequencing of cloned PCR products rather than direct sequencing as 
performed in the current study.
Mutation G500->A (R167Q), observed in one patient in this study, has been previously 
described in four different families (Beukeveld et al., 1990; Picat et al., 1990; Delfau et al.,
1990). It is probably the most common mutation in AIP. Mutation G518->A (R173Q) occurring 
18 nucleotides downstream to this, has been observed in two unrelated individuals. The transition 
of G to A in this mutation leads to the alteration of codon CGG for arginine to CAG for 
glutamine and at the same time, the supression of an Mspl restriction site. Both this and the 
previous mutation result in CRIM-positive phenotype. Moreover, Lee and co-workers 
(unpublished data) have observed another mutation affecting this codon due to transition of C to
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T changing the codon CGG for arginine this time to UGG (TGG) coding for trytophan. This 
change also creates a recognition site for the restriction enzyme Zte/NI which can therefore be 
used for screening of the mutation in affected families. Although both C517->T (R173T) and 
G518->A (R173Q) are occurring at the same codon, it is interesting to note that while the former 
leads to CRIM negative the later causes CRIM positive phenotype. Therefore, the same CRIM 
phenotype may arise from different mutations and conversely, similar mutations arising from the 
same codon may result in different phenotype subtypes. Although all these three mutations 
involving exon 10 affect highly conserved amino acids, they do not seem to significantly alter 
secondary structure of the PBG-D. In their report Delfau et al. (1990), characterised two of these 
mutations (G500->A and G518->A) by sequencing of cloned PCR products. Subsequent detection 
in other affected individuals was then performed by restriction analysis, in the case of the 
G5i8->A mutation which suppresses an Ms p i  site and by ASO hybridisation in the G500->A 
mutation. The C517->T mutation was on the other hand characterised by direct sequencing of 
PCR products.
The eleventh mutation depicted in table 2, is caused by a G to A transition at nucleotide 
position 593 in exon 10. Although this does not affect a conserved amino acid, it changes codon 
UGG (TGG) for tryptophan at amino acid residue 198 to a stop codon UAG (TAG) leading to the 
production of inactive truncated protein. This nonsense mutation also creates a new restriction 
site for the enzyme NheI and leads to CRIM negative phenotype. The mutation was observed in 
16 families in Sweden, accounting for 40% of AIP cases in the investigated community. 
Genealogical studies, however, have revealed that almost all these families were related to the 
index family implying a ‘founder effect’ of this mutation in these families and confirming the 
high degree of heterogeneity in the CRIM negative phenotype. This and the G517->A are the only 
PBG-D mutations in the literature that have been fully characterised by exclusively using PCR 
amplification and direct sequencing. Unlike in this study, the amplification was performed by a 
standard PCR producing double-stranded products which where then directly sequenced with 
Taq DNA polymerase using a novel technique referred to as cycling sequencing (Lee and
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Anvret, 1991; Lee, 1991b). In this new technique, the sequencing reactions are performed on a 
programmable heating block using one of the primers that had been originally used in the PCR. 
The primer is mixed with the appropriate extension-termination mixes in four separate reactions 
and overlaid with light mineral oil to prevent evaporation just like in a PCR. After a 3 min 
denaturation step, cycling is performed by heating the samples in a cyclic manner at temperatures 
of 94°C for 1 min, 60°C for 1 min and 72°C for 40 sec. This is repeated for for 25 cycles and at 
the end of the reaction the samples are concentrated to 4 ul, a stop mix added and 
electrophoresed in the usual way. Following characterisation of the mutation in the index case, 
family members were screened using another novel technique of cyclic reactions. In this 
technique, employing the principles of dideoxy DNA sequencing, PCR amplified templates and 
appropriate termination mixes in a final volume of 10 ul, are mixed with end-labelled primers 
designed to generate the first termination at the mutation site. Thus for example if there is a G to 
A mutation, termination mix A containing ddATP, dCTP, dGTP and dTTP is used. The reaction 
mixture is then amplified for 15 cycles using Taq DNA polymerase. At the end of the 
amplification, 4 ul of a stop solution containing 95% fonnamide, 0.01% bromophenol blue,
0.01% xylene is added and 2.5 ul of the mixture, denatured and electrophoresed in a 10% 
denaturing polyacrylamide gel. The results are read on autoradiographs in which homozygote 
normal individuals will show a single band different from affected homozygotes and 
heterozygotes will show two bands. This method unlike ASO hybridisation, requires the use of 
only one primer and no additional equipment other then a programmable heating block.
The twelfth mutation, in table 2, also involves exon 10. It is due to a G to T transversion of the 
last base of exon 10 (nucleotide position 612) which results in a splicing defect and a new 
restriction site forZtamHI. This mutation which has been partially characterised by direct 
sequencing of PCR amplified products, leads to a deletion of the last nine bases of this exon, 
activating a cryptic site three codons upstream of the normal site. This results in the production 
of a stable but abnormal mRNA which is CRIM-negative. It is interesting to note that the 
deletion of these nine bases involve three amino acids residues, valine, glycine and glutamine at
positions 202 to 204. All these amino acid residues are not conserved including valine at residue 
202 which has been described in one of silent mutations in the current study. It is therefore 
difficult to explain how this mutation results in CRIM-negative phenotype. The absence of 
immunoreactive protein is compatible with the possibility that the enzyme is present but its 
three-dimensional structure is sufficiently altered to prevent recognition by antibodies. Among 
the possible explanations given include, the fact that the PBG-D activity depends on the covalent 
binding of a dipyrrolmethane as a cofactor which protects the enzyme from degradation 
(Umanoff et al., 1988). It has been postulated that, this mutation may prevent binding of the 
cofactor leading to an unstable protein (Delfau et al., 1991). As a counter argument, it is 
important to note that the mutation, however, does not involve the cysteine residue 261 of the 
human PBG-D which is highly conserved through the evolution and is most likely to be the 
cofactor binding site. The cysteine residue 242, located at a homologous position in the 
Escherichia coli PBG-D has indeed been shown to bind the cofactor (Miller et al., 1988).
The thirteenth mutation, T734-G (L245R), alters codon CTT (CUU) for leucine to CGT (CGU) 
for arginine at position 245. This mutation does not involve a conserved amino acid. Moreover, 
being located towards the end of a helix, is not likely to result in any predictable secondary 
structure change. Therefore, this mutation resembles the nearby G766-T (H256N) mutation, 
observed in the same exon in the current study. It may be possible that, despite this region not 
being a conserved domain, nevertheless, is important in the function of the human PBG-D. It is 
interesting to note that this region is close to the highly conserved cysteine residue 261, which 
may be the binding site for the cofactor and that the H256N mutation described in this study is 
actually closer to this cysteine residue than mutation L245R. This mutation which results in 
CRIM-negative phenotype has been detected in one individual via sequencing of cloned PCR 
amplified products.
The fifteenth mutation in table 2, is a G to A transition at nucleotide position 117, causing a 
splice defect and skipping of exon 12 (Grandchamp et al., 1989c). This was observed in one 
patient out of six investigated using PCR. In their study, Grandchamp et al. (1989c), on
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amplifying the entire PBG-D cDNA from these patients, observed that in one individual there 
was an additional band of about 120 bp, suggesting the presence of a truncated protein besides 
the normal PBG-D. Direct sequencing of the eluted abnormal product confirmed this to be due to 
the skipping of exon 12, but the presence of several ambiguities within the sequencing ladder 
precluded definite characterisation of the mutation. To circumvent this, the abnormal PCR 
product was then cloned into a plasmid vector and subsequently sequenced. This revealed the 
above mentioned G to A transition at the last position of exon 12 within the donor splicing site of 
the intron 12, causing this exon to be skipped in such a way that the exon 11 was directly joined 
to exon 13. The resultant abnormal protein although stable, is catalytically inactive and gives rise 
to CRIM positive phenotype. This mutation also suppress a recognition site for the restriction 
enzyme BstNl.
The sixteenth mutation is a single base deletion, affecting the nucleotide T at position 900. This 
results in a premature introduction of a stop codon located 15 codons downstream from the 
deletion. The mutation has been characterised by sequencing of cloned PCR amplified products.
It leads to CRIM-negative phenotype.
Silent mutations involving the PBG-D gene have also been reported before. For instance, 
Grandchamp et al. (1987) have reported T633->G and C731->T mutations. Unfortunately due to 
lack of detail regarding to the location of these mutations in relation to the translational initiation 
codon, it is not possible to compare them to any great detail to the ones observed in the current 
study. More recently, two more silent mutations of the PBG-D gene due to G to T transversion in 
exon 10 (Gu et al., 1991) and C to T substitution in exon 1 (Picat et al., 1991) have been 
reported. In the present study, a G to T transversion in exon 10 has also been observed, but as the 
mutation detected by Gu and his co-workers is yet to be described fully, no comparison is 
possible at the moment. On the other hand, the C to T substitution in exon 1 described by Picat et 
al (1991), occurs at position -64  relative to the initiation translational codon and can be detected 
by digestion with the enzyme Apal.
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Therefore, data from both previous and the present work indicates that the majority of 
mutations are clustered around exon 10. Of the sixteen well documented putative disease causing 
mutations described to date (including those from this study), six of them involve this exon 
indicating this to be a hot spot for mutations of the PBG-D gene. All mutations identified so far 
have been due point mutations resulting in either splicing defects (Grandchamp et al., 1989a; 
1989b; 1989c), nonsense mutations leading to synthesis of inactive truncated protein (Scobie et 
al.,1990; Lee and Anvret, 1991) and missense mutations with single ammo acid substitutions 
(Delfau et al., 1990; Lee et al 1990). Of the missense mutations, all except two, including one 
seen in the current study, affect highly conserved amino acids. In all these cases the amino acid 
concerned was conserved in all six species for which information on the PBG-D sequences are 
available. In the exceptional case seen in the current study, the mutation, nevertheless, affected a 
conserved charge. The commonest involved amino acid is arginine, which is affected in eight out 
of the ten reported cases of missense mutations of die PBG-D gene. In six cases this involve the 
replacement of this amino acid to another and in two cases it is replaced by another amino acid.
In the current study as in several others (Grandchamp et al., 1989a; 1989b; 1989c; Delfau et al., 
1990 and 1991) the starting material was mRNA. By starting with mRNA and using R-T PCR, it 
allows the in vitro amplification of the entire coding sequence of the PBG-D gene to be 
performed in a single step. When using this method some of die possible mutations of the 
CRIM-negative phenotype may, however, be missed since for tiiis approach to be successful it 
requires the mutant gene to be transcribed and the resultant abnormal mRNA to be present in the 
cells. In the case of CRIM positive mutations this problem does not arise, since in demonstrating 
the evidence of the presence of abnormal protein, it can be assumed that a pathological mRNA 
should also be present in the nucleated cells of the affected individuals, and that the mutations 
should lie in the coding sequence of the mRMA (Grandchamp et al., 1989c). It is likely, 
however, that many CRIM negative mutations can also be detected using mRNA, including most 
splicing mutations and amino acid substitution diat result in protein instability (Delfau et al., 
1990). Working widi mRNA as the starting material has also been necessary because it is only
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recently that the genomic sequence of the PBG-D gene including introns has been published 
(Lee, 1991a).
Methods used in the detection and characterisation of the PBG-D gene have evolved from the 
sequencing of partial libraries of cloned cDNA (Grandchamp et al., 1989a; Grandchamp et al., 
1989b) through the sequencing of cloned PCR amplified cDNA and DNA (Lee et al., 1990; 
Scobie et al., 1990; Delfau et al., 1990) to the direct sequencing of PCR amplified cDNA as 
reported in this study. Construction of genomic or cDNA libraries is time consuming and labour 
intensive. This problem has partially been alleviated by sequencing of cloned PCR amplified 
templates. In this technique, the cDNA or DNA fragments of interest are amplified with primers 
that add restriction sites to the template to enable cloning into vectors. As mentioned earlier, this 
method has three main disadvantages. Firstly, any misincorporation caused by Taq DNA 
polymerase during PCR amplification will be passed onto the cloned products and require several 
clones to be examined before such mistakes are recognised. Secondly, in an autosomal condition 
like AIP, several clones need to be examined and both alleles demonstrated before the 
heterozygosity can be confirmed. Lastly, the cloning is an additional step increasing labour and 
time. To circumvent this, attempts albeit unsuccessful, have been made before at characterisation 
of mutations in the PBG-D gene by direct sequencing (1989c). Recently, Lee (1991a) by using 
an alternative DNA method which simultaneously applied PCR and dideoxy sequencing, was 
able to demonstrate a new RFLP due to the suppression of an ApalA restriction site created by a 
C to A transversion in the PBG-D gene. By using the same method Lee and Anvret (1991) have 
also been able to detect and characterise the G593->A mutation mentioned earlier. The method, 
however, requires elaborate optimisation of several parameters which include the cycling thermal 
profile and different sequencing primerrtemplate and dideoxynucleotiderdeoxynucleotide ratios. 
This precludes the use of standard or commercially available chain termination-extension mixes. 
In the current study these problems were circumvented by direct sequencing of asymmetric PCR 
amplified templates. Through this method it was possible to characterise four possible 
pathological mutations and a new RFLP caused by the suppression an Rsal restriction site in
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exon 4 as shown in figures 23-29. The method was found to be reliable and in comparison to 
other methods that have been used before in studying this condition, was time saving and less 
labour-intensive. This method can be applied to investigate other monogenic disorders and 
should be particularly useful in the investigation of conditions which have molecular 
heterogeneity similar to AIP.
In practice, after characterisation of the mutation in the index case, subsequent tracking of the 
mutation in affected families can be done either by ASO hybridisation or by haplotype analysis if 
new restriction sites are created by the mutations as discussed before. The main problem, 
however, is to prove that the observed change is the putative cause of the condition being 
investigated rather than a neutral polymorphism. This is particularly true for missense mutations, 
where the only change may be a substitution of a single ammo acid residue. The problem can be 
partially solved by comparing the prevalence of the mutation in the affected and normal controls, 
as has been done in this study. If the mutation can be demonstrated to occur in the affected 
individuals and to be absent in the controls, it is then most likely to be the cause of the disorder. 
This approach is, however, of limited use when investigating very rare conditions. Mutations 
may also be indirectly proved to be the putative cause of diseases if shown to alter the structure 
or to affect critical or conserved regions of the concerned protein molecule. In this study for 
instance, PEPTIDESTRUCTURE and PLOTSTRUCTURE computer programmes were used to 
predict the likely changes in the protein molecule secondary structure resulting from the 
mutations. In addition it was demonstrated that three of the mutations affect highly conserved 
amino acids. Alternatively, expression studies can be performed to demonstrate abnormal 
properties of the mutated protein. Thus, for example, the functional consequence of the mutated 
protein can be be studied by cloning PCR amplified cDNA containing the mutation from affected 
individuals, into procaryotic expression vectors and determine its activity. Using this method, 
Delfau et al. (1990), were able to demonstrate a causal association between the G500->A mutation 
and an abnormal PBG-D. Moreover, in some cases, the causal effects of mutations may be
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obvious, for example, when they cause premature insertion of stop codons or frame-shifts, 
resulting in severely truncated or grossly abnormal protein products.
The delineation of molecular pathology may also be used to study genes of unknown function. 
This can be achieved by studying these genes in cloned cDNA or genomic DNA. To achieve this, 
several approaches can be used. First, by using what are referred to as transient expression 
systems, one can introduce the normal or mutant genes and determine the quantity and structure 
of their transcripts. Alternatively, the same may be achieved by introducing the genes into 
appropiate cell lines, as for example human haemoglobin genes into mouse erythroleukaemia cell 
lines or by transfecting them into embryos so that their patterns of integration and expression can 
be studied over several generations (Weatherall, 1985). Such studies may, threfore, lead to 
understanding of the pathogenesis of some monogenic disorders.
In this study, a system for the characterisation of molecular pathology has been developed and 
applied to delineate mutations in AIP. This has be accomplished through direct sequencing of 
PCR amplified cDNA derived from total cellular RNA. The method has been found to be reliable 
and can be used as a prototype to investigate molecular pathology of other monogenic disorders.
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7. APPENDICES.
APPENDIX A: Regional assignment of PBG-D gene to chromosome 11. 
From the work of Meisner et al. (1980,1981), Wang 
et al. (1981) and de Vemeuil et al. (1982), PBG-D 
gene has been mapped to chromosome llq23-qter.
APPENDIX B: The sequence PBG-D cDNA showing mutations that have 
been characterised to date.
APPENDIX C: Amino acid sequence alignments of the PBG-D from 
various species. The open boxes denote the conserved 
residues. The underlined amino acids are some of 
those involved in mutations that have been reported 
in the literature, including the current study. The 
amino acid residue positions of the human PBG-D 
differ from that which has been described by 
Grandchamp et al. (1987), because of its alignment to 
other deaminases from different species. (Adapted 
from Prof. T. L. Blundell, University of London).
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APPENDIX D: Three-dimensional structural diagram of the human 
non-erythroid PBG-D showing the positions of 
mutations detected in the current study after 
alignment with other deaminases. The amino acid 
positions differ to that which has been originally 
described by Grandchamp et al (1987). Thus Gin 19 is 
referred to in the text as Gin 34, Arg 149 as Arg 
167, Leu 159 as Leu 177 and His 237 as His 256. 
(Drawn by Prof. T.L. Blundell).
APPENDIX E: Summarised protocol for PCR amplification and direct 
sequencing of the PBG-D cDNA.
A PPE N D IX  % PQSDJQN-QF THE PBG-D GENE ON CHROMOSOME 11
APPENDIX B
SEQUENCE OF THE PORPHOBILINOGEN DEAMINASE cDNA.
5*------------------------------ tea agactgtagg acgacctcgg
gtcccacgtg tccccggtac tcgccggccg gagcctccgg cttcccgggg
♦t
ccgggggacc ttagcggcac ccacacacag cctactttcc aageggagee 
10 20 30 E1/E2 40 Fl-> 50
ATGTCTGGTA ACGGCAATGC GGCTGCAACG GCGGAAGAAA ACAGCCCAAA
M
F2-> 60 70 80 TA E2/E3 100
GATGAGAGTG ATTCGCGTGG GTACCCGCAA GAGCCAGCTT GCTCGCATAC
♦
110 F3-> 120 130 140 A
AGACGGACAG TGTGGTGGCA ACATTGAAAG CCTCCTACCC TGGCCTGCAG
\ *
E4/E5 A <-R6 180 A 190 200
TTTGAAATCA TTGCTATGTC CACCACAGGG GACAAGATTC TTGATACTGC
E5/E6 220 230 240 250
ACTCTCTAAG ATTGGAGAGA AAAGCCTGTT TACCAAGGAG CTTGAACATG
260 E6/E7 280 290 300
CCCTGGAGAA GAATGAAGTG GACCTGGTTG TTCACTCCTT GAAGGACCTG
F4-> 310 320 330 340 E7/E8
CCCACTGTGC TTCCTCCTGG CTTCACCATC GGAGCCATCT GCAAGCGGGA
\
360 370 380 390 T 400
AAACCCTCAT GATGCTGTTG TCTTTCACCC AAAATTTGTT GGGAAGACCC 
410 420 E8/E9 430 440 450
TAGAAACCCT GCCAGAGAAG AGTGTGGTGG GAACCAGCTC CCTGCGAAGA
460 470 480 490 E9/E10
GCAGCCCAGC TGCAGAGAAA GTTCCCGCAT CTGGAGTTCA GGAGTATTCG 
510 T 520 530 540 550
GGGAAACCTC AACACCCGGC TTCGGAAGC T GGACGAGCAG CAGGAGTTCA
\ »
A F5-> G
560 570 580 590 600
GTGCCATCAT CCTGGCAACA GCTGGCCTGC AGCGCATGGG CT GGCACAAC
E10/E11 620 630 640 j 650
CGGGTGGGGC AGATCCTGCA CCCTGAGGAA TGCATGTATG CTGTGGGCCA
/El2 T 660 T 670 680 690 <-R5 700
GGGGGCCTTG GGCGTGGAAG TGCGAGCCAA GGACCAGGAC ATCTTGGATC
710 720 730 740 750
TGGTGGGTGT GCTGCACGAT CCCGAGACTC TGC7TCGCTG TATCGCTGAA
\
7 6 0 E12/E13 780 G 7 9 0  8 0 0
AGGGCCTTCC TGAGGCACCT GGAAGGAGGC TGCAGTGTGC CAGTAGCCGT
810 820 1 83 <-R4 840 850
GCATACAGCT ATGAAGGATG GGCAACTGTA CCTGACTGGA GGAGTCTGGA
860 870 880 890 900
GTCTAGACGG CTCAGATAGC ATACAAGAGA CCATGCAGGC TACCATCCAT*
♦
El 4/El 5 920 930 940 <-R3 deletion
GTCCCTGCCC AGCATGAAGA TGGCCCTGAG GATGACCCAC AGTTGGTAGG 
960 970 980 990 1000
CATCACTGCT CGTAACATTC CACGAGGGCC CCAGGTGGCT GCCCAGAACT 
1010 1020 1030 1040 1050
TGGGCATCAG CCTGGCCAAC TTGTTGCTGA GCAAAGGAGC CAAAAACATC 
1060 1070 1080
CTGGATGTTG CACGGCAGCT TAACGATGCC CATtaactgg tttgtggggc <-R2
-  2 -
acagatgcct gggttgcctg tgtccagtgc ctacatcccg ggcctcagtg
<-Rl
ccccattctc actgctatct ggggagtgat taccccggga gactgaactg 
cagggttcaa gccttccagg gatttgcctc accttggggc cttgatgact 
gccttgcctc ctcagtatgt gggggcttca tctctttaga gaagtccaag 
caacagcctt tgaatgtaac caatcctact aataaaccag ttctgaaggt 3*
the lower case letters denote the untranslated sequences and 
the upper case letters the open reading frame of the PBG-D geno. 
The letters in i t a l i c s  are the known mutations with arrows 
pointing to the nature of the change. The underlined letters arc 
the sequences of the oligonucleotide used in PCR amplifications 
and sequencing in the case of forward (F) primers and 
complementary sequences in the case of reverse (R) primers. E 
stands for exon, with the slash symbol / indicating the exact, 
location of the splicing sites.
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APPENDIX D.
THREE-DIMENSIONAI, STRUCTURE OF 
PORPHOBILINOGEN DEAMINASE.
APPENDIX E.
PROTOCOL FOR RAPID PCR AMPLIFICATION AND DIRECT
1. To a cell pellet containing approximately 4 X 106 
lymphocytes, add 50 ul of 0.1% DEPC in water and boil in 
a water bath at 100°C for 5 min to lyse the cells. Remove 
the cell debris by centrifugation and transfer 50 ul of 
the cell lysate to a 500 ul microfuge tube.
2. Prepare PCR amplification mixture as follows:
Cell lysate 50.0 ul
SEQUENCING OF PBG-D cDNA.
dH20 2.5 ul
10X PCR buffer 10.0 ul
4 mixed dNTPs (1.25 mM each dNTP) 16.0 ul
Oligo (dT)12_18 (100 ug/ml) 
Forward primer (10 uM) 
Reverse primer (10 uM)
10.0 ul
5.0 ul
5.0 ul
Vortex thoroughly and add:
MMLV-reverse transcriptase(200 u) 1.0 ul
Vortex and spin briefly, then incubate at 42°C for 30 
min. At the end of incubation add:
Taq DNA Polymerase (2.5 units) 0.5 ul
Mix gently, overlay with approximately 100 ul of light 
mineral oil and spin briefly. Perform a 30 cycle PCR 
amplification as follows:
Denature at 95°C for 3 min in the first cycle and 
thereafter for 1 min in the subsequent cycles. Anneal at 
60°C for 1 min and perform the extension reaction at 72°C 
for 1.5 min with the last extension lasting 7 min.
3. At the end of PCR amplification, remove the reaction mix 
below the mineral oil and resolve in 1.4% agarose. Excise 
the appropriate cDNA band and elute for 4 h in 100 ul TE 
buffer. The eluted cDNA can be stored for future use at 
-20°C.
4. Prepare a second PCR mix with unequal concentrations of 
primers (asymmetric PCR) as follows:
dH20  70.5 ul
10X PCR buffer 10.0 ul
4 mixed dNTPs (1.25 mM each dNTP) 4.0 ul
Forward primer (10.0 uM) 5.0 ul
Reverse primer (0.1 uM) 5.0 ul
Also prepare a second set of reaction mix with a reversed 
ratio of the primers. Treat with U.V. light for 10 min 
and add:
cDNA 5.0 ul
Vortex mix thoroughly and add:
Taq DNA polymerase (2.5 units) 5.0 ul
Mix gently, overlay with 100 ul of mineral oil and spin 
briefly. Perform 41 cycles of PCR using the same thermal 
parameters as in the first PCR.
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At the end of the second PCR remove 5 ul of the reaction 
mix and resolve in 1.4% agarose. If sufficient amount of 
ssDNA is noted, remove the rest of the mixture below the 
oil and purify.
To the remaining 95 ul of the PCR product, add 95 ul 4 M 
ammonium acetate and 190 ul propan-2-ol. Mix thoroughly 
and store for 10 min at room temperature. Recover the 
cDNA pellet by centrifuging at 12,000 g  for 10 min.
Wash the cDNA pellet once with 70% ethanol, dry and 
resuspend in 10 ul of TE buffer.
Perform sequencing reactions using either Sequenase™ or 
Taq DNA polymerase from sequencing kits (USB) following 
the manufacturer’s instructions.
